0001681622-20-000005.txt : 20200218 0001681622-20-000005.hdr.sgml : 20200218 20200218160522 ACCESSION NUMBER: 0001681622-20-000005 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20200103 FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Varex Imaging Corp CENTRAL INDEX KEY: 0001681622 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC COMPONENTS, NEC [3679] IRS NUMBER: 813434516 STATE OF INCORPORATION: DE FISCAL YEAR END: 1002 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37860 FILM NUMBER: 20625271 BUSINESS ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 BUSINESS PHONE: 801-972-5000 MAIL ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 10-Q 1 varex10q2020q1.htm 10-Q Document
false--10-02Q1202000016816220.010.01150000000150000000383713053849434938371305384943490.010.012000000020000000000.0750.0537.6022.6337.6022.6337.6022.6337.1022.8422.8422.84 0001681622 2019-09-28 2020-01-03 0001681622 2020-02-11 0001681622 2018-09-29 2018-12-28 0001681622 2020-01-03 0001681622 2019-09-27 0001681622 2018-09-28 0001681622 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 0001681622 us-gaap:ParentMember 2018-12-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2018-12-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 2018-12-28 0001681622 us-gaap:ParentMember 2018-09-29 2018-12-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 2018-12-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 2018-12-28 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-29 2018-12-28 0001681622 2018-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-09-29 2018-12-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-12-28 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-28 2020-01-03 0001681622 us-gaap:CommonStockMember 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-28 2020-01-03 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:RetainedEarningsMember 2019-09-28 0001681622 2019-09-28 0001681622 us-gaap:RetainedEarningsMember 2020-01-03 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-28 2020-01-03 0001681622 us-gaap:AdditionalPaidInCapitalMember 2020-01-03 0001681622 us-gaap:RetainedEarningsMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2020-01-03 0001681622 us-gaap:NoncontrollingInterestMember 2020-01-03 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-03 0001681622 us-gaap:RetainedEarningsMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2018-12-28 0001681622 srt:MinimumMember 2019-09-28 2020-01-03 0001681622 us-gaap:AccountingStandardsUpdate201602Member 2019-09-28 0001681622 srt:MaximumMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 srt:AsiaPacificMember 2019-09-28 2020-01-03 0001681622 us-gaap:EMEAMember 2018-09-29 2018-12-28 0001681622 srt:AsiaPacificMember 2018-09-29 2018-12-28 0001681622 srt:AmericasMember 2019-09-28 2020-01-03 0001681622 us-gaap:EMEAMember 2019-09-28 2020-01-03 0001681622 srt:AmericasMember 2018-09-29 2018-12-28 0001681622 country:US 2018-09-29 2018-12-28 0001681622 country:US 2019-09-28 2020-01-03 0001681622 2020-01-04 2019-09-27 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:InProcessResearchAndDevelopmentMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 2019-04-29 0001681622 var:ReliableHealthcareImagingTechnologyMember 2019-09-28 2020-01-03 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2020-01-03 0001681622 var:VECImagingGmbHCo.KGMember 2020-01-03 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-30 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2013-10-01 2013-10-31 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-29 2018-12-28 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-01 2020-01-03 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-28 2020-01-03 0001681622 var:DpiXHoldingMember srt:ScenarioForecastMember var:FixedCostCommitmentsMember us-gaap:EquityMethodInvesteeMember 2020-01-01 2020-12-31 0001681622 var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember srt:ScenarioForecastMember 2020-02-18 2020-02-18 0001681622 srt:MinimumMember var:SantaClaraFacilityRelocationMember 2020-01-03 0001681622 var:SantaClaraFacilityRelocationMember 2019-09-28 2020-01-03 0001681622 var:SantaClaraFacilityRelocationMember 2018-09-29 2018-12-28 0001681622 srt:MaximumMember var:SantaClaraFacilityRelocationMember 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2018-12-28 0001681622 us-gaap:CrossCurrencyInterestRateContractMember 2019-09-28 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2018-12-28 0001681622 us-gaap:InterestRateSwapMember 2019-09-28 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:CashFlowHedgingMember 2019-09-28 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 us-gaap:FairValueInputsLevel2Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel3Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member 2020-01-03 0001681622 us-gaap:FairValueInputsLevel3Member 2020-01-03 0001681622 us-gaap:FairValueInputsLevel2Member 2020-01-03 0001681622 var:IndustrialMember 2019-09-27 0001681622 var:MedicalMember 2020-01-03 0001681622 var:MedicalMember 2019-09-27 0001681622 var:IndustrialMember 2020-01-03 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2020-01-03 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2020-01-03 0001681622 us-gaap:DevelopedTechnologyRightsMember 2020-01-03 0001681622 us-gaap:DevelopedTechnologyRightsMember 2019-09-27 0001681622 var:OtherDebtMember 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-28 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2019-09-28 2020-01-03 0001681622 var:OtherDebtMember 2019-09-28 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-29 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-27 0001681622 var:OtherDebtMember 2019-09-27 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodOneMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodThreeMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2019-10-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2018-10-03 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:FederalFundsEffectiveSwapRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFiveMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:SecondRevolvingCreditFacilityMember var:DebtInstrumentRepaymentPeriodTwoMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:SecondRevolvingCreditFacilityMember var:DebtInstrumentRepaymentPeriodFourMember 2017-05-01 2017-05-01 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2020-01-03 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2020-01-03 0001681622 var:JointVentureInSaudiArabiaMember 2018-09-28 0001681622 var:DirectConversionABMember 2019-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-28 2020-01-03 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 us-gaap:CostOfSalesMember 2019-09-28 2020-01-03 0001681622 us-gaap:CostOfSalesMember 2018-09-29 2018-12-28 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-09-28 2020-01-03 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-09-29 2018-12-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-29 2018-12-28 0001681622 srt:MaximumMember 2019-09-27 0001681622 srt:MaximumMember 2020-01-03 0001681622 srt:MinimumMember 2020-01-03 0001681622 srt:MinimumMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2018-09-29 2018-12-28 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-28 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-28 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2018-09-29 2018-12-28 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-27 var:derivative iso4217:USD iso4217:USD xbrli:shares xbrli:pure var:member xbrli:shares iso4217:EUR xbrli:shares var:segment


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ____________________________________________________________
FORM 10-Q
 ____________________________________________________________
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended January 3, 2020
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-37860
 ____________________________________________________________ 
logoa34.jpg
VAREX IMAGING CORPORATION
(Exact name of registrant as specified in its charter)
 ____________________________________________________________ 
Delaware
 
 
81-3434516
(State or other jurisdiction of
incorporation or organization)
 
 
(I.R.S. Employer
Identification Number)
 
 
 
 
1678 S. Pioneer Road
Salt Lake City
Utah
84104
(Address of principal executive offices)
(Zip Code)
(801) 972-5000
(Registrant’s telephone number, including area code)
 ____________________________________________________________ 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
VREX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ☒ No   ☐     
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   ☒     No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer
 
☒
 
Accelerated filer
 
☐
 
 
 
 
 
 
 
Non-Accelerated filer
 
☐  
 
Smaller reporting company
 
☐
 
 
 
 
 
 
 
 
 
 
 
Emerging growth company
 
☐
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ☐  No  ☒
As of February 11, 2020, there were 38.5 million shares of the registrant’s common stock outstanding.



VAREX IMAGING CORPORATION
FORM 10-Q for the Quarter Ended January 3, 2020
INDEX
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


1

PART I
FINANCIAL INFORMATION

Item 1. Financial Statements

VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
 

Three Months Ended
(In millions, except per share amounts)
January 3, 2020
 
December 28, 2018
Revenues, net
$
200.1


$
185.7

Cost of revenues
139.0


125.7

Gross margin
61.1


60.0

Operating expenses:





Research and development
21.7


18.8

Selling, general and administrative
34.8


30.8

Total operating expenses
56.5


49.6

Operating earnings
4.6


10.4

Interest expense
(5.4
)

(5.1
)
Other expense, net
(0.4
)

(1.2
)
Interest and other expense, net
(5.8
)

(6.3
)
(Loss) earnings before taxes
(1.2
)

4.1

Taxes on earnings
—


1.1

Net (loss) earnings
(1.2
)

3.0

Less: Net earnings attributable to noncontrolling interests
0.1


—

Net (loss) earnings attributable to Varex
$
(1.3
)

$
3.0

Net (loss) earnings per common share attributable to Varex
 
 
 
Basic
$
(0.03
)
 
$
0.08

Diluted
$
(0.03
)
 
$
0.08

Weighted average common shares outstanding
 
 
 
Basic
38.5

 
38.1

Diluted
38.5

 
38.3

 
See accompanying notes to the condensed consolidated financial statements.

2



VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS
(Unaudited)


Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Net (loss) earnings
$
(1.2
)

$
3.0

Other comprehensive (loss) earnings, net of tax:





Unrealized (loss)/gain on interest rate swap contracts
—

 
(2.3
)
Foreign currency translation adjustments
(0.9
)

—

Other comprehensive (loss) earnings, net of tax
(0.9
)

(2.3
)
Comprehensive (loss) earnings
(2.1
)

0.7

Less: Comprehensive earnings attributable to noncontrolling interests
0.1


—

Comprehensive (loss) earnings attributable to Varex
$
(2.2
)

$
0.7



 See accompanying notes to the condensed consolidated financial statements.


3

VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except share and per share amounts)
January 3, 2020
 
September 27, 2019
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
30.0

 
$
29.9

Accounts receivable, net
122.9

 
141.0

Inventories
269.1

 
248.2

Prepaid expenses and other current assets
18.2

 
19.3

Total current assets
440.2

 
438.4

Property, plant and equipment, net
146.2

 
142.3

Goodwill
290.8

 
290.8

Intangible assets, net
81.8

 
86.3

Investments in privately-held companies
54.9

 
53.6

Operating lease assets
25.1

 
—

Other assets
29.4

 
27.5

Total assets
$
1,068.4

 
$
1,038.9

Liabilities, redeemable noncontrolling interests and equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
73.2

 
$
58.2

Accrued liabilities and other current liabilities
70.9

 
75.7

Current operating lease liabilities
6.7

 
—

Current maturities of long-term debt
30.4

 
30.7

Deferred revenues
9.7

 
10.5

Total current liabilities
190.9

 
175.1

Long-term debt, net
350.9

 
364.4

Deferred tax liabilities
8.9

 
8.2

Operating lease liabilities
19.2

 
—

Other long-term liabilities
36.6

 
32.5

Total liabilities
606.5

 
580.2

Commitments and contingencies


 


Redeemable noncontrolling interests
10.7

 
10.5

Equity:
 
 
 
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued
—

 
—

Common stock, $.01 par value:
 
 
 
Authorized shares - 150,000,000
 
 
 
Shares issued and outstanding - 38,494,349 and 38,371,305 at January 3, 2020 and September 27, 2019, respectively.
0.4

 
0.4

Additional paid-in capital
377.6

 
371.8

Accumulated other comprehensive loss
(2.6
)
 
(1.7
)
Retained earnings
72.5

 
74.4

Total Varex equity
447.9

 
444.9

Noncontrolling interests
3.3

 
3.3

Total equity
451.2

 
448.2

Total liabilities, redeemable noncontrolling interests and equity
$
1,068.4

 
$
1,038.9

See accompanying notes to the condensed consolidated financial statements.

4

VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Cash flows from operating activities:
 
 
 
Net (loss) earnings
$
(1.2
)

$
3.0

Adjustments to reconcile net earnings to net cash provided by operating activities:





Share-based compensation expense
3.2


2.6

Depreciation
5.2


9.8

Amortization of intangible assets
4.5


3.7

Deferred taxes
0.5


(2.5
)
Income from equity method investments
(0.7
)

(0.8
)
Amortization of deferred loan costs
0.6

 
0.6

Other, net
—

 
0.1

Changes in assets and liabilities, net of effects of acquisition:





Accounts receivable
18.5


20.6

Inventories
(21.1
)

(22.0
)
Prepaid expenses and other assets
3.7


3.7

Accounts payable
15.4


(0.5
)
Accrued liabilities and other current and long-term operating liabilities
(4.8
)

3.1

Deferred revenues
(0.8
)

(1.4
)
Net cash provided by operating activities
23.0


20.0

Cash flows from investing activities:





Purchases of property, plant and equipment
(8.1
)

(3.4
)
Acquisitions of businesses, net of cash acquired
(1.2
)

—

Contributions and advances to joint ventures
(1.3
)
 
—

Net cash used in investing activities
(10.6
)
 
(3.4
)
Cash flows from financing activities:





Borrowings under credit agreements
3.0

 
4.0

Repayments of borrowing under credit agreements
(17.8
)
 
(19.0
)
Proceeds from exercise of stock options
1.1

 
—

Proceeds from shares issued under employee stock purchase plan
1.8

 
1.9

Other financing activities
(0.1
)
 
—

Net cash used in financing activities
(12.0
)

(13.1
)
Effects of exchange rate changes on cash and cash equivalents and restricted cash
(0.3
)

(0.4
)
Net increase in cash and cash equivalents and restricted cash
0.1


3.1

Cash and cash equivalents and restricted cash at beginning of period
31.3


53.4

Cash and cash equivalents and restricted cash at end of period
$
31.4


$
56.5

Supplemental cash flow information:
 
 
 
Cash paid for interest
$
5.0

 
$
3.0

Cash paid for income tax
0.5

 
0.6

Supplemental non-cash activities:
 
 
 
Purchases of property, plant and equipment financed through accounts payable
$
0.8

 
$
1.8

See accompanying notes to the condensed consolidated financial statements.

5

VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)

 
Three Months Ended January 3, 2020
 
Common Stock
 
Additional Paid-in Capital
 
Accumulated Other Comprehensive Loss
 
Retained Earnings
 
Total Varex Equity
 
Noncontrolling Interests
 
Total Equity
 
 
 
 
 
 
 
(In millions)
Shares
 
Amount
 
 
 
 
 
 
September 27, 2019
38.4

 
$
0.4

 
$
371.8

 
$
(1.7
)
 
$
74.4

 
$
444.9

 
$
3.3

 
$
448.2

Cumulative effect of accounting changes
—

 
—

 
—

 
—

 
(0.6
)
 
(0.6
)
 
—

 
(0.6
)
Net earnings
—

 
—

 
—

 
—

 
(1.3
)
 
(1.3
)
 
—

 
(1.3
)
Exercise of stock options
—

 
—

 
1.1

 
—

 
—

 
1.1

 
—

 
1.1

Common stock issued under employee stock purchase plan
0.1

 
—

 
1.8

 
—

 
—

 
1.8

 
—

 
1.8

Share-based compensation
—

 
—

 
3.2

 
—

 
—

 
3.2

 
—

 
3.2

Currency translation adjustments
—

 
—

 
—

 
(0.9
)
 
—

 
(0.9
)
 
—

 
(0.9
)
Other
—

 
—

 
(0.3
)
 
—

 
—

 
(0.3
)
 
—

 
(0.3
)
January 3, 2020
38.5

 
$
0.4

 
$
377.6

 
$
(2.6
)
 
$
72.5

 
$
447.9

 
$
3.3

 
$
451.2


 
Three Months Ended December 28, 2018
 
Common Stock
 
Additional Paid-in Capital
 
Accumulated Other Comprehensive Income (Loss)
 
Retained Earnings
 
Total Varex Equity
 
Noncontrolling Interests
 
Total Equity
 
 
 
 
 
 
 
(In millions)
Shares
 
Amount
 
 
 
 
 
 
September 28, 2018
38.0

 
$
0.4

 
$
357.6

 
$
5.8

 
$
62.4

 
$
426.2

 
$
2.1

 
$
428.3

Cumulative effect of accounting change
—

 
—

 
—

 
—

 
(4.1
)
 
(4.1
)
 
—

 
(4.1
)
Net earnings
—

 
—

 
—

 
—

 
3.0

 
3.0

 
(0.2
)
 
2.8

Common stock issued under employee stock purchase plan
0.1

 
—

 
1.9

 
—

 
—

 
1.9

 
—

 
1.9

Share-based compensation
—

 
—

 
2.6

 
—

 
—

 
2.6

 
—

 
2.6

Unrealized loss on interest rate swap contracts, net of tax
—

 
—

 
—

 
(2.3
)
 
—

 
(2.3
)
 
—

 
(2.3
)
December 28, 2018
38.1

 
$
0.4

 
$
362.1

 
$
3.5

 
$
61.3

 
$
427.3

 
$
1.9

 
$
429.2


See accompanying notes to the condensed consolidated financial statements.


6

VAREX IMAGING CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary imaging systems, to independent service companies, distributors and directly to end-users for replacement purposes.
The Company also designs, manufacturers, sells and services industrial products, which include Linatron® X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 and is listed on the NASDAQ Global Select Market under the ticker “VREX.”
Basis of Presentation and Principle of Consolidation
The accompanying condensed consolidated financial statements are unaudited. These condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods.
These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements for the fiscal years ended 2019, 2018 and 2017 included in the Company’s Form 10-K, which was filed with the SEC on December 20, 2019. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2019.
Segment Reporting
The Company has two reportable operating segments, Medical and Industrial, which align with how its Chief Executive Officer, who has been identified as the Company's Chief Operating Decision Maker ("CODM"), views and measures the Company’s business performance. See Note 16, Segment Information, for further information on the Company’s segments.
Fiscal Year
The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2020 is the 53-week period ending October 2, 2020. Fiscal year 2019 was the 52-week period that ended on September 27, 2019.  The fiscal quarters ended January 3, 2020 and December 28, 2018 were 14-week and 13-week periods, respectively.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates

7

include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
Restricted Cash
Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended January 3, 2020
 
Three Months Ended December 28, 2018
 
Beginning of Period
 
End of Period
 
Beginning of Period
 
End of Period
Cash and cash equivalents
$
29.9

 
$
30.0

 
$
51.9

 
$
55.1

Restricted cash
1.4

 
1.4

 
1.5

 
1.4

Cash and cash equivalents and restricted cash as reported per statement of cash flows
$
31.3

 
$
31.4

 
$
53.4

 
$
56.5


Concentration of Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, as follows:
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Canon Medical Systems Corporation
18.8%
 
18.3%

Canon Medical Systems Corporation accounted for 14.5% and 10.1% of the Company’s accounts receivable as of January 3, 2020 and September 27, 2019, respectively.
Loss Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision.
Product Warranty
The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, the Company bases warranty

8

estimates on historical experience for similar products and adds a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
The following table reflects the changes in the Company’s accrued product warranty:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Accrued product warranty, at beginning of period
$
8.1

 
$
7.3

Charged to cost of revenues
4.1

 
2.0

Product warranty expenditures
(3.2
)
 
(2.7
)
Accrued product warranty, at end of period
$
9.0

 
$
6.6


Leases
The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represents the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate ("IBR"). The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases ("Topic 842"), referred to as ASC 842. The purpose of ASC 842 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and is effective for the Company in fiscal year 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases ("Topic 842"): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 28, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840.
Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 28, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Also, the Company applied the hindsight practical expedient. Furthermore, as a lessee the Company elected to combine lease and non-lease components for the majority of its leases, which means that the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. The only asset class that did not combine lease and non-lease components were vehicle leases.
The most significant impact of the standards for the Company relate to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $26.8 million and $0.6 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $27.5 million and $0.6 million, respectively. This includes the recording of the Company’s existing capital leases as finance leases at transition. The cumulative impact of adoption was a $0.3 million decrease to retained earnings. Refer to Note 3, Leases, for a detailed impact of adopting this standard and its impact on the consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional

9

disclosures. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Effective September 28, 2019, the Company adopted ASU 2018-02 and it did not have a material effect on the Company’s financial statements and related disclosures.
Recent Accounting Standards or Updates Not Yet Effective
In December 2019, the FASB issued ASU 2019-12 which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021 and must be applied on a modified retrospective basis. The Company is evaluating the potential impact of this standard to its condensed consolidated financial statements.
2. REVENUE RECOGNITION
The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.
The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
Transaction price and allocation to performance obligations
Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction , to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.
The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.

Contracts and performance obligations

10

The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Revenue recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.
The following table disaggregates the Company’s revenue by geographic region:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Americas
$
70.3

 
$
68.4

EMEA
65.2

 
62.6

APAC
64.6

 
54.7

 
$
200.1

 
$
185.7


Revenue in the United States of America was $68.9 million and $67.2 million for the three months ended January 3, 2020 and December 28, 2018, respectively.
Refer to Note 16, Segment Information, for the disaggregation of the Company’s revenue based on reportable operating segments.
Contract Balances
Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities and other current liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the three months ended January 3, 2020:
(In millions)
Contract Assets
Balance at September 28, 2019
$
23.7

Costs recovered from product returns during the period
(0.8
)
Contract asset from shipments of products, subject to return during the period
1.6

Balance at January 3, 2020
$
24.5


11

(In millions)
Refund Liabilities
Balance at September 28, 2019
$
26.4

Release of refund liability included in beginning of year refund liability
(0.9
)
Additions to refund liabilities
1.7

Balance at January 3, 2020
$
27.2


Remaining Performance Obligations
Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of January 3, 2020, total remaining performance obligations amounted to $268.3 million. The Company expects to recognize the remaining performance obligations over the next 12 months.
Costs to Obtain or Fulfill a Customer Contract
The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
3. LEASES
On September 28, 2019, the Company adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement. The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of one year to approximately five years, some of which may include options to extend the leases for up to six years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, our incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease.

12

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
January 3, 2020
(In millions)
Balance Sheet Location
 
Operating Leases
 
Finance Leases
Assets
 
 
 
 
 
Operating lease right-of-use assets
Operating lease assets
 
$
25.1

 
$
—

Finance lease right-of-use assets
Property, plant and equipment, net
 
$
—

 
$
0.6

Liabilities
 
 
 
 
 
Operating lease liabilities (current)
Current operating lease liabilities
 
$
6.7

 
$
—

Finance lease liabilities (current)
Accrued liabilities and other current liabilities
 
$
—

 
$
0.2

Operating lease liabilities (non-current)
Operating lease liabilities
 
$
19.2

 
$
—

Finance lease liabilities (non-current)
Other long-term liabilities
 
$
—

 
$
0.4

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:
 
January 3, 2020
 
Operating Leases
 
Finance Leases
Weighted average remaining lease term (in years)
5.2

 
3.0

Weighted average discount rate
4.2
%
 
3.8
%

The following table provides information related to the Company’s operating and finance leases:
(In millions)
Three Months Ended January 3, 2020
Total operating lease costs (a)
$
2.1

 
 
Total finance lease costs
$
0.1

 
 
Operating cash flows from operating leases
$
2.0

Financing cash flows from finance leases
0.1

Total cash paid for amounts included in the measurement of lease liabilities
$
2.1

(a) Includes variable and short-term lease expense, which were immaterial for the three months ended January 3, 2020.


13


As of January 3, 2020, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:
(In millions)
 
 
 
Fiscal years:
Operating Leases
 
Finance Leases
2020 remaining
$
5.8

 
$
0.2

2021
6.5

 
0.2

2022
5.6

 
0.1

2023
3.3

 
0.1

2024
2.5

 
—

Thereafter
5.3

 
—

Total future lease payments
$
29.0

 
$
0.6

Less: imputed interest
(3.2
)
 
—

Present value of lease liabilities
25.8

 
0.6



At September 27, 2019, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as follows: $7.5 million, $5.4 million, $4.7 million, $1.8 million, $0.9 million, and $0.2 million, respectively.
4. BUSINESS COMBINATION
On April 29, 2019, Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for $69.5 million in cash, net of cash acquired, the assumption of Direct Conversion's debt of $4.5 million and deferred consideration equal to $9.9 million or 0.3 million shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.

14

The following table summarizes the preliminary purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts receivable
$
2.4

Inventories
5.7

Prepaid expenses and other current assets
0.7

Property, plant, and equipment
0.9

Goodwill
47.2

Intangible assets
32.9

Total assets acquired
$
89.8

Accounts payable
$
(1.0
)
Accrued liabilities and other current liabilities
(1.5
)
Current maturities of long-term debt
(1.0
)
Deferred revenues
(0.9
)
Long-term debt
(3.5
)
Other long-term liabilities
(1.1
)
Total liabilities assumed
$
(9.0
)
Noncontrolling interest
$
(1.4
)
Net assets acquired, less noncontrolling interest
$
79.4

Net cash paid
$
69.5

Deferred consideration
9.9

Total consideration
$
79.4



The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of January 3, 2020, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.
The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated Weighted Average
Useful Life
(In Years)
Backlog
$
0.2

 
1
Trade names
2.5

 
5
Developed technology
18.4

 
10
In-process research and development
2.8

 
indefinite
Customer relationships
9.0

 
10
Total intangible assets acquired
$
32.9

 
 

The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the prior year period.

During the first quarter of fiscal year 2020, the Company made a $1.2 million acquisition to enhance our X-ray tube development and manufacturing operations.

15

5. RELATED PARTY TRANSACTIONS
Investment in Privately-Held Companies
The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a four-member consortium that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.
The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated. During the three months ended January 3, 2020 and December 28, 2018, the Company recorded (loss) and income on the equity investment in dpiX Holding of $0.9 million and $(0.7) million, respectively. Income and loss on the equity investment in dpiX Holding is included in other expense, net in the condensed consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding was $48.5 million and $48.1 million at January 3, 2020 and September 27, 2019, respectively.
During the three months ended January 3, 2020 and December 28, 2018, the Company purchased glass transistor arrays from dpiX totaling $5.9 million and $2.8 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the condensed consolidated balance sheets or cost of revenues in the condensed consolidated statements of earnings.
As of January 3, 2020, and September 27, 2019, the Company had accounts payable to dpiX totaling $3.4 million and $3.6 million, respectively.
In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of January 3, 2020, the Company had no remaining fixed cost commitments related to the agreement remaining for calendar year 2019. In January 2020, the fixed cost commitment was determined and approved by the dpiX board of directors to be $12.7 million for calendar year 2020. The amended agreement will continue unless the ownership structure of dpiX changes as provided in the amended agreement.
The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of $48.5 million and fixed cost commitments.
In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. As of January 3, 2020, the Company has made contributions totaling $4.2 million, and has committed to contribute an additional $1.1 million as milestones are achieved, and to provide certain full-time employees to support prototyping and manufacturing activities in exchange for a 50% interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a 50% interest in VEC. The Company's investment in VEC was $3.0 million and $2.0 million at January 3, 2020 and September 27, 2019, respectively .
6. RESTRUCTURING
In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of September 2020 and all activities related to the closure of the facility to be complete by the end of December 2020. In connection with the relocation of the glass production and site closure the Company recorded $0.8 million and $5.1 million for the three months ended January 3, 2020 and December 28, 2018, respectively. The Company expects to incur an additional $7.3 million to $11.3 million of restructuring charges through December 2020.

16

Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the three months ended January 3, 2020 and December 28, 2018, respectively, which predominately relate to the Company's Medical segment:
 
 
 
Three Months Ended
(In millions)
Location of Restructuring Charges in Consolidated Statements of Earnings
 
January 3, 2020
 
December 28, 2018
Accelerated depreciation
Cost of revenues
 
$
0.3

 
$
4.2

Severance costs
Selling, general and administrative
 
0.5

 
0.9

Total restructuring charges
 
 
$
0.8

 
$
5.1


7. FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Cash Flow Hedges
The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.
As of January 3, 2020, the Company had the following outstanding derivatives designated as hedging instruments:
(In millions, except for number of instruments)
 
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
 
6

 
$
253.1

The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:
 
Amount of Gain (Loss) Recognized in OCI on Derivative
Three months ended
 
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income
 
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income
Three months ended
(In millions)
January 3, 2020
 
December 28, 2018
 
 
January 3, 2020
 
December 28, 2018
Interest Rate Swap Contracts
$
—

 
$
(2.5
)
 
Interest expense
 
$
—

 
$
0.4


The Company expects that approximately $(0.3) million of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.
These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. The following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the

17

accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as cash flow hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Interest rate swap contracts
 
Accrued liabilities and other current liabilities
 
$
(0.3
)
 
$
—

Interest rate swap contracts
 
Other long-term liabilities
 
(0.2
)
 
(0.5
)
 
 
 
 
$
(0.5
)
 
$
(0.5
)

Derivatives Designated as Hedging Instruments - Net Investment Hedges
The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of January 3, 2020, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7

The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain (Loss) Recognized in OCI on Derivative
Three months ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
January 3, 2020
 
December 28, 2018
 
 
January 3, 2020
 
December 28, 2018
Cross Currency Swap Contracts
$
(0.8
)
 
$
—

 
Interest expense
 
$
0.4

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as net investment hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Cross Currency Swap Contracts
 
Other current assets
 
$
1.3

 
$
—

Cross Currency Swap Contracts
 
Other long-term liabilities
 
(2.2
)
 
—

 
 
 
 
$
(0.9
)
 
$
—

Balance Sheet Hedges
The Company’s foreign currency management objective is to mitigate the potential impact of currency fluctuations on the value of its U.S. dollar cash flows and to reduce the variability of certain cash flows at the subsidiary level. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The Company does not and does not intend to use derivative financial instruments for speculative or trading purposes.
The following table shows the notional amounts of outstanding foreign currency contracts as of January 3, 2020:

18

 
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions)
Buy contracts
 
Sell contract
Japanese yen
$
2.3

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.7

 
—

Euro
—

 
(3.4
)
 
$
4.0

 
$
(4.4
)

8. FAIR VALUE
Assets/Liabilities Measured at Fair Value on a Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
 
Fair Value Measurements at January 3, 2020
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
4.7

 
$
—

 
$
4.7

Derivative assets
—

 
1.3

 
—

 
1.3

Total assets measured at fair value
$
—

 
$
6.0

 
$
—

 
$
6.0

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
2.7

 
$
—

 
$
2.7

Deferred consideration
9.7

 
—

 
—

 
9.7

Total liabilities measured at fair value
$
9.7

 
$
2.7

 
$
—

 
$
12.4


As of January 3, 2020, the outstanding borrowings under the Company's credit agreement were $381.3 million, net of deferred loan costs, which approximated its fair value. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during the three months ended January 3, 2020.

19

At September 27, 2019, the Company determined the following levels of inputs at fair value for the following assets or liabilities:
 
Fair Value Measurements at September 27, 2019
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
8.8

 
$
—

 
$
8.8

Total assets measured at fair value
$
—

 
$
8.8

 
$
—

 
$
8.8

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
0.7

 
$
—

 
$
0.7

Deferred Consideration
8.9

 
—

 
—

 
8.9

Total liabilities measured at fair value
$
8.9

 
$
0.7

 
$
—

 
$
9.6


9. INVENTORIES
The following table summarizes the Company’s inventories:
(In millions)
January 3, 2020
 
September 27, 2019
Raw materials and parts
$
184.2


$
160.1

Work-in-process
27.6


27.9

Finished goods
57.3


60.2

Total inventories
$
269.1


$
248.2


10. GOODWILL AND INTANGIBLE ASSETS
The following table reflect goodwill by reportable operating segment:
(In millions)
Medical
 
Industrial
 
Total
Balance at September 27, 2019
$
173.0

 
$
117.8

 
$
290.8

Balance at January 3, 2020
$
173.0

 
$
117.8

 
$
290.8


The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the condensed consolidated balance sheets:
 
January 3, 2020
 
September 27, 2019
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(30.8
)
 
$
43.3

 
$
74.1

 
$
(28.4
)
 
$
45.7

Patents, licenses and other
12.7

 
(8.7
)
 
4.0

 
12.7

 
(8.4
)
 
4.3

Customer contracts and supplier relationship
50.7

 
(19.0
)
 
31.7

 
50.7

 
(17.2
)
 
33.5

Total intangible assets with finite lives
137.5

 
(58.5
)
 
79.0

 
137.5

 
(54.0
)
 
83.5

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
2.8

 
0.0

 
2.8

Total intangible assets
$
140.3

 
$
(58.5
)
 
$
81.8

 
$
140.3

 
$
(54.0
)
 
$
86.3

 
 
 
 
 
 
 
 
 
 
 
 

Amortization expense for intangible assets was $4.5 million and $3.7 million for the three months ended January 3, 2020 and December 28, 2018, respectively.    

20

11. BORROWINGS
The following table summarizes the Company's short-term and long-term debt:
 
January 3, 2020
 
September 27, 2019
 
$ Change
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
 
 
Current maturities of long-term debt
 
 
 
 
 
 
 
 
 
Term facility
$
29.4

 
5.3
%
 
$
29.4

 
5.6
%
 
$
—

Other debt
1.0

 
 
 
1.3

 
 
 
(0.3
)
Total current maturities of long-term debt
$
30.4

 
 
 
$
30.7

 
 
 
$
(0.3
)
 
 
 
 
 
 
 
 
 
 
Non-current maturities of long-term debt:
 
 
 
 
 
 
 
 
 
Revolving credit facility
$
52.0

 
5.3
%
 
$
59.0

 
5.6
%
 
$
(7.0
)
Term facility
301.1

 
5.3
%
 
308.6

 
5.6
%
 
(7.5
)
Other debt
2.6

 
 
 
2.5

 
 
 
0.1

Debt issuance costs
(4.8
)
 
 
 
(5.7
)
 
 
 
0.9

Non-current maturities of long-term debt
350.9

 
 
 
364.4

 
 
 
(13.5
)
Total long-term debt, net
$
381.3

 
 
 
$
395.1

 
 
 
$
(13.8
)

Existing Credit Facility
On May 1, 2017 Varex entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to $200 million with a term of five years, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of $400 million, which is subsequently amended. The Company reduced the Revolving Credit Facility to $150 million on October 3, 2018 and to $125 million on October 1, 2019. At January 3, 2020, the Company had $73.0 million of the Revolving Credit Facility available for borrowings, subject to covenants contained in the Credit Agreement. The Term Facility will be repaid over five years, with 5.0% payable in quarterly installments during each of the first two years of the term thereof, 7.5% payable in quarterly installments during the third and fourth years of the term thereof, and 10% payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.
The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of January 3, 2020.
The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus 0.50% or the LIBOR rate for a one-month period plus 1.00%). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between 1.75% and 2.75% (for LIBOR rate loans) and 0.75%-1.75% (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of 0.125%, and a fee on unused commitments which ranges from 0.25% to 0.40%.     
12. REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
In April 2019, a subsidiary of Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.

21

In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.
In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015; and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity.
At January 3, 2020, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.
Changes in redeemable noncontrolling interests were as follows:
(In millions)
Redeemable Noncontrolling Interests
 
Noncontrolling Interest
Balance at beginning of period, September 27, 2019
$
10.5

 
$
3.3

Net earnings attributable to noncontrolling interests
0.1

 
—

Other, including foreign currency remeasurement
0.1

 
—

Balance at end of period, January 3, 2020
$
10.7

 
$
3.3


13. NET (LOSS) EARNINGS PER SHARE
Basic net (loss) earnings per common share is computed by dividing the net (loss) earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net (loss) earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
 
Three Months Ended
(In millions, except per share amounts)
January 3, 2020
 
December 28, 2018
Net earnings attributable to Varex
$
(1.3
)
 
$
3.0

Weighted average shares outstanding - basic
38.5

 
38.1

Dilutive effect of potential common shares
—

 
0.2

Weighted average shares outstanding - diluted
38.5

 
38.3

Net earnings per share attributable to Varex - basic
$
(0.03
)
 
$
0.08

Net earnings per share attributable to Varex - diluted
$
(0.03
)
 
$
0.08

Anti-dilutive shared based awards, excluded
1.7

 
2.1


The Company excludes potentially dilutive common shares (consisting of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to (loss) earnings per share. Because the Company incurred a net loss for the three months ended January 3, 2020, none of the potentially dilutive common shares were included in the diluted share calculation for that period as they would have been anti-dilutive.

22

14. EMPLOYEE STOCK PLANS
Share-Based Compensation Expense
Share-based compensation expense recognized in the condensed consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.
The table below summarizes the effect of recording the share-based compensation expense (which includes the option component of the employee stock purchase plan shares):
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Cost of revenues
$
0.3

 
$
0.3

Research and development
0.6

 
0.5

Selling, general and administrative 
2.3

 
1.8

Total share-based compensation expense
$
3.2

 
$
2.6


Stock Option Activity
The following table summarizes the activity for stock options under Varex’s 2017 Omnibus Stock Plan and 2017 Employee Stock Purchase Plan for the Company’s employees:
 
Options Outstanding
(In thousands, except per share amounts and the remaining term)
Options
 
Price Range
 
Weighted Average Exercise Price
 
Weighted Average Remaining Term (in years)
 
Aggregate Intrinsic Value(1)
Outstanding at September 27, 2019
2,269

 
$22.63 - $37.60

 
$
30.60

 
 
 
 
Granted
—

 
—

 
—

 
 
 
 
Canceled, expired or forfeited
(19
)
 
$22.84 - $37.10

 
30.99

 
 
 
 
Exercised
(49
)
 
$22.84 - $22.84

 
22.84

 
 
 
 
Outstanding at January 3, 2020
2,201

 
$22.63 - $37.60

 
$
30.77

 
3.92
 
$
1,735.0

 
 
 
 
 
 
 
 
 
 
Exercisable at January 3, 2020
1,500

 
$22.63 - $37.60

 
$
30.04

 
3.34
 
$
1,735.0

(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $30.00 as of January 3, 2020, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
Restricted Stock Units
The following table summarizes the activity for restricted stock units under Varex’s 2017 Omnibus Stock Plan for the Company’s employees:
(In thousands, except per share amounts)
Number of Shares

Weighted Average Grant-Date Fair Value
Balance at September 27, 2019
678


$
33.18

Granted
3


26.78

Vested
(2
)

30.21

Canceled or expired
(8
)

33.49

Balance at January 3, 2020
671


$
33.16



23

15. TAXES ON EARNINGS
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Estimated effective tax rate
0.9
%
 
26.8
%

The Company recognized an income tax benefit of $0.0 million and an income tax expense of $1.1 million for the three months ended January 3, 2020 and December 28, 2018, respectively, for effective rates of 0.9% and 26.8%, respectively.
The Company's effective tax rate for the three months ended January 3, 2020, decreased primarily due to losses in certain jurisdictions for which no benefit can be recorded due to full valuation allowance positions and a nearly equivalent overall pre-tax book loss.
As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are indefinitely reinvested outside the U.S. The Company is maintaining this prior assertion for the quarter ended January 3, 2020. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend.
16. SEGMENT INFORMATION
The Company has two reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.
The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.
Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.

24

Information related to the Company’s segments is as follows:

Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Revenues
 
 
 
Medical
$
155.6


$
143.9

Industrial
44.5


41.8

Total revenues
$
200.1


$
185.7

Gross margin
 
 
 
Medical
$
43.8

 
$
45.1

Industrial
17.3

 
14.9

Total gross margin
$
61.1

 
$
60.0

Total operating expenses
56.5

 
49.6

Interest and other income (expenses), net
(5.8
)
 
(6.3
)
Earnings before taxes
(1.2
)
 
4.1

Taxes on earnings
—

 
1.1

Net earnings
(1.2
)
 
3.0

Less: Net earnings attributable to noncontrolling interests
0.1

 
—

Net earnings attributable to Varex
$
(1.3
)
 
$
3.0


The following table summarizes the Company’s total assets by its reportable segments:
(In millions)
January 3, 2020
 
September 27, 2019
Identifiable assets
 
 
 
Medical
$
830.8


$
794.3

Industrial
237.6


244.6

Total reportable segments
$
1,068.4


$
1,038.9



25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of the financial condition and results should be read together with our Annual Report on Form 10-K for the fiscal year ended September 27, 2019.
Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a “safe harbor” for statements about future events, products and future financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of Varex Imaging Corporation (“we,” “our,” “us,” the “Company,” “Varex,” or “Varex Imaging”). The outcome of the events described in these forward-looking statements are subject to risks and uncertainties (including the risks and uncertainties contained in Part II, Item 1A - Risk Factors of this Quarterly Report), and actual results and the outcome or timing of certain events may differ significantly from those projected in these forward-looking statements or management’s current expectations.

Statements concerning: industry or market segment outlook; market acceptance of or transition to new products or technology such as advanced X-ray tube and digital flat panel detector products; growth drivers; future orders, revenues, backlog, earnings or other financial results; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intended,” “potential,” and “possible” or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations.

Any forward-looking statement made in this Quarterly Report (including in any exhibits or documents incorporated by reference) is based only on information currently available to Varex and its management and speaks only as of the date on which it is made. By making forward-looking statements, we have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.
Overview
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, digital detectors, linear accelerators and other image processing solutions, which are key components of X-ray imaging systems. Our components are used in medical imaging as well as in industrial and security imaging applications. Global original equipment manufacturers (“OEM”) incorporate our X‑ray imaging components in their systems to detect, diagnose, protect and inspect. Varex has approximately 2,000 full-time equivalents employees, located at manufacturing and service center sites in North America, Europe, and Asia. 

Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, Russia, the Middle East, India and Africa. APAC includes Asia and Australia. Revenues by region are based on the known final destination of products sold.

Our success depends, among other things, on our ability to anticipate and respond to changes in our markets, the direction of technological innovation and the demands of our customers. We continue to invest in research and development and employ over 500 engineers. Combining this focus on innovation and product performance with strong long-term customer relationships allows us to partner with our customers to bring industry-leading products to the X-ray imaging market. We continue to work to improve the life and quality of our imaging components and leverage our scale as the largest X-ray imaging component supplier to provide cost-effective solutions for our customers. Demand for our products can also be impacted by geo-political factors, including tariffs on key imported materials used in manufacturing our products and on X-ray imaging products we sell to customers outside the United States. Trade conflicts between the United States and China has negatively impacted our business and are expected to continue.
Operating Segments and Products
Our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), evaluates our product groupings and measures our business performance in two reportable operating segments: Medical and Industrial. The segments align our products and service offerings with customer use in medical and industrial markets and are consistent with how the CODM evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin.

26

Medical
In our Medical business segment, we design, manufacture, sell and service X-ray imaging components for use in a range of radiographic or fluoroscopic imaging applications including, computed tomography (“CT”), mammography, oncology, cardiac, surgery, dental, and computer-aided detection. We provide a broad range of X-ray imaging components for Medical customers, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers and buckys.

A significant portion of our revenues come from the sales of high-end X-ray tubes used in CT imaging and high-end dynamic digital detectors used in fluoroscopic and 3D dental imaging applications. These upper-tier imaging components are characterized by increased levels of technological complexity, engineering and intellectual property that typically allow these products to have a higher sales price and gross margin.

The digital detector market has matured from initial product introductions that were made over 15 years ago. For the past few years, we have experienced price erosion for these products, predominantly in the highly-competitive market for radiographic detectors. We anticipate this trend will continue in the foreseeable future.

Our X-ray imaging components are primarily sold to OEM customers that incorporate our products into their X-ray imaging systems for a variety of medical modalities and industrial applications. To a much lesser extent, we also sell our X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.

In China, the government is broadening the availability of healthcare services throughout the country. As a result, the number of diagnostic X-ray imaging systems, including CT, has grown significantly. We are developing CT tubes and related subsystems for Chinese OEMs as they introduce new CT imaging systems in China. Over the long-term, we anticipate that China-based revenues will increase as a percentage of our revenues.

To help mitigate the impact of trade war conflicts between the United States and China, we have implemented changes to secure more non-China sources of supply of parts and materials used to manufacture our X-ray imaging products. We continue to expand manufacturing capabilities at our facilities in China, Germany and the Philippines.

Industrial

In our Industrial business segment, we design, manufacture, sell and service X-ray imaging products for use in a number of markets, including security applications, such as cargo screening at ports and borders and baggage screening at airports, as well as nondestructive testing and inspection applications used in a number of other markets. Our industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors and high voltage connectors. In addition, we provide proprietary image-processing and detection software designed to work with these other Varex products to provide package solutions to our Industrial customers.

The security market primarily consists of airport security for carry-on baggage, checked baggage and palletized cargo, as well as cargo security for the screening of trucks, trains and cargo containers at ports and borders. The-end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there has been significant year-over-year variation in buying patterns.

The non-destructive testing market utilizes X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including the aerospace, automotive, oil and gas, food packaging, metal castings and 3D printing industries. We provide X-ray sources, digital detectors, high voltage connectors and image processing software to OEM customers, system integrators and manufacturers. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging.
Critical Accounting Policies and Estimates
The preparation of our condensed consolidated financial statements and related disclosures in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies that are affected by accounting estimates require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates.

27

We periodically review our accounting policies, estimates and assumptions and make adjustments when facts and circumstances dictate. Refer to our Annual Report on Form 10-K for the fiscal year ended September 27, 2019 filed with the SEC on December 20, 2019 and Note 1 “Summary of Significant Accounting Policies” of the notes to the condensed consolidated financial statements of this report for further details. Our critical accounting policies that are affected by accounting estimates include revenue recognition, impairment of investments, assessment of recoverability of goodwill and intangible assets, valuation of derivative instruments, valuation of warranty obligations, and taxes on earnings. Such accounting policies require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. There have been no material changes to our critical accounting policies, estimates and assumptions or the judgments affecting the application of those estimates and assumptions since the filing of our Annual Report on Form 10-K for year ended September 27, 2019, except for the adoption of Accounting Standards Update No. 2016-02, Leases ("Topic 842"), referred to as ASC 842, effective September 28, 2019.
Fiscal Year
Our fiscal year is a 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2020 is the 53-week period ending October 2, 2020. Fiscal year 2019 was a 52-week period that ended on September 27, 2019. The fiscal quarters ended January 3, 2020 and December 28, 2018 were 14-week and 13-week periods, respectively.
Discussion of Results of Operations for the Three Months Ended January 3, 2020 Compared to the Three Months Ended December 28, 2018
Revenues
 
Three Months Ended
 
 
 
 
(In millions)
January 3, 2020
 
December 28, 2018
 
$ Change
 
% Change
Medical
$
155.6

 
$
143.9

 
$
11.7

 
8.1
%
Industrial
44.5

 
41.8

 
2.7

 
6.5
%
Total revenues
$
200.1

 
$
185.7

 
$
14.4

 
7.8
%
Medical as a percentage of total revenues
77.8
%
 
77.5
%
 
 
 
 
Industrial as a percentage of total revenues
22.2
%
 
22.5
%
 
 
 
 
Medical revenues increased by $11.7 million primarily due to increased sales of CT X-ray tubes and digital detectors and X-ray tubes for oncology applications, partially offset by decreased sales of radiographic digital detectors.
Industrial revenues increased $2.7 million primarily due to increased sales of X-ray tubes for airport security.
Gross Margin
 
Three Months Ended
 
 
 
 
(In millions)
January 3, 2020
 
December 28, 2018
 
$ Change
 
% Change
Medical
$
43.8

 
$
45.1

 
$
(1.3
)
 
(2.9
)%
Industrial
17.3

 
14.9

 
2.4

 
16.1
 %
Total gross margin
$
61.1

 
$
60.0

 
$
1.1

 
1.8
 %
Medical gross margin %
28.1
%
 
31.3
%
 
 
 
 
Industrial gross margin %
38.9
%
 
35.6
%
 
 
 
 
Total gross margin %
30.5
%
 
32.3
%
 
 
 
 
The decrease in total gross margin percentage was due to the decrease in medical gross margin percentage. The decrease in medical gross margin percentage was primarily due to additional reserves for the settlement of a German customs audit, higher warranty and slow-moving inventory reserves and customer price decreases for digital detectors. The industrial gross margin percentage increased due to a favorable mix of higher margin products.

28

Operating Expenses
 
Three Months Ended
 
 
 
 
(In millions)
January 3, 2020
 
December 28, 2018
 
$ Change
 
% Change
Research and development
$
21.7

 
$
18.8

 
$
2.9

 
15.4
%
As a percentage of total revenues
10.8
%
 
10.1
%
 
 
 
 
Selling, general and administrative
$
34.8

 
$
30.8

 
$
4.0

 
13.0
%
As a percentage of total revenues
17.4
%
 
16.6
%
 
 
 
 
Operating expenses
$
56.5

 
$
49.6

 
$
6.9

 
13.9
%
As a percentage of total revenues
28.2
%
 
26.7
%
 
 
 
 
Research and Development
We are committed to investing in the business to support long-term growth and believe long-term research and development expenses of approximately 8% to 10% of annual revenues is the appropriate range that will allow us to innovate and bring new products to market for our global OEM customers. Research and development costs increased to 10.8% of revenues for the first quarter of 2020 due to an additional week of expenses in the quarter and the addition of Direct Conversion.
Selling, General and Administrative
Selling, general and administrative expenses for the first quarter of 2020 increased to 17.4% primarily due to an additional week of expenses in the quarter and higher audit and consulting fees.
Interest and Other Expense, Net
The following table summarizes the Company’s interest and other expense, net:
 
Three Months Ended
 
 
(In millions)
January 3, 2020
 
December 28, 2018
 
$ Change
Interest expense
(5.4
)
 
(5.1
)
 
(0.3
)
Other (expense) income, net
(0.4
)
 
(1.2
)
 
0.8

Interest and other expense, net
$
(5.8
)
 
$
(6.3
)
 
$
0.5

Interest and other expense, net decreased, primarily due to an increase in our income from equity method investments compared to the three months ended December 28, 2018.
Taxes on Earnings
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Estimated effective tax rate
0.9
%
 
26.8
%
We recognized an income tax benefit of $0.0 million and an income tax expense of $1.1 million for the three months ended January 3, 2020 and December 28, 2018, respectively, for effective rates of 0.9% and 26.8%, respectively.
Our effective tax rate for the three months ended January 3, 2020, decreased primarily due to losses in certain jurisdictions for which no benefit can be recorded due to full valuation allowance positions and a nearly equivalent overall pre-tax book loss.
Liquidity and Capital Resources
We assess our liquidity in terms of our ability to generate cash to fund our operating and investing activities. We continue to generate substantial cash from operating activities and believe that our operating cash flow, credit facility, and other sources of liquidity will be sufficient to allow us to continue to invest in our existing businesses, consummate strategic acquisitions and manage our capital structure on a short and long-term basis. Availability under our credit facility was $73.0 million as of January 3, 2020.

29

Cash and Cash Equivalents
The following table summarizes our cash and cash equivalents:
(In millions)
January 3, 2020
 
September 27, 2019
 
$ Change
Cash and cash equivalents
$
30.0

 
$
29.9

 
$
0.1

Borrowings
The following table summarizes the changes in our debt outstanding:
(In millions)
January 3, 2020
 
September 27, 2019
 
$ Change
Current portion of Term Facility
$
29.4

 
$
29.4

 
$
—

Current portion of other long-term debt
1.0

 
1.3

 
(0.3
)
Revolving Credit Facility
52.0

 
59.0

 
(7.0
)
Long-term portion of Term Facility
301.1

 
308.6

 
(7.5
)
Long-term portion of other debt
2.6

 
2.5

 
0.1

Total debt outstanding, gross
386.1

 
400.8

 
(14.7
)
Debt issuance costs
(4.8
)
 
(5.7
)
 
0.9

Total debt outstanding, net
$
381.3

 
$
395.1

 
$
(13.8
)
Cash Flows
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Net cash flow provided by (used in):
 
 
 
Operating activities
$
23.0

 
$
20.0

Investing activities
(10.6
)
 
(3.4
)
Financing activities
(12.0
)
 
(13.1
)
Effects of exchange rate changes on cash and cash equivalents and restricted cash
(0.3
)
 
(0.4
)
Net increase in cash and cash equivalents and restricted cash
$
0.1

 
$
3.1

Net Cash Provided by Operating Activities. Cash from operating activities consists primarily of the net (loss) earnings adjusted for certain non-cash items, including share-based compensation, depreciation, amortization of intangible assets, deferred income taxes, income from equity investments and the effect of changes in operating assets and liabilities.
For the three months ended January 3, 2020, compared to the three months ended December 28, 2018, cash provided by operating activities were as follows:
•
Net (loss) earnings were $(1.2) million compared to $3.0 million
•
Non-cash adjustments to net earnings of $13.3 million compared to $13.5 million
•
Operating assets and liabilities activity:
◦
Accounts receivable decreased by $18.5 million compared to $20.6 million,
◦
Inventories increased by $21.1 million compared to $22.0 million,
◦
Prepaid expenses and other assets decreased by $3.7 million compared to $3.7 million,
◦
Accounts payable increased by $15.4 million compared to a decrease of $0.5 million, and
◦
Accrued liabilities and other current and long-term operating liabilities decreased by $4.8 million compared to an increase of $3.1 million.
Net Cash Used in Investing Activities. Net cash used in investing activities was $10.6 million and $3.4 million for the three months ended January 3, 2020 and December 28, 2018, respectively. The increase in cash used in investing activities was primarily due to an increase in capital expenditures for property plant and equipment during the three months ended January 3, 2020.
Net Cash Used in Financing Activities. Financing activities for the three months ended January 3, 2020 consisted of borrowings under our credit agreement of $3.0 million and repayments of borrowings of $17.8 million. Financing activities for the three months ended December 28, 2018 consisted of borrowings under our credit agreement of $4.0 million, and repayments of borrowings of $19.0 million.

30

Days Sales Outstanding
Trade accounts receivable days sales outstanding (“DSO”) was 55 days at January 3, 2020 and 63 days at September 27, 2019. Our accounts receivable and DSO are impacted by a number of factors, primarily including the timing of product shipments, collections performance, payment terms, the mix of revenues from different regions and the effects of economic instability.
Contractual Obligations
In October 2013, we entered into an amended agreement with dpiX and other parties that, among other things, provides us with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires us to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of January 3, 2020, we had no fixed cost commitments related to this agreement remaining for calendar year 2019. In January 2020, the fixed cost commitment was determined and approved by the dpiX board of directors to be $12.7 million for calendar year 2019. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
In October 2015, we committed to grant the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share; and (2) a put right for their MeVis shares at €19.77 per MeVis share. As of January 3, 2020, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares. See Note 12, “Redeemable Noncontrolling Interests” of the notes to the condensed consolidated financial statements for more information.
Contingencies
From time to time, we are a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits and other loss contingency matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.
Off-Balance Sheet Arrangements
In conjunction with the sale of our products in the ordinary course of business, we provide standard indemnification of business partners and customers for losses suffered or incurred for property damages, death and injury and for patent, copyright or any other intellectual property infringement claims by any third parties with respect to our products. The terms of these indemnification arrangements are generally perpetual. Except for losses related to property damages, the maximum potential amount of future payments we could be required to make under these arrangements is unlimited. As of January 3, 2020, we have not incurred any material costs to defend lawsuits or settle claims related to these indemnification arrangements. As a result, we believe the estimated fair value of these arrangements is minimal.
We have indemnification obligations to our directors and officers and certain of our employees that serve as officers or directors of our foreign subsidiaries that may require us to indemnify our directors and officers and those certain employees against liabilities that may arise by reason of their status or service as directors or officers, and to advance their expenses incurred as a result of any legal proceeding against them as to which they could be indemnified. There is no maximum limit on the indemnification that may be required under these obligations. As of January 3, 2020, we have not incurred any material costs related to these indemnification obligations. As a result, we believe the estimated fair value of these obligations is minimal.
Recent Accounting Standards or Updates Not Yet Effective
See Note 1, “Summary of Significant Accounting Policies” of the notes to the condensed consolidated financial statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risks
We are exposed to four primary types of market risks: foreign currency exchange rate risk, credit and counterparty risk, interest rate risk and commodity price risk.
Foreign Currency Exchange Rate Risk
A significant portion of our customers are outside the United States and our products are generally priced in U.S. Dollars. A strong U.S. Dollar may result in pricing pressure for our customers that are located outside the United States and that conduct their businesses in currencies other than the U.S. Dollar. Such pricing pressure has caused, and could continue to cause, some of our

31

customers to ask for discounted prices, delay purchasing decisions, consider moving to in-sourcing supply of components or migrate to lower cost alternatives. In addition, because our business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact our revenues and expenses and the profitability in U.S. Dollars of products and services that we provide in foreign markets.
We may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, and net investments in foreign subsidiaries. We generally hedge portions of forecasted foreign currency, typically for one month. In addition, we hold a cross-currency swap between the Euro and U.S. Dollar as a net investment hedge of our acquisition of Direct Conversion. Depending on the spot rate between the Euro and U.S. Dollar at the time of settlement and whether we have sufficient Euros available, we may have to borrow incrementally in U.S. Dollars to settle this obligation. However, we may choose not to hedge certain foreign exchange exposures for a variety of reasons including, but not limited to, accounting considerations or the prohibitive economic cost of hedging particular exposures.
Credit and Counterparty Risk
We use a centralized approach to manage substantially all of our cash and to finance our operations. Our cash and cash equivalents may be exposed to a concentration of credit risk and we may also be exposed to credit risk and interest rate risk to the extent that we enter into credit facilities.
We perform ongoing credit evaluations of our customers and we maintain what we believe to be strong credit controls in evaluating and granting customer credit, including performing ongoing evaluations of our customers’ financial condition and creditworthiness and often using letters of credit and requiring industrial customers to provide a down payment.
Interest Rate Risk
At January 3, 2020, we had total borrowings of $381.3 million (net of deferred loan costs). Borrowings under our credit facilities bear interest at floating interest rates. As a result, we are exposed to fluctuations in interest rates to the extent of our borrowings under the credit facilities. As part of our overall risk management program, we entered into several interest rate swaps designed as cash flow hedges, to hedge the floating LIBOR components of our interest rate which represented a notional value of $253.1 million of our debt as of January 3, 2020. See Note 7, “Financial Derivatives and Hedging Activities” for further information on hedging activities. Excluding the amount of our borrowings that is subject to fixed interest rates under our interest rate swaps, and assuming the current level of borrowings remained the same, we estimate that our interest expense would change by approximately $1.3 million annually for each one percentage point change in the average interest rate under our borrowings.
Commodity Price Risk
We are exposed to market risks related to volatility in the prices of raw materials used in our products. The prices of these raw materials fluctuate in response to changes in supply and demand fundamentals and our product margins and level of profitability tend to fluctuate with changes in these raw materials prices. We try to protect against such volatility through various business strategies. During the three months ended January 3, 2020, we did not have any commodity derivative instruments in place to manage our exposure to price changes.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that such information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. The Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO"), with assistance from other members of management, have evaluated the effectiveness of our disclosure controls and procedures as of January 3, 2020 and, based on their evaluation, the CEO and CFO have concluded that the disclosure controls and procedures were not effective as of such date due to the material weaknesses in internal control over financial reporting that were disclosed in our Annual Report on Form 10-K for the fiscal year ended September 27, 2019.

32

Changes in Internal Control Over Financial Reporting
In addition to the implementation of the remediation measures described below, during the quarter ended January 3, 2020, in connection with our adoption of ASU 842, we implemented new controls related to the adoption process, the gathering and validation of our lease population, and the accounting and disclosures for right of use assets and lease liabilities. There were no other changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Remediation
As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended September 27, 2019, we began implementing a remediation plan to address the material weaknesses mentioned above. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

33

PART II
OTHER INFORMATION

Item 1. Legal Proceedings
We are subject to various claims, complaints and legal actions in the normal course of business from time to time. We do not believe we have any currently pending litigation for which the outcome could have a material adverse effect on our operations or financial position.
Item 1A. Risk Factors
The following risk factors and other information included in this quarterly report on Form 10-Q should be carefully considered. Although the risk factors described below are the ones management deems significant, additional risks and uncertainties not presently known to us or that we presently deem less significant may also adversely affect our business operations. If any of the following risks or additional risks and uncertainties actually occur, our business, operating results, and financial condition could be adversely affected.
Varex sells its products and services to a limited number of OEM customers, many of which are also its competitors, and a reduction in or loss of business of one or more of these customers may materially reduce its sales.
Varex had one customer during the three months ended January 3, 2020, that accounted for 19% of its revenue. Varex’s ten largest customers as a group accounted for approximately 53% and 52% of its revenue for the three months ended January 3, 2020 and December 28, 2018, respectively.
Varex sells its products to a limited number of OEM customers, many of which are also its competitors with in-house X-ray component manufacturing operations. Although Varex seeks to broaden its customer base, it will continue to depend on sales to a relatively small number of major customers. Because it often takes significant time to replace lost business, it is likely that Varex’s operating results would be materially and adversely affected if one or more of its major OEM customers were to cancel, delay, or reduce orders in the future.
Furthermore, Varex generates significant accounts receivables from the sale of its products and the provision of services directly to its major customers. If one or more of these customers were to cancel a product order or service contract (whether in accordance with its terms or otherwise), become insolvent or otherwise be unable or fail to pay for Varex products and services, Varex’s operating results and financial condition could be materially and adversely affected.
Varex may not be able to accurately predict the demand for its products by its customers.
End-user product demand, economic uncertainties, natural disasters, and other matters beyond Varex’s control make it difficult for its customers to accurately forecast and plan future business activities; which makes it difficult for Varex to accurately predict the demand for its products. Because the manufacture of our products requires some lead-time, changes in customer purchasing forecasts have previously impacted Varex’s business, resulting in excess inventory and slowdowns in sales. Similar inventory adjustments and slowdowns in sales are likely to occur in the future. Changes to customer forecasts can occur on short notice. Varex’s customers also face inherent competitive issues and new product introduction delays which can result in changes in forecasts. The market and regulatory risks faced by Varex’s customers also ultimately impact Varex’s ability to forecast future business. Varex’s agreements for imaging components, such as its three-year pricing agreement with Canon Medical Systems, may contain purchasing estimates that are based on its customers’ historical purchasing patterns rather than firm commitments, and actual purchasing volumes under the agreements may vary significantly from these estimates. The variation from forecasted purchasing volume may be due, in part, to the increasing life of X-ray tubes, which can result in reduced demand for replacement X-ray tubes in ways Varex may not be able to accurately forecast. Reductions in purchasing patterns have in the past and may in the future materially and adversely affect Varex’s operating results.
Varex competes in highly competitive markets, and it may lose business to its customers or other companies with greater resources or the ability to develop more effective technologies, or it could be forced to reduce its prices.
Rapidly-evolving technology, intense competition and pricing pressure characterize the market in which Varex competes. Varex often competes with companies that have greater financial, marketing and other resources than Varex. Some of the major

34

diagnostic imaging systems companies, which are the primary OEM customers for Varex’s X-ray components, also manufacture X-ray components, including X-ray tubes, for use in their own imaging systems products. Varex must compete with these in-house manufacturing operations for business. If these customers manufacture a greater percentage of their components in-house or otherwise decrease purchases from external sources, which may occur for a number of reasons, including a strong U.S. Dollar, or a general economic slowdown, Varex could experience reductions in purchasing volume by, or loss of, one or more of these customers. Such a reduction or loss may have a material and adverse effect on its business. In addition, Varex competes against other stand-alone, independent X-ray tube manufacturers for both the OEM business of major diagnostic imaging equipment manufacturers and the independent servicing business for X-ray tubes.
The market for flat panel detectors is also very competitive, and Varex faces intense competition from over a dozen smaller competitors. As a result of these competitive dynamics, to effectively retain the business of its customers and compete with its competitors Varex must have an advantage in one or more significant areas, such as lower product cost, better product quality and/or superior technology and/or performance. Varex has made price concessions to maintain existing customers and attract new customers, and may have to make additional price concessions in the future.
In its industrial segment, Varex competes with other OEM suppliers, primarily outside of the United States. The market for its X-ray tube and flat panel products used for nondestructive testing in industrial applications is small and highly fragmented. Some of Varex’s competitors outside the United States may have resources and support from their governments that Varex does not, such as preferences for local manufacturers, and may not be subject to the same trade compliance regulations as Varex. Therefore, Varex’s ability to compete in certain high-growth markets may be limited compared to its competitors.
Varex’s competitors could develop technologies and products that are more effective than those Varex currently uses or produces or that could render its products obsolete or noncompetitive. In addition, the timing of Varex’s competitors’ introduction of products into the market could affect the market acceptance and sales of Varex’s products. Some competitors offer specialized products that provide, or may be perceived by customers to provide, an advantage over Varex’s products. Also, some of Varex’s non-U.S. competitors may not be subject to the same standards, regulatory and/or other legal requirements to which Varex is subject and, therefore, they could have a competitive advantage in developing, manufacturing and marketing products and services. Any inability to develop, gain regulatory approval for and supply commercial quantities of competitive products to the market as quickly and effectively as Varex’s competitors could limit market acceptance of Varex’s products and reduce its sales. Any of these competitive factors could negatively and materially affect Varex’s pricing, sales, revenues, market share and gross margins and its ability to maintain or increase its operating margins.
Changes in import/export regulatory regimes and tariffs could continue to negatively impact our business.
Tariffs and changes in international trade agreements or trade-related laws and regulations may have an indirect adverse impact on our business. As a component manufacturer, our products are integrated into the systems and products of our OEM customers. If the United States, China or other countries levy tariffs, duties or other additional taxes or restrictions on our customer’s products, the demand for such products, and our components included in such products, could decrease, which could have a material adverse effect on our business. Uncertainty over tariffs and trade wars could also cause our customers to delay or cancel orders for our products.
In 2018 and 2019, the United States has imposed tariffs on items imported from China that are incorporated into our products. Tariffs on items imported by us from China and other countries have increased our costs and has increased prices and lowered gross margins on some of our products. These tariffs have had a direct adverse impact on our business and results of operations, and future tariffs could have a more significant impact on our business. China has imposed retaliatory tariffs that impact a number of Varex products including U.S. origin X-ray tubes, heat exchange units, and certain flat panel detectors. The tariffs levied by China have increased our customers’ costs for products imported into China, which has caused us to make price concessions on some products and has caused some customers to stop purchasing products from us. We expect that tariffs will continue to have a negative effect on our business and results of operations, including the possibility of continued price concessions or loss of business. Tariffs could limit our ability to compete for increased market share in China, which could cause our long-term prospects in China to suffer. The imposition of additional tariffs by the United States could result in the adoption of additional tariffs by China and other countries, as well as further retaliatory actions by any affected country, which could negatively impact the global market for imaging equipment and could have a significant adverse effect on our business.

35

Varex’s success depends on the successful development, introduction, and commercialization of new generations of products and enhancements to or simplifications of existing product lines.
Rapid change and technological innovation characterize the markets in which Varex operates, particularly with respect to flat panel technology. Varex’s customers use its products in their medical diagnostic, security, and industrial imaging systems, and Varex must continually introduce new products at competitive costs while also improving existing products with higher quality, lower costs, and increased features. To be successful, Varex must anticipate its customers’ needs and demands, as well as potential shifts in market preferences. Varex’s failure to do so has in the past resulted, and may in the future result, in the loss of customers and an adverse impact to its financial performance. With a relatively strong U.S. Dollar, Varex’s ability to meet its customers’ pricing expectations is particularly challenging and may result in erosion of product margin and market share.
Varex has in the past spent, and in the future may need to spend, more time and money than it expects to develop, market and introduce new products or enhancements, and, even if Varex succeeds, Varex may not be able to recover all or a meaningful part of its investment. Once introduced, new products may materially and adversely impact sales of Varex’s existing products or make them less desirable or even obsolete, which could materially and adversely impact Varex’s revenues and operating results. In addition, certain costs, including installation and warranty costs, associated with new products may be proportionately greater than the costs associated with other products and may therefore disproportionately, materially, and adversely affect Varex’s gross and operating margins. If Varex is unable to lower these costs over time, Varex’s operating results could be materially and adversely affected. Some of the electronic components and integrated circuits used in Varex’s flat panel detectors are susceptible to discontinuance and obsolescence risks, which may force Varex to incorporate newer generations of these components, resulting in unplanned additional R&D expenses, delays in the launch of new products, supply disruption, or inventory write downs.
Varex’s ability to successfully develop and introduce new products and product enhancements and simplifications, and the revenues and costs associated with these efforts, are affected by Varex’s ability to, among other things:
properly identify customer needs or long-term customer demands;
prove the feasibility of new products;
•
properly manage and control research and development costs;
•
limit the time required from proof of feasibility to routine production;
•
timely and efficiently comply with internal quality assurance systems and processes;
•
limit the timing and cost of regulatory approvals;
•
accurately predict and control costs associated with inventory overruns caused by the phase-in of new products and the phase-out of old products;
•
price its products competitively and profitably, which can be particularly difficult with a strong U.S. Dollar;
•
manufacture, deliver, and install its products in sufficient volumes on time and accurately predict and control costs associated with manufacturing installation, warranty, and maintenance of the products;
•
appropriately manage its supply chain;
•
manage customer acceptance and payment for products; and
•
anticipate, respond to, and compete successfully with competitors.

Furthermore, as discussed in greater detail elsewhere in this “Risk Factors” section, Varex cannot be sure that it will be able to successfully develop, manufacture, or introduce new products or enhancements, the roll-out of which involves compliance with complex quality assurance processes, including the Quality System Regulation of the U.S. Food and Drug Administration (“FDA”). Failure to complete these processes timely and efficiently could result in delays that could affect Varex’s ability to attract and retain customers or cause customers to delay or cancel orders, which would materially and adversely affect Varex’s revenues and operating results.
More than half of Varex’s revenues are generated from customers located outside the United States, and economic, political, and other risks associated with international sales and operations could materially and adversely affect Varex’s sales or make them less predictable.
Varex conducts business globally. Revenues generated from customers located outside the United States accounted for approximately 66% and 64% of Varex’s total revenues during the three months ended January 3, 2020 and December 28, 2018, respectively. As a result, Varex must provide significant service and support globally. Varex intends to continue to expand its presence in international markets and expects to expend significant resources in doing so. Varex cannot be sure that it will be able to meet its

36

sales, service, and support objectives or obligations in these international markets or recover its investment in these international markets. Varex’s future results could be harmed by a variety of factors, including:
•
currency fluctuations, and in particular the strength of the U.S. Dollar (which is our functional and reporting currency) relative to many currencies, which have and may in the future adversely affect Varex’s financial results and cause some customers to delay purchasing decisions or move to in-sourcing supply or migrate to lower cost alternatives or ask for additional discounts;
•
the longer payment cycles associated with many customers located outside the United States;
•
difficulties in interpreting or enforcing agreements and collecting receivables through many foreign countries’ legal systems;
•
changes in restrictions on trade between the United States and other countries or unstable regional political and economic conditions;
•
changes in the political, regulatory, safety or economic conditions in a country or region
•
the imposition by governments of additional taxes, tariffs, global economic sanctions programs, or other restrictions on foreign trade such as the tariffs recently put into place by both China and the United States;
•
any inability to obtain required export or import licenses or approvals, including the inability to obtain required export licenses during a U.S. government shutdown;
•
natural disasters and pandemics;
•
failure to comply with export laws and requirements, which may result in civil or criminal penalties and restrictions on Varex’s ability to export its products, particularly its industrial linear accelerator products;
•
risks unique to the Chinese market, including import barriers and preferences for local manufacturers;
•
failure to obtain proper business licenses or other documentation or to otherwise comply with local laws and requirements regarding marketing, sales, service, or any other business Varex conducts in a foreign jurisdiction, which may result in civil or criminal penalties and restrictions on its ability to conduct business in that jurisdiction; and
•
difficulties in protecting Varex’s intellectual property in foreign countries.
Although Varex’s sales fluctuate from period to period, in recent years Varex’s international operations have represented a larger share of its business. The more Varex depends on international sales, the more vulnerable Varex becomes to these factors.
A change in the percentage of Varex’s total earnings from international sales or additional changes in tax laws could increase Varex’s effective tax rate.     
Varex’s effective tax rate is impacted by tax laws in both the United States and in foreign countries. Earnings from Varex’s international subsidiaries are generally taxed at rates that differ from U.S. rates. A change in the percentage of Varex’s total earnings from the international subsidiaries, a change in the mix of particular tax jurisdictions between the international subsidiaries, or a change in currency exchange rates could cause Varex’s effective tax rate to increase. The Tax Cuts and Jobs Act of 2017 (“U.S. Tax Reform”) was signed into law on December 22, 2017. Prior to the enactment of U.S. Tax Reform, Varex was not taxed in the United States on certain undistributed earnings of certain foreign subsidiaries. While U.S. Tax Reform imposed a current tax on cumulative undistributed earnings, these earnings could also become subject to incremental foreign withholding or U.S. state taxes should they be actually remitted to the United States, in which case Varex’s financial results could be materially and adversely affected.
The changes included in U.S. Tax Reform are broad, complex, and subject to change and interpretation. Additional statutory changes or interpretive guidance issued by Federal or local authorities could have a material impact on income tax expense, the effective rate, or the value of deferred tax assets and liabilities. In addition, significant judgments and estimates are required to evaluate our tax position and the impact of the new tax law. If these judgments and estimates are incorrect, or if the underlying assumptions are modified by subsequent guidance or are different from what we expect, our tax liability could differ significantly from our current estimates.  Changes in the valuation of Varex’s deferred tax assets or liabilities, additional changes in tax laws or rates, changes in the interpretation of tax laws in other jurisdictions, or other changes beyond Varex’s control could materially and adversely affect its financial position and results of operations.
Varex has entities in certain jurisdictions with cumulative net operating losses for which no income tax benefit can be recorded due to full valuation allowance positions. There could be additional future losses in these and other jurisdictions that would negatively impact Varex's effective tax rate.

37

Our secured revolving credit facility and secured term loan credit facility (collectively the “Credit Facility”) restrict certain activities, and failure to comply with the terms of this facility may have an adverse effect on our business, liquidity and financial position.
Varex is party to a secured revolving credit facility and a secured term loan credit facility, each of which contains restrictive financial covenants, including financial covenants that require Varex to comply with specified financial ratios. If we do not increase our earnings, we are at risk of not being in compliance with certain of our financial covenants, including our consolidated total leverage ratio and our consolidated senior secured leverage ratio. Varex may have to curtail some of its operations to comply with these covenants. In addition, its credit facilities contain other affirmative and negative covenants that could restrict its operating and financing activities. These provisions limit its ability to, among other things, incur future indebtedness, contingent obligations or liens, guarantee indebtedness, make certain investments and capital expenditures, sell stock or assets, pay dividends and consummate certain mergers or acquisitions. Failure to comply with the credit facility requirements, including the requirement to timely deliver financial statements within applicable grace periods, could result in an event of default under our credit facility. Upon an event of default, if the credit facility documents are not amended or the event of default is not waived, the lender could declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. If this happens, Varex may not be able to make those payments or borrow sufficient funds from alternative sources to make those payments. Even if Varex were to obtain additional financing, that financing may be on unfavorable terms.
Varex has significant debt obligations that could adversely affect Varex’s business, profitability and ability to meet its obligations.
As of January 3, 2020, Varex’s total combined indebtedness was approximately $381.3 million (net of deferred loan costs). The borrowings under Varex’s credit facilities bear interest at floating interest rates. As part of its overall risk management practices, Varex entered into financial derivatives, particularly interest rate swaps designed as cash flow hedges, to hedge the floating LIBOR interest rate on $253.1 million of its debt. As a result, Varex will be exposed to fluctuations in interest rates to the extent of the balance of its borrowings under the LIBOR-based portion of its credit facilities.
Varex's debt could potentially have important consequences to Varex and its investors, including:
•
requiring that a portion of Varex’s cash flow from operations be used to make principal and interest payments on this debt, which would reduce cash flow available for other corporate purposes;
•
increasing Varex’s vulnerability to shifts in interest rates and to general adverse economic and industry conditions;
•
limiting Varex’s flexibility in planning for, or reacting to, changes in its business and the industry; and
•
limiting Varex’s ability to borrow additional funds as needed or increasing the costs of any such borrowing.
In addition, Varex’s actual cash requirements in the future may be greater than expected. Varex’s cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and Varex may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance Varex’s debt.
Fulfilling obligations incidental to being a public company place significant demands on Varex’s management, administrative, and operational resources, including accounting and information technology resources.
As a public company, Varex is subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), and is required to prepare its financial statements according to the rules and regulations required by the SEC. The Exchange Act requires that Varex file annual, quarterly, and current reports. Varex’s failure to prepare and disclose this information in a timely manner or to otherwise comply with applicable law could subject it to penalties under federal securities laws, cause it to be out of compliance with applicable stock exchange listing requirements, and expose it to lawsuits and restrict its ability to access financing. For example, as a result of the delayed filing of our Annual Report on Form 10-K, we received a notification letter from Nasdaq advising us that we were not in compliance with Nasdaq listing requirements.  While with the filing of our Form 10-K we regained compliance with the Nasdaq listing requirements, if we had failed to regain compliance in a timely manner, it would have negatively impacted Varex.
Varex must, among other things, establish and maintain effective internal controls and procedures for financial reporting and disclosure purposes. Internal control over financial reporting is complex and may be revised over time to adapt to changes in Varex’s business or changes in applicable accounting rules. As described in the following risk factor, Varex has identified material weaknesses in its internal control over financial reporting. Varex cannot assure that its internal control over financial reporting will be effective in the future or that additional material weaknesses will not be discovered with respect to a prior period for which it had previously believed that internal controls were effective.

38

Matters impacting Varex’s internal controls may cause Varex to be unable to report its financial information on a timely basis or may cause Varex to restate previously-issued financial information, thereby subjecting Varex to adverse regulatory consequences, including sanctions or investigations by the SEC or in respect of violations of applicable stock exchange listing rules. There could also be a negative reaction in the financial markets due to a loss of investor confidence in Varex and the reliability of its financial statements, which could affect Varex’s stock price.
The delayed filing of our Annual Report has made Varex currently ineligible to use a registration statement on Form S-3 to register the offer and sale of securities, which could adversely affect its ability to raise future capital or complete acquisitions.

As a result of the delayed filing of our Annual Report on Form 10-K, Varex will not be eligible to register the offer and sale of our securities using a registration statement on Form S-3 until one year from the date it regained and maintains its status as a current filer. Should Varex wish to register the offer and sale of its securities to the public prior to the time it is eligible to use Form S-3, both the transaction costs and the amount of time required to complete the transaction could increase, making it more difficult to execute any such transaction successfully and potentially harming our financial condition.

Varex identified material weaknesses in its internal control over financial reporting which, if not remediated appropriately or timely, could result in loss of investor confidence and adversely impact our stock price.

As further described in Item 9A in our Annual Report on Form 10-K, for the fiscal year ended September 27, 2019, at the end of each of fiscal year 2019 and 2018, management determined that Varex’s internal control over financial reporting and its disclosure controls and procedures were not effective and that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified material weaknesses within our risk assessment process and control environment. Management also identified business process control deficiencies which resulted in material weaknesses in the business processes for revenue, inventory and financial close. These material weaknesses resulted in immaterial audit adjustments and out of period adjustments to Varex's consolidated financial statements. Until remediated, these material weaknesses could result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected on a timely basis. There can be no assurance that the remedial measures being implemented by Varex's management will be successful. If Varex is unable to remediate the material weaknesses, or is otherwise unable to maintain effective internal control over financial reporting or disclosure controls and procedures, Varex's ability to record, process and report financial information accurately, and to prepare financial statements within required time periods, could be adversely affected, which could subject Varex to litigation or investigations requiring management resources and payment of legal and other expenses, including civil penalties, negatively affect investor confidence in our financial statements and adversely impact our stock price.

Varex may face additional risks from the acquisition or development of new lines of business.
From time to time, Varex may acquire or develop new lines of business. There are substantial risks and uncertainties associated with new lines of business, particularly in instances where the markets are not fully developed. Risks include developing knowledge of and experience in the new business, recruiting market professionals, increasing research and development expenditures, and developing and capitalizing on new relationships with experienced market participants. This may mean significant investment and involvement of Varex’s senior management to acquire or develop, then integrate, the business into its operations. Timelines for integration of new businesses may not be achieved, and price and profitability targets may not prove feasible, as new products can carry lower gross margins than existing products. External factors, such as compliance with regulations, competitive alternatives, and shifting market preferences may also impact whether implementation of a new business will be successful. Failure to manage these risks could have a material and adverse effect on Varex’s business, results of operations, and/or financial condition.
Varex may be unable to complete future acquisitions or realize expected benefits from acquisitions of or investments in new businesses, products, or technologies, which could harm Varex’s business.
Varex’s ability to identify and take advantage of attractive acquisitions or other business development opportunities is an important component in implementing its overall business strategy. Varex must grow its businesses in response to changing technologies, customer demands, and competitive pressures. In some circumstances, Varex may decide to grow its business through the acquisition of complementary businesses, products, or technologies, rather than through internal development; however, there is no guarantee that these acquisitions will be successful or that Varex will realize a return on its investment.
Identifying suitable acquisition candidates can be difficult, time consuming, and costly, and Varex may not be able to identify suitable candidates or successfully complete or finance identified acquisitions, including as a result of failing to obtain regulatory or competition clearances, which could impair Varex’s growth and ability to compete. In addition, completing an acquisition can divert

39

Varex’s management and key personnel from its current business operations, which could harm its business and affect its financial results. Even if Varex completes an acquisition, Varex may not be able to successfully integrate newly-acquired organizations, products, technologies, or employees into its operations or may not fully realize some of the expected synergies.
Integrating an acquisition can also be expensive and time consuming and may strain Varex’s resources. It may cost Varex more to commercialize new products than originally anticipated or cause Varex to increase its expenses related to research and development, either of which could materially and adversely impact its results of operations. In many instances, integrating a new business will also involve implementing or improving internal controls appropriate for a public company into a business that lacks them. It is also possible that an acquisition could increase Varex’s risk of litigation, as a third party may be more likely to assert a legal claim following an acquisition because of perceived deeper pockets or a perceived greater value of a claim. In addition, Varex may be unable to retain the employees of acquired companies or the acquired company’s customers, suppliers, distributors, or other partners for a variety of reasons, including the fact that these entities may be Varex’s competitors or may have close relationships with its competitors.
Further, Varex may find that it needs to restructure or divest acquired businesses or assets of those businesses. Even if it does so, an acquisition may not produce the full efficiencies, growth, or benefits that were expected. If Varex decides to sell assets or a business, it may be difficult to identify buyers or alternative exit strategies on acceptable terms, in a timely manner, or at all, which could delay the accomplishment of its strategic objectives. Varex may be required to dispose of a business at a lower price or on less advantageous terms, or to recognize greater losses than it had anticipated.
If Varex acquires a business, it allocates the total purchase price to the acquired business’ tangible assets and liabilities, identifiable intangible assets, and liabilities based on their fair values as of the date of the acquisition and records the excess of the purchase price over those values as goodwill. If it fails to achieve the anticipated growth from an acquisition, or if it decides to sell assets or a business, it may be required to recognize an impairment loss on the write down of its assets and goodwill, which could materially and adversely affect its financial results. In addition, acquisitions can result in potentially dilutive issuances of equity securities or the incurrence of debt, contingent liabilities or expenses, or other charges, any of which could harm Varex’s business and affect its financial results.
Additionally, Varex participates in joint ventures and has investments in privately-held companies (for example, its 40% ownership in dpiX LLC, its major supplier of its amorphous silicon-based thin film transistor arrays (flat panels used in its digital detectors) that are subject to risk of loss of investment capital. These investments are inherently risky, in some instances because the markets for the technologies or products these companies have under development may never materialize. If these companies do not succeed, Varex could lose some or all of its investment in these companies.
A disruption at Varex’s manufacturing facilities, as well as fluctuating manufacturing costs, could materially and adversely affect its business.
The majority of Varex’s products are manufactured at its facility in Salt Lake City, Utah. Varex’s manufacturing operations are subject to potential power failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment, and natural or other disasters. Loss or damage to its manufacturing facility due to any of these factors or otherwise could materially and adversely affect Varex’s ability to manufacture sufficient quantities of its products or otherwise deliver products to meet customer demand or contractual requirements, which may result in a loss of revenue and other adverse business consequences. Because of the time required to obtain regulatory approval and licensing of a manufacturing facility, Varex may not be available on a timely basis to replace any lost manufacturing capacity. The occurrence of these or any other operational issues at Varex’s manufacturing facilities could have a material and adverse effect on Varex’s business, financial condition, and results of operations.
Some of Varex’s products are manufactured in Wuxi, China; Walluf, Germany; Heerlen and Dinxperlo, the Netherlands; and Calamba City, Philippines, which are subject to similar risks but may also face additional regulatory and political risks, which could impact Varex’s ability to manufacture and ship products in a timely manner or at all. Varex manufactures its security products in Las Vegas, Nevada, and certain flat panels in Santa Clara, California, and these operations are also subject to potential power failures, the breakdown, failure, or substandard performance of equipment, the improper installation or operation of equipment, earthquakes, and other disasters, all of which could materially and adversely affect Varex’s ability to deliver products to meet customer demand. In addition, Varex’s costs associated with manufacturing its products can vary significantly from quarter to quarter, and fluctuations thereof may adversely affect its business, operating results, and/or financial condition.

40

Varex’s results have been and may continue to be affected by continuing worldwide economic instability, including changes in foreign currency exchange rates and fluctuations in the price of crude oil and other commodities.
The global economy has been impacted by a number of economic and political factors. In many markets, these conditions have shrunk capital equipment budgets, slowed decision-making and made it difficult for Varex’s customers and vendors to accurately forecast and plan future business activities. This, in turn, has caused Varex’s customers to be more cautious with, and sometimes freeze, delay, or dramatically reduce purchases and capital project expenditures. Some countries have adopted and may in the future adopt austerity or stimulus programs that could negatively affect Varex’s results from period to period. In addition, actions taken by the current U.S. administration and the pending withdrawal of the United Kingdom from the European Union (“EU”) may also create global economic uncertainty, which may cause our customers to reduce their spending, which, in turn, could adversely affect our business, financial condition, operating results, and cash flows. An uncertain economic environment may also disrupt supply or affect our service business, as customers’ constrained budgets may result in pricing pressure, extended warranty provisions, and even cancellation of service contracts.
In addition, concerns over continued economic instability could make it more difficult for Varex to collect outstanding receivables. A weak or deteriorating healthcare market would inevitably materially and adversely affect Varex’s business, financial conditions, and results of operations.
Because Varex’s products are generally priced in U.S. Dollars, the strengthening of the U.S. Dollar in the last several years has caused, and could continue to cause, some customers to ask for discounts, delay purchasing decisions, or consider moving to in-sourcing such components or migrating to lower cost alternatives. Further, because Varex’s business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact its results by affecting product demand, revenues and expenses, and/or the profitability in U.S. Dollars of products and services that Varex provides in foreign markets.
Changes in monetary or other policies here and abroad, including as a result of economic and/or political instability or in reaction thereto, would also likely affect foreign currency exchange rates. Furthermore, if one or more European countries were to replace the Euro with another currency, Varex’s sales in these countries, or in Europe generally, would likely be materially and adversely affected until stable exchange rates are established.
Additionally, fluctuations in commodities prices could materially and adversely affect Varex’s performance. Rising commodities prices will increase Varex’s costs and those of Varex’s medical OEM customers, which could in turn result in reduced demand for Varex’s products. Further, Varex’s security product revenues from oil-producing countries, in which Varex has a significant customer base, have in the past suffered as a result of volatility in oil prices and remain sensitive to fluctuations in the future.
The loss of a supplier or any inability to obtain supplies of important components could restrict Varex’s ability to manufacture products, cause delays in its ability to deliver products, or significantly increase its costs.
Varex obtains from a limited group of suppliers or from sole-source suppliers some of the components included in its products, such as wave guides for industrial linear accelerators, transistor arrays, cesium iodide coatings and specialized integrated circuits for flat panel detectors, X-ray tube targets, housings, glass frames, high-voltage cable, bearings and various other components. For example, Varex’s major supplier of its amorphous silicon-based thin film transistor arrays (flat panels) used in its digital image detectors is dpiX LLC. Although Varex holds a 40% ownership interest in dpiX, Varex does not have majority voting rights and does not have the power to direct the activities of dpiX. In addition, Varian is Varex’s sole source supplier for a key component in linear accelerators used in Varex’s security and inspection products subsystems, which are specially made for Varex. If current suppliers cease producing these components, there can be no assurance that the components will be available from other suppliers on reasonable terms or at all.
If Varex loses any of these limited- or sole-source suppliers, if their operations are substantially interrupted, or if any of them fail to meet performance or quality specifications or delivery deadlines, Varex may be required to obtain and qualify one or more replacement suppliers. Such an event (1) may then also require Varex to redesign or modify its products to incorporate new parts and/or further require Varex to obtain clearance, qualification, or certification of these products, including by the FDA, or obtain other applicable regulatory approvals in other countries, or (2) could significantly increase costs for the affected products and cause material delays in delivery of those and other related products. In addition, manufacturing capacity limitations of any of Varex’s suppliers or other inability of these suppliers to meet increasing demand or delivery deadlines could limit growth opportunities for the affected product lines and damage customer relationships. Shortage of, and greater demand for, components and subassemblies could also

41

increase manufacturing costs if the supply/demand imbalance increases the price of the components and subassemblies. Any of these events could materially and adversely affect Varex’s business and financial results.
A shortage or change in source of, or increase in price of, raw materials could restrict Varex’s ability to manufacture products, cause delays, or significantly increase its cost of goods.
Varex relies on the supplies of certain raw materials such as tungsten, lead, iridium, and copper for security and inspection products and copper, lead, tungsten, rhenium, molybdenum zirconium, and various high grades of steel alloy for X-ray tubes. Worldwide demand, availability, and pricing of these raw materials have been volatile, and Varex expects that availability and pricing will continue to fluctuate in the future. If supplies are restricted or become unavailable or if prices increase, this could constrain Varex’s manufacturing of affected products, reduce its profit margins, or otherwise materially and adversely affect its business.
Varex is required to disclose (1) the presence in a company’s products of certain metals known as “conflict minerals,” which are metals mined from the Democratic Republic of the Congo and adjoining countries, and (2) procedures regarding a manufacturer’s efforts to identify the sourcing of those minerals from this region. Varex’s complex supply chain may inhibit Varex’s ability to sufficiently verify the origins of the relevant minerals used in its products through the due diligence procedures that it implements, which may harm Varex’s reputation. In addition, Varex may encounter challenges in satisfying customers who require that all of the components of Varex products are certified as conflict-free, which could place Varex at a competitive disadvantage if it is unable to do so. Moreover, complying with these rules requires investigative efforts, which has and will continue to cause Varex to incur associated costs and could materially and adversely affect the sourcing, supply, and pricing of materials used in Varex’s products or result in process or manufacturing modifications, all of which could materially and adversely affect its results of operations.

The trading price of Varex’s common stock may decline or fluctuate significantly and fluctuations in Varex’s operating results, including quarterly revenues, and margins, may cause its stock price to be volatile, which could cause losses for its stockholders.

In the past year, Varex's stock price has ranged from a low of $22.73 to a high of $35.00. Varex cannot guarantee that an active trading market will be sustained for its common stock. Nor can Varex predict the prices at which shares of its common stock may trade. Varex has experienced and expects in the future to experience fluctuations in its operating results, including revenues and margins, from period to period. These fluctuations may cause Varex’s stock price to be volatile, which could cause losses for its stockholders.
Varex’s quarterly and annual operating results, including its revenues and margins, may be affected by a number of other factors, including:
•
the introduction and timing of announcement of new products or product enhancements by Varex and its competitors;
•
change in its or its competitors’ pricing or discount levels;
•
changes in foreign currency exchange rates and other economic uncertainty;
•
changes in import/export regulatory regimes including the imposition of tariffs on our products or those of our customers;
•
changes in the relative portion of its revenues represented by its various products, including the relative mix between higher margin and lower-margin products;
•
the ability to identify and remediate significant deficiencies and material weaknesses in internal controls;
•
changes in the relative portion of its revenues represented by its international region as a whole and by regions within the overall region, as well as by individual countries (notably, those in emerging markets);
•
fluctuation in its effective tax rate, which may or may not be known to Varex in advance;
•
the availability of economic stimulus packages or other government funding, or reductions thereof;
•
disruptions in the supply or changes in the costs of raw materials, labor, product components or transportation services;
•
changes to its organizational structure, which may result in restructuring or other charges;
•
disruptions in its operations, including its ability to manufacture products, caused by events such as earthquakes, fires, floods, terrorist attacks or the outbreak of epidemic diseases;
•
the unfavorable outcome of any litigation or administrative proceeding or inquiry, including governmental audits, as well as ongoing costs associated with legal proceedings and governmental audits; and
•
accounting changes and adoption of new accounting pronouncements.
Because many of Varex’s operating expenses are based on anticipated capacity levels, and a high percentage of these expenses are fixed for the short term, a small variation in the timing of revenue recognition can cause significant variations in operating results from quarter to quarter. If Varex’s gross margins fall below the expectation of securities analysts and investors, the trading price of Varex common stock may decline.

42

Compliance with foreign laws and regulations applicable to the marketing, manufacture, and distribution of Varex’s products may be costly, and failure to comply may result in significant penalties and other harm to Varex’s business.
Regulatory requirements affecting Varex’s operations and sales outside the United States vary from country to country, often differing significantly from those in the United States. In general, outside the United States, some of Varex’s products are regulated as medical devices by foreign governmental agencies similar to the FDA.
For Varex to market its products internationally, Varex must obtain clearances or approvals for products and product modifications. These processes (including, for example, in the EU, the European Economic Area (“EEA”), Switzerland, Brazil, Australia, China, Japan and Canada) can be time consuming, expensive and uncertain, which can delay Varex’s ability to market products in those countries. Delays in the receipt of or failure to receive regulatory approvals, the inclusion of significant limitations on the indicated uses of a product, the loss of previously obtained approvals or failure to comply with existing or future regulatory requirements could restrict or prevent Varex from doing business in a country or subject Varex to a variety of enforcement actions and civil or criminal penalties, which would materially and materially and adversely affect its business. In addition, compliance with changing regulatory schemes, such as what may occur in connection with Brexit, may add additional complexity, cost and delays in marketing or selling Varex’s products. The Brexit process has caused legal uncertainty and will likely lead to divergent national laws and regulations. While the full financial, regulatory and legal effects of Brexit are unknown, if the United Kingdom’s regulatory scheme is materially different from the current EU regulatory process, Varex’s regulatory compliance burden will likely increase.
Within the EU/EEA, Varex must obtain, and in turn affix, a CE mark certification, which is a European marking of conformity that indicates that a product meets the essential requirements of the Medical Device Directive. Compliance with the Medical Device Directive is done through a self-certification process that is then verified by an independent certification body called a “Notified Body,” which is an organization empowered by the legislature to conduct this verification. Once the CE mark is affixed, the Notified Body will regularly audit Varex to ensure that it remains in compliance with the applicable European laws and Medical Device Directive. By affixing the CE mark to its product, Varex is certifying that its products comply with the laws and regulations required by the EU/EEA countries, thereby allowing the free movement of its products within these countries and others that accept CE mark standards. If Varex cannot support its performance claims and demonstrate compliance with the applicable European laws and the Medical Device Directive, Varex would lose its right to affix the CE mark to its products, which would prevent Varex from selling its products within the EU/EEA/Switzerland territory and in other countries that recognize the CE mark. In April 2017, the European Commission adopted two new regulations on medical devices. These new regulations impose stricter requirements for placing medical devices in the EU market, as well as for Notified Bodies. These new regulations have resulted in the limited availability of recognized Notified Bodies, which could delay our ability to obtaining CE marks. Varex may be subject to risks associated with additional testing, modification, certification, or amendment of its existing market authorizations, or Varex may be required to modify products already installed at its customers’ facilities to comply with the official interpretations of these revised regulations.
Varex is also subject to international laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, and manufacturing practices, as well as others. These are often comparable to, if not more stringent than, the equivalent regulations in the United States. Sales overseas are also affected by regulation of matters such as product standards, packaging, labeling, environmental and product recycling requirements, import and export restrictions, tariffs, duties, and taxes.
In addition, Varex is required to timely file various reports with international regulatory authorities similar to the reports it is required to timely file with U.S. regulatory authorities, including reports required by international adverse event reporting regulations. If these reports are not timely filed, regulators may impose sanctions, including temporarily suspending Varex’s market authorizations or CE mark, and sales of its products may suffer.
Further, as Varex enters new businesses or pursues new business opportunities internationally, or as regulatory schemes change, Varex may become subject to additional laws, rules, and regulations. Becoming familiar with and implementing the infrastructure necessary to comply with these laws, rules, and regulations is costly. Additionally, in some countries, Varex relies or may rely in the future on foreign distributors and agents to assist in complying with foreign regulatory requirements, and Varex cannot be sure that they will always do so. The failure of Varex or its agents to comply with these laws, rules, and regulations could delay the introduction of new products, cause reputational harm, or result in investigations, fines, injunctions, civil penalties, criminal prosecution, or an inability to sell Varex’s products in or to import its products into certain countries, which could materially and adversely affect Varex’s business.

43

Compliance with U.S. laws and regulations applicable to the marketing, manufacture, and distribution of Varex’s products may be costly, and failure or delays in obtaining regulatory clearances or approvals or failure to comply with applicable laws and regulations could prevent Varex from distributing its products, require Varex to recall its products, or result in significant penalties or other harm to Varex’s business.
Some of Varex’s products and those of OEMs that incorporate Varex’s products are subject to extensive and rigorous government regulation in the United States. Compliance with these laws and regulations is expensive and time-consuming, and failure to comply with these laws and regulations could materially and adversely affect Varex’s business.
Generally, Varex’s manufacturing operations for medical devices, and those of its third-party manufacturers, are required to comply with the Quality System Regulations (“QSR”) of the FDA, as well as other federal and state regulations for medical devices and radiation-emitting products. The FDA makes announced and unannounced periodic and on-going inspections of medical device manufacturers to determine compliance with QSR and, in connection with these inspections, issues reports known as Form FDA 483 reports when the FDA believes the manufacturer has failed to comply with applicable regulations and/or procedures. If observations from the FDA issued on Form FDA 483 reports are not addressed and/or corrective action is not taken in a timely manner and to the FDA’s satisfaction, the FDA may issue a warning letter and/or proceed directly to other forms of enforcement action. Similarly, if a warning letter were issued, prompt corrective action to come into compliance would be required. Failure to respond in a timely manner to Form FDA 483 observations, a warning letter, or any other notice of noncompliance and to promptly come into compliance could result in the FDA bringing an enforcement action, which could include the total shutdown of Varex’s production facilities, denial of importation rights to the United States for products manufactured in overseas locations, adverse publicity, and criminal and civil fines. The expense and costs of any corrective actions that Varex may take, which may include product recalls, correction and removal of products from customer sites, and/or changes to its product manufacturing and quality systems, could materially and adversely impact Varex’s financial results and may also divert management resources, attention, and time. Additionally, if a warning letter were issued, customers could delay purchasing decisions or cancel orders, and Varex could face increased pressure from its competitors, who could use the warning letter against Varex in competitive sales situations, either of which could materially and adversely affect Varex’s reputation, business, and stock price.
In addition, Varex is required to timely file various reports with the FDA, including reports required by the medical device reporting regulations (“MDRs”), that require Varex report to regulatory authorities if its devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If Varex initiates a correction or removal of a device to reduce a risk to health posed by the device, Varex would be required to submit a publicly-available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall, which could lead to increased scrutiny by the FDA, other international regulatory agencies, and Varex’s customers regarding the quality and safety of Varex’s devices. If these MDRs or correction and removal reports are not filed on a timely basis, regulators may impose sanctions, sales of Varex’s products may suffer, and Varex may be subject to product liability or regulatory enforcement actions, all of which could harm its business.
Government regulation may also cause significant delays or even prevent the marketing and full commercialization of future products or services that Varex may develop and/or may impose costly requirements on Varex’s business. Further, as Varex enters new businesses or pursues new business opportunities, Varex will become subject to additional laws, rules, and regulations, including FDA and foreign rules and regulations. Becoming familiar with and implementing the infrastructure necessary to comply with these laws, rules, and regulations is costly and time consuming. In addition, failure to comply with these laws, rules and regulations could delay the introduction of new products and could materially and adversely affect Varex’s business.
If Varex or any of its suppliers, distributors, agents, or customers fail to comply with FDA, Federal Trade Commission, or other applicable U.S. regulatory requirements or are perceived to have failed to comply with regulations, Varex may face:
•
adverse publicity affecting both Varex and its customers;
•
increased pressures from competitors;
•
investigations by governmental authorities;
•
fines, injunctions, civil penalties, and criminal prosecution;
•
partial suspension or total shutdown of production facilities or the imposition of operating restrictions;
•
increased difficulty in obtaining required clearances or approvals or losses of clearances or approvals already granted;
•
seizures or recalls of Varex products or those of its customers;
•
delays in purchasing decisions by customers or cancellation of existing orders;
•
the inability to sell Varex products; and
•
difficulty in obtaining product liability or operating insurance at a reasonable cost, or at all.

44

Varex is also subject to federal and state laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices, and other matters. Insurance coverage is not commercially available for violations of law, including the fines, penalties, or investigatory costs that Varex may incur as the consequence of regulatory violations. Consequently, Varex does not have insurance that would cover this type of liability.
Varex sells certain X-ray tube products as replacements which are subject to medical device certification and product registration laws and regulations, which vary by country and are subject to change, and Varex may be unable to receive registration approval or renewal of existing registrations if it fails to meet regulatory approval requirements or if the approval process becomes commercially infeasible or impractical.

Varex markets and distributes certain X-ray tubes through distributors and third-party/multi-vendor service organizations that are used as equivalent replacements for specific OEM tubes. Varex is subject to medical device certification and product registration laws, which vary by country and are subject to periodic reviews and changes by regulatory authorities in those countries. For example, to sell X-ray tubes for replacement applications in China, product registrations must be approved by the new National Medical Products Administration (“NMPA”). Varex must comply with the requirements of the NMPA, and Varex may not be able to receive registration approval or renewal of existing registrations if it fails to meet regulatory approval requirements or if the process of gaining approval becomes commercially infeasible or impractical. Certain of these local laws and regulations have the effect of serving as a barrier to trade and can be difficult to navigate predictably.
In addition, certain countries in which Varex products are sold require products to undergo re-registration if the product is altered in any significant way, and it may be determined that the separation of Varex from Varian, including Varex’s new name, will require these products to be re-registered as Varex products, even if they are physically unchanged.
These registration processes can be costly and time consuming, and customers may decide to purchase products from Varex’s competitors that do not have to be involved in a re-registration process. In addition, Varex’s inability to receive or renew product registrations may prevent Varex from marketing and/or distributing those particular products for replacement applications in the specific country.
Existing and future healthcare reforms, including the Affordable Care Act and changes to reimbursement rates, may indirectly have a material adverse effect on Varex’s business and results of operations.
Sales of Varex’s products to OEMs in the medical sector indirectly depend on whether adequate reimbursement is available for its customers’ products from a variety of sources, such as government healthcare insurance programs, including U.S. Medicare and Medicaid programs, foreign government programs, private insurance plans, health maintenance organizations, and preferred provider organizations. Without adequate reimbursement, the demand for Varex’s customers’ products, and therefore indirectly Varex’s products, may be limited.
Healthcare reform proposals and medical cost containment measures in the United States and in many foreign countries could limit the use of both Varex’s and its customers’ products, reduce reimbursement available for such use, further tax the sale or use of Varex’s products, and further increase the administrative and financial burden of compliance. These reforms and measures, including the uncertainty in the medical community regarding their nature and effect, could have a material and adverse effect on Varex’s and its customers’ purchasing decisions regarding its products and treatments and could harm Varex’s business, results of operations, financial condition, and prospects. Varex cannot predict the specific healthcare programs and regulations that will be ultimately implemented by local, regional, and national governments globally. However, any changes that lower reimbursements for Varex’s or its customers’ products and/or procedures using these products, including, for example, existing reimbursement incentives to convert from analog to digital X-ray systems, or changes that reduce medical procedure volumes or increase cost containment pressures on Varex or others in the healthcare sector could materially and adversely affect Varex’s business and results of operations.
Varex is subject to federal, state, and foreign laws governing its business practices which, if violated, could result in substantial penalties. Additionally, challenges to or investigations into Varex’s practices could cause adverse publicity and be costly to respond to and thus could harm its business.
Anti-corruption laws and regulations. Varex is subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, as well as similar laws in foreign countries, such as the U.K. Bribery Act and the Law On the Fundamentals of Health Protection in the Russian Federation. In general, there is a worldwide trend to strengthen anti-corruption laws and their enforcement, and the healthcare industry and medical equipment manufacturers have been particular targets of these investigation and enforcement efforts. Any violation of these laws by Varex or its agents or distributors could create substantial liability for Varex, subject its officers and

45

directors to personal liability, and cause a loss of reputation in the market. Varex operates in many countries, including India and China, where the public sector is perceived as being corrupt. Varex’s strategic business plans include expanding its business in regions and countries that are rated as higher risk for corruption activity by Transparency International e.V., an international non-profit that publishes an annual corruption perception index. Becoming familiar with and implementing the infrastructure necessary to comply with laws, rules, and regulations applicable to new business activities and mitigating and protecting against corruption risks could be costly. Failure by Varex or its agents or distributors to comply with these laws, rules, and regulations could delay its expansion into high-growth markets and could materially and adversely affect its business. Varex will likely do more business, directly and potentially indirectly, in countries where the public sector is perceived to be corrupt. Increased business in higher-risk countries could subject Varex and its officers and directors to increased scrutiny and increased liability from its business operations.
Competition and trade compliance laws. Varex is subject to various competition and trade compliance laws in the jurisdictions where it operates. Regulatory authorities in those jurisdictions may have the power to subject Varex to sanctions and impose changes or conditions in the way Varex conducts its business. An increasing number of jurisdictions provide private rights of action for competitors or consumers to assert claims of anti-competitive conduct and seek damages. Increased government scrutiny of Varex’s actions or enforcement or private rights of action could materially and adversely affect its business or damage its reputation. Varex may be required to conduct internal investigations or face audits or investigations by one or more domestic or foreign government agencies, which could be costly and time consuming and could divert its management and key personnel from its business operations. An adverse outcome under any such investigation or audit could subject Varex to fines and/or or criminal or other penalties, which could materially and adversely affect Varex’s business and financial results. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that Varex may desire to undertake.
Laws and ethical rules governing interactions with healthcare providers. Varex does not generally sell its products directly to healthcare providers, but may occasionally sell its products to healthcare providers through distributors. The U.S. Medicare and Medicaid “anti-kickback” laws, and similar state laws, prohibit payments or other remuneration that is intended to induce hospitals, physicians, or others either to refer patients or to purchase, lease, or order, or to arrange for or recommend the purchase, lease, or order of healthcare products or services for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. These laws affect Varex’s sales, marketing, and other promotional activities by limiting the kinds of financial arrangements Varex may have with hospitals, physicians, or other potential purchasers of its products. They particularly impact how Varex structures its sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants, and other fee-for-service arrangements. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances.
Federal and state “false claims” laws generally prohibit knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government payors that are false or fraudulent, or for items or services that were not provided as claimed. Although Varex does not submit claims directly to payors, manufacturers can be, and have been, held liable under these laws if they are deemed to “cause” the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers or through certain other activities, including promoting products for uses not approved or cleared by the FDA, which is called off-label promotion. Violating “anti-kickback” and “false claims” laws can result in civil and criminal penalties, which can be substantial, as well as potential mandatory or discretionary exclusion from healthcare programs for noncompliance. Even an unsuccessful challenge or investigation into Varex’s practices could cause adverse publicity and be costly to defend and thus could harm its business and results of operations. Additionally, several recently-enacted state and federal laws, including laws in Massachusetts and Vermont, and the federal Physician Payment Sunshine Act, now require, among other things, extensive tracking and maintenance of databases regarding the disclosure of equity ownership and payments to physicians, healthcare providers, and hospitals. These laws may require Varex to implement the necessary and costly infrastructure to track and report certain payments to healthcare providers. Failure to comply with these new tracking and reporting laws could subject Varex to significant civil monetary penalties.
Varex is subject to similar laws in foreign countries where it conducts business. For example, within the EU, the control of unlawful marketing activities is a matter of national law in each of the member states. The member states of the EU closely monitor perceived unlawful marketing activity by companies. Varex could face civil, criminal, and administrative sanctions if any member state determines that Varex has breached its obligations under such state’s national laws. Industry associations also closely monitor the activities of member companies. If these organizations or authorities name Varex as having breached its obligations under their regulations, rules, or standards, its reputation would suffer, and its business and financial condition could be materially and adversely affected.

46

Warranty claims may materially and adversely affect Varex’s business.
Varex could experience an increase in warranty claims as a result of issues with product quality or product failures as a direct result of Varex’s design, manufacturing, or issues in its supply chain. Such an occurrence may damage Varex’s market reputation, cause sales to decline, or require repairs or voluntary remedial measures to enhance customer satisfaction, which could materially and adversely impact Varex’s financial results. Increased warranty claims on any given product could cause Varex to halt production on that product and significantly impair Varex’s liquidity and profitability, and cause reputational harm to Varex. Because some categories of products tend to experience higher numbers of warranty claims than others, a shift in the types of products that Varex’s customers purchase could lead to an increase in warranty claims. If actual levels of warranty claims are greater than the level of claims Varex estimates, cost of sales could increase, and Varex’s financial condition could be materially and adversely affected. In addition, product quality issues could result in significant follow-on effects for Varex, including, among other things, reputational harm to Varex and its customers, loss of customers, and liability as a result of product quality issues. These outcomes would materially and adversely affect Varex’s business and financial condition.
If Varex is not able to match its manufacturing capacity with demand for its products, its financial results may suffer.
Many of Varex’s products have a long production cycle, and Varex must anticipate demand for its products to ensure adequate manufacturing or testing capacity. If Varex is unable to anticipate demand, and its manufacturing or testing capacity does not keep pace with product demand, Varex will not be able to fulfill orders in a timely manner, which may negatively impact its financial results and overall business. Conversely, if demand for Varex’s products decreases, the fixed costs associated with excess manufacturing capacity may harm its financial results, including by decreasing gross margins and increasing research and development costs as a percentage of revenue.    
Delivery schedules for Varex’s security, industrial, and inspection products tend to be unpredictable.
Varex designs, manufactures, sells, and services Linatron® X-ray accelerators, image-processing software, and image detection products for security and inspection, such as cargo screening at ports and borders and nondestructive examination for a variety of applications, as well as industrial applications. Varex generally sells security and inspection products to OEMs who incorporate its products into their inspection systems, which are then sold to customs and other government agencies, as well as to commercial organizations in the casting, power, aerospace, chemical, petro-chemical, and automotive industries. Varex believes growth in its security and inspection products will be driven by security cargo screening and border protection needs, as well as by the needs of customs agencies to verify shipments for assessing duties and taxes. This business is heavily influenced by domestic and international government policies on border and port security, political change, and government budgets. In addition, Varex believes growth in this product line may be driven in part by industrial customers engaged in 3-D printing, which, as a developing market, may be difficult to predict. Orders for Varex’s security and inspection products have been and may continue to be unpredictable, as governmental agencies may place large orders with Varex or its OEM customers in a short time period and then may not place any orders for a long time period thereafter. Because it is difficult to predict Varex’s OEM customer delivery, the actual timing of sales and revenue recognition varies significantly. The market for border protection systems has slowed significantly, and end customers, particularly in oil-based economies and war zones in which Varex has a significant customer base, are delaying system deployments or tenders and considering moving to alternative sources, resulting in a decline in the demand for security and inspection products.
The demand for Varex’s security and inspection products is heavily influenced by U.S. and foreign governmental policies on national and homeland security, border protection, and customs activities, which depend upon government budgets and appropriations that are subject to economic conditions, as well as political changes and oil prices. Varex has seen customers freeze or dramatically reduce purchases and capital project expenditures, delay projects, or act cautiously as governments around the world wrestle with spending priorities. As economic growth remains sluggish in various jurisdictions and appears to be deteriorating in others, and as concerns about levels of government employment and government debt continue, Varex expects that these effects will also continue. Bid awards in this business may be subject to challenge by third parties, as Varex has previously encountered with a large government project. These factors make this business more unpredictable and could cause volatility in Varex’s revenues and earnings.
Varex’s international manufacturing operations subject it to volatility and other risks, including high security risks, which could result in harm to its employees and contractors or substantial costs.
Varex conducts certain manufacturing operations internationally to reduce costs and streamline its manufacturing operations. There are administrative, legal, and governmental risks to operating internationally that could increase operating expenses or hamper the development of these operations. The risks from operating internationally that could increase Varex’s operating expenses and

47

materially and adversely affect its operating results, financial condition, and ability to deliver its products and grow its business include, among others:
•
difficulties in staffing and managing employee relations and foreign operations, particularly in attracting and retaining personnel qualified to design, sell, test, and support its products;
•
fluctuations in currency exchange rates;
•
difficulties in coordinating its operations globally and in maintaining uniform standards, controls, procedures, and policies across its operations;
•
difficulties in enforcing contracts and protecting intellectual property;
•
diversion of management attention;
•
imposition of burdensome governmental regulations, including changing laws and regulations with respect to collection and maintenance of personally identifiable data;
•
regional and country-specific political and economic instability, as discussed in greater detail below; and
•
inadequacy of the local infrastructure to support its operations.
Varex’s international locations expose it to higher security risks compared to its United States locations, which could result in both harm to its employees and contractors or substantial costs. Some of its services are performed in or adjacent to high-risk locations where the country or location and surrounding area is suffering from political, social, or economic turmoil, war or civil unrest, or has a high level of criminal or terrorist activity. In those locations where Varex has employees or operations, Varex may incur substantial costs to maintain the safety of its personnel. Despite these precautions, the safety of its personnel in these locations may continue to be at risk, and Varex may in the future suffer the loss of employees and contractors, which could harm its business reputation and operating results.
Varex’s competitive position would be harmed if it is not able to maintain its intellectual property rights and protecting Varex’s intellectual property can be costly.

Varex files applications as appropriate for patents covering new products and manufacturing processes. Varex cannot be sure, however, that patents will be issued from any of Varex’s pending or future patent applications. Varex also cannot be sure that its current patents, the claims allowed under its current patents, or patents for technologies licensed to Varex will be sufficiently broad to protect its technology position against competitors. Issued patents owned by, or licensed to, Varex may be challenged, invalidated, or circumvented, or the rights granted under the patents may not provide Varex with competitive advantages. Asserting Varex’s patent rights against others in litigation or other legal proceedings is costly and diverts managerial resources. For example, during fiscal year 2019, Varex initiated litigation asserting claims of patent infringement against a third party. Varex intends to prosecute its claims vigorously, and Varex has experienced, and will continue to experience, increased legal expenses related to this litigation that could adversely affect its financial results. An adverse finding in this or similar patent infringement litigation could adversely impact Varex’s competitive position. In addition, Varex may not be able to detect patent infringement by others or may lose its competitive position in the market before Varex is able to do so.
Varex also relies on a combination of copyright, trade secret, and other laws, and contractual restrictions on disclosure, copying and transferring title (including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants, and other third parties), to protect its proprietary, and other confidential rights. These protections may prove to be inadequate, since agreements may still be breached, and Varex may not have adequate remedies for a breach. Varex’s trade secrets may become known to or be independently developed by others, including as a result of misappropriation by unauthorized access to Varex’s technology systems. If Varex’s proprietary or confidential information is misappropriated, its business and financial results could be materially and adversely impacted. Varex has trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for its products in the marketplace, but unauthorized parties may still use them. Varex also licenses certain patented or proprietary technologies from others. In some cases, products with substantial revenues may depend on these license rights. If Varex were to lose the rights to license these technologies, or its costs to license these technologies were to materially increase, its business would suffer. As Varex expands its manufacturing capabilities outside of the United States, more of Varex’s intellectual property may be held in jurisdictions that do not have robust intellectual property protections, which may make it harder for Varex to adequately protect its Intellectual Property.
Third parties may claim that Varex is infringing upon their intellectual property, and Varex could suffer significant litigation or licensing expenses or be prevented from selling its products.
There is a substantial amount of litigation over patent and other intellectual property rights in the industries in which Varex competes. Varex’s competitors, like companies in many high technology businesses, continually review other companies’ activities for

48

possible conflicts with their own intellectual property rights. In addition, non-practicing entities may review Varex’s activities for conflicts with their patent rights. Determining whether a product infringes on a party’s intellectual property rights involves complex legal and factual issues, and the outcome of this type of litigation is often uncertain. Parties may claim that Varex is infringing upon their intellectual property rights. Varex may not be aware of intellectual property rights of others that relate to its products, services, or technologies. From time to time, Varex has received notices from parties asserting infringement, and Varex has been subject to lawsuits alleging infringement of patent or other intellectual property rights. Any dispute regarding patents or other intellectual property could be costly and time consuming and could divert Varex’s management and key personnel from its business operations. Varex may not prevail in a dispute. Varex does not maintain insurance for intellectual property infringement, so costs of defense, whether or not Varex is successful in defending an infringement claim, will be borne by Varex and could be significant. If Varex is unsuccessful in defending or appealing an infringement claim, Varex may be subject to significant damages, and its combined financial position, results of operations, or cash flows could be materially and adversely affected. Varex may also be subject to injunctions against development and sale of its products, the effect of which could be to materially reduce its revenues. Furthermore, a third party claiming infringement may not be willing to license its rights to Varex, and even if a third-party rights holder is willing to do so, the amounts Varex might be required to pay under the associated royalty or license agreement could be significant. Varex could decide to alter its business strategy or voluntarily cease the allegedly infringing actions rather than face litigation or pay a royalty, which could materially and adversely impact its business and results of operations.
Product defects or misuse may result in material product liability or professional errors and omissions claims, litigation, investigation by regulatory authorities, or product recalls that could harm Varex’s future revenues and require it to pay material uninsured claims.
Varex’s business exposes it to potential product liability claims that are inherent in the manufacture, sale, installation, servicing, and support of components that are used in medical devices and other devices that deliver radiation. Because Varex’s products, through incorporation in OEMs’ systems, are involved in the intentional delivery of radiation to the human body and other situations where people may come into contact with radiation (for example, when Varex’s security and inspection products are being used to scan cargo or in the diagnosis of medical problems), the possibility for significant personal injury or loss of life exists. Although Varex’s products are incorporated into OEMs’ systems, and thus only perform pursuant to the design and operating systems of OEMs, Varex may also be subject to claims for property damage, personal injury, or economic loss related to or resulting from any errors or defects in its products or the installation, servicing, or support of its products. Any accident or mistreatment could subject Varex to legal costs, litigation, adverse publicity, and damage to its reputation, whether or not its products or services were a factor.
If Varex’s X-ray inspection systems fail to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, Varex could be subject to product and other liability claims or negative publicity, which could result in increased costs, reduced sales, and a decline in the market price of Varex’s common stock. There are many factors beyond Varex’s control that could result in the failure of its products to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, including operator error and misuse of or malfunction of Varex equipment. The failure of Varex’s systems to detect the presence of these dangerous materials may lead to personal injury, loss of life, and extensive property damage and may result in potential claims against Varex.
Product liability actions are subject to uncertainty and may be expensive, time consuming, and disruptive to Varex’s operations. For these and other reasons, Varex may choose to settle product liability claims against it regardless of their actual merit. A product liability action determined against Varex could result in adverse publicity or significant damages, including the possibility of punitive damages, and Varex’s combined financial position, results of operations, or cash flows could be materially and adversely affected.
If a product Varex designs or manufactures were defective (whether due to design, labeling or manufacturing defects, improper use of the product, or other reasons), Varex may be required to correct or recall the product and notify regulatory authorities. The adverse publicity resulting from a correction or recall could damage Varex’s reputation and cause customers to review and potentially terminate their relationships with Varex. A product correction or recall could consume management time and have an adverse financial impact on its business, including incurring substantial costs, losing revenues, and accruing losses.
Varex maintains limited product liability insurance coverage. Varex’s product liability insurance policies are expensive and have high deductible amounts and self-insured retentions. Varex’s insurance coverage may prove to be inadequate, and future policies may not be available on acceptable terms or in sufficient amounts, if at all. If a material claim is not insured or is in excess of Varex’s insurance coverage, Varex could have to pay substantial damages, which could have a material and adverse effect on its financial position and/or results of operations.

49

Certain of Varex’s products are subject to regulations relating to use of radioactive material, compliance with which may be costly, and a failure to comply therewith may materially and adversely affect Varex’s business.
As a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, Varex and some of its suppliers and distributors are subject to extensive regulation by United States governmental authorities, such as the FDA, the Nuclear Regulatory Commission (“NRC”), and state and local regulatory agencies, which is intended to ensure the devices are safe and effective and comply with laws governing products which emit, produce, or control radiation. These regulations govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale, and marketing and disposal of Varex’s products. Varex is also subject to international laws and regulations that apply to manufacturers of radiation-emitting devices and products utilizing radioactive materials. These are often comparable to, if not more stringent than, the equivalent regulations in the United States.
Varex’s industrial and medical devices utilizing radioactive material are subject to NRC clearance and approval requirements, and the manufacture and sale of these products are subject to extensive federal and state regulation that varies from state to state and among regions. Varex’s manufacture, distribution, installation, service, and removal of industrial devices utilizing radioactive material or emitting radiation also requires Varex to obtain a number of licenses and certifications for these devices and materials. Service of these products must also be in accordance with a specific radioactive materials licenses. Obtaining licenses and certifications may be time consuming, expensive, and uncertain.
The handling and disposal of radioactive materials resulting from the manufacture, use, or disposal of Varex’s products may impose significant costs and requirements. Disposal sites for the lawful disposal of materials generated by the manufacture, use, or decommissioning of Varex’s products may no longer accept these substances in the future or may accept them on unfavorable terms.
If Varex is unable to obtain required FDA clearances or approvals for a product or is unduly delayed in doing so, or the uses of that product were limited, Varex’s business could suffer.
Typically, Varex’s OEM customers are responsible for obtaining 510(k) pre-market notification clearance on their systems that integrate Varex products. A substantial majority of Varex’s products are “Class I” devices that do not require 510(k) clearance, but Varex does produce software that is classified as a Class II device subject to 510(k) clearance. Unless an exception applies, Varex may be required by FDA regulations to obtain a 510(k) pre-market notification clearance in connection with the manufacture of a new medical device or a new indication for use of, or other significant change in, an existing currently marketed medical device before it can market or sell those products in the United States. Modifications or enhancements to a product that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, labeling, packaging, or manufacturing process also require a new 510(k) clearance. Although manufacturers make the initial determination whether a change to a cleared device requires a new 510(k) clearance, Varex cannot ensure that the FDA will agree with its decisions not to seek additional approvals or clearances for particular modifications to its products or that Varex will be successful in obtaining new 510(k) clearances for modifications. Obtaining clearances or approvals is time consuming, expensive, and uncertain. Varex may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm its business. Furthermore, even if Varex is granted regulatory clearances or approvals, they may include significant limitations on the indicated uses of the product, which may limit the market for the product. If Varex is unable to obtain required FDA clearance or approval for a product or is unduly delayed in doing so, or the uses of that product were limited, Varex’s business could suffer.
Disruption of critical information systems or material breaches in the security of Varex’s systems may materially and adversely affect its business and customer relations.
Information technology (including technology from third party providers) helps Varex operate efficiently, interface with and support its customers, maintain financial accuracy and efficiency, and produce its financial statements. In the ordinary course of its business, Varex collects, processes and stores sensitive data, including intellectual property, proprietary business information and that of customers, suppliers and business partners, third parties accessing its website, patient data and personally identifiable information of customers and employees, in Varex’s data centers, and on its networks, as well as third party off-site infrastructure. Despite security measures, there is an increasing threat of information security attacks, including from computer viruses or other malicious codes, unauthorized access attempts, and cyber-attacks that pose risks to companies, including Varex. Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, have become increasingly sophisticated and generally are not recognized until launched against a target, Varex may be unable to anticipate these techniques or to implement adequate preventative measures, which could result in data leaks or otherwise compromise our confidential or proprietary information and disrupt our operations. If Varex does not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, Varex could be subject to, among other things, transaction errors, processing inefficiencies, the loss of customers,

50

business disruptions, or the loss of or damage to intellectual property through a security breach or misappropriation of intellectual property. Such security breaches could expose Varex to a risk of loss of information, litigation, and possible liability to employees, customers, and/or regulatory authorities. If Varex’s data management systems do not effectively collect, secure, store, process, and report relevant data for the operation of its business, whether due to equipment malfunction or constraints, software deficiencies, or human error, Varex’s ability to effectively plan, forecast, and execute its business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect Varex’s financial condition, results of operations, cash flows, and the timeliness with which Varex reports its operating results internally and externally.
Varex uses certain cloud-based software. A security breach, whether of Varex’s products, of Varex’s customers’ network security and systems, or of third-party hosting services could disrupt access to Varex’s customers’ stored information and could lead to the loss of, damage to or public disclosure of Varex’s customers’ stored information, including patient health information. Such an event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced demand for Varex’s solutions, an unwillingness of its customers to use its solutions, harm to its reputation and brand, and time-consuming and expensive litigation, any of which could have a material and adverse effect on Varex’s financial results.
Unfavorable results of legal proceedings could materially and adversely affect Varex’s financial results.
From time to time, Varex is a party to or otherwise involved in legal proceedings, claims, government inspections, audits or investigations, and other legal matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. Legal proceedings are often lengthy, taking place over a period of years with interim motions or judgments subject to multiple levels of review (such as appeals or rehearings) before the outcome is final. Litigation and other legal proceedings, claims, government inspections, audits and investigations are subject to significant uncertainty and may be expensive, time consuming, and disruptive to Varex’s operations. For these and other reasons, Varex may choose to settle legal proceedings and claims, regardless of their actual merit.
If a legal proceeding were ultimately resolved against Varex, it could result in significant compensatory damages, and, in certain circumstances, punitive damages, disgorgement of revenue or profits, remedial corporate measures, or injunctive relief imposed on Varex. If Varex’s existing insurance does not cover the amount or types of damages awarded, or if other resolution or actions taken as a result of such legal proceeding were to restrain its ability to market one or more of its material products or services, its combined financial position, results of operations, or cash flows could be materially and adversely affected. In addition, legal proceedings, and any adverse resolution thereof, can result in adverse publicity and damage to Varex’s reputation, which could materially and adversely impact its business.
Varex’s business may suffer if it is not able to hire and retain qualified personnel.
Varex’s future success depends, to a great degree, on its ability to retain, attract, expand, integrate, and train its management team and other key personnel, such as qualified engineering, service, sales, marketing, and other staff. Varex competes for key personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions. Because this competition is intense, particularly in Utah, where unemployment rates are relatively low, compensation-related costs could increase significantly if the supply of qualified personnel decreases or demand increases. If Varex is unable to hire and train qualified personnel, Varex may not be able to maintain or expand its business. Additionally, if Varex is unable to retain key personnel, Varex may not be able to replace them readily or on terms that are reasonable, which also could hurt its business.
New accounting pronouncements or changes in interpretation or application of generally accepted accounting principles may materially and adversely affect Varex’s operating results.

VaVarex prepares its financial statements in accordance with GAAP. These principles are subject to interpretation by the FASB, American Institute of Certified Public Accountants, the SEC, and various other regulatory and/or accounting bodies. New accounting pronouncements, or a change in interpretations of, or its application of, existing principles can have a significant effect on Varex’s reported results and may even affect its reporting of transactions completed before a change is announced. In addition, when Varex is required to adopt new accounting standards, Varex’s methods of accounting for certain items may change, which could cause its results of operations to fluctuate from period to period, make it more difficult to compare its financial results to prior periods, and could cause Varex to delay required filings under the Exchange Act, such as the delay that occurred with the filing of this Quarterly Report on Form 10-Q to implement ASC 842.
As its operations evolve over time, Varex may introduce new products and/or new technologies that require Varex to apply different accounting principles, including ones regarding revenue recognition, than Varex has applied in past periods. The application

51

of different types of accounting principles and related potential changes may make it more difficult to compare its financial results from quarter to quarter, and the trading price of Varex common stock could suffer or become more volatile as a result.
Environmental laws impose compliance costs on Varex’s business and may also result in liability.
Varex is subject to environmental laws around the world. These laws regulate many aspects of its operations, including its handling, storage, transport, and disposal of hazardous substances, such as the chemicals and materials that Varex uses in the course of its manufacturing operations. They can also impose cleanup liabilities, including with respect to discontinued operations. As a consequence, Varex can incur significant environmental costs and liabilities, some recurring and others not recurring. Although its follows procedures intended to comply with existing environmental laws, Varex, like other businesses, may mishandle or inadequately manage hazardous substances used in its manufacturing operations and can never completely eliminate the risk of contamination or injury from certain materials that it uses in its business and, therefore, it cannot completely eliminate the prospect of resulting claims and damage payments. Varex may also be assessed fines and/or other penalties for failure to comply with environmental laws and regulations. Insurance has provided coverage for portions of cleanup costs resulting from historical occurrences, but Varex does not expect to maintain insurance coverage for costs or claims that might result from any future contamination.
Future changes in environmental laws could also increase its costs of doing business, perhaps significantly. Several countries, including some in the EU, now require medical equipment manufacturers to bear certain disposal costs of products at the end of the product’s useful life, increasing its costs. The EU has also adopted directives that may lead to restrictions on the use of certain hazardous substances or other regulated substances in some of its products sold there. These directives, along with another that requires substance information to be provided upon request, could increase Varex’s operating costs in order to maintain its access to certain markets. All of these costs, and any future violations or liabilities under environmental laws or regulations, could have a material adverse effect on its business.
Varex’s operations are vulnerable to interruption or loss due to natural or other disasters, power loss, strikes, and other events beyond its control.

Varex conducts some of its activities, including manufacturing, research and development, administration, and data processing at facilities located in areas that have in the past experienced or may in the future experience natural disasters. Varex’s insurance coverage for such disasters may not be adequate or continue to be available at commercially-reasonable terms, or at all. A major disaster (such as a major fire, hurricane, earthquake, flood, tsunami, volcanic eruption or terrorist attack) affecting Varex’s facilities, or those of its suppliers, could significantly disrupt its operations and delay or prevent product manufacture and shipment during the time required to repair, rebuild, or replace its or its suppliers’ damaged manufacturing facilities. These delays could be lengthy and costly. If any of Varex’s customers’ facilities are adversely affected by a disaster, shipments of its products could be delayed. Additionally, customers may delay purchases of Varex’s products until its operations return to normal. For example, following the earthquake and tsunami disasters in Japan in 2011, the operations of Canon Medical Systems, our largest customer, were impacted, and, as a consequence, orders to and product shipment from our business were delayed for several months. Even if Varex's suppliers or customers are able to quickly respond to a disaster, the ongoing effects of the disaster could create some uncertainty in the operations of its business. In addition, Varex’s facilities may be subject to a shortage of available electrical power and other energy supplies. Any shortages may increase its costs for power and energy supplies or could result in blackouts, which could disrupt the operations of its affected facilities and harm its business. Further, Varex’s products are typically shipped from a limited number of ports, and any disaster, strike, or other event blocking shipment from these ports could delay or prevent shipments and harm its business. In addition, concerns about terrorism, the effects of a terrorist attack, political turmoil, or an outbreak of epidemic diseases could have a negative effect on Varex’s business operations, those of its suppliers and customers, and the ability to travel, resulting in adverse consequences on its revenues and financial performance.

Certain provisions in Varex’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, and of Delaware law, may prevent or delay an acquisition of Varex, which could decrease the trading price of Varex’s common stock.
Varex’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws contain, and Delaware law contains, provisions that are intended to deter coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and to encourage prospective acquirers to negotiate with Varex’s board of directors rather than to attempt a hostile takeover. These provisions include, among others:
•
the inability of Varex’s stockholders to call a special meeting;
•
the inability of Varex’s stockholders to act without a meeting of stockholders;
•
rules regarding how stockholders may present proposals or nominate directors for election at stockholder meetings;

52

•
the right of Varex’s board of directors to issue preferred stock without stockholder approval;
•
the division of Varex’s board of directors into three classes of directors, with each class serving a staggered three-year term, and this classified board provision could have the effect of making the replacement of incumbent directors more time-consuming and difficult, until the 2022 annual meeting of stockholders, after which directors will be elected annually;
•
a provision that stockholders may only remove directors with cause while the board is classified;
•
the ability of Varex’s directors, and not stockholders, to fill vacancies on Varex’s board of directors; and,
•
the requirement that the affirmative vote of stockholders holding at least 66 2/3% of Varex’s voting stock is required to amend certain provisions in Varex’s Amended and Restated Certificate of Incorporation (relating to the term and removal of its directors, the filling of its board vacancies, the calling of special meetings of stockholders, stockholder action by written consent, the elimination of liability of directors to the extent permitted by Delaware law and indemnification of directors and officers), although this requirement will expire on the completion of the 2021 annual meeting of stockholders, after which Varex's Amended and Restated Certificate of Incorporation may be amended by the affirmative vote of the holders of at least a majority of the outstanding voting stock.
In addition, because Varex did not elect to be exempt from Section 203 of the Delaware General Corporation Law (the “DGCL”), this provision could also delay or prevent a change of control that stockholders may favor. Section 203 provides that, subject to limited exceptions, persons that acquire, or who are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation (an “interested stockholder”) shall not engage in any business combination with that corporation, including by merger, consolidation, or acquisitions of additional shares, for a three-year period following the date on which the person became an interested stockholder, unless: (1) prior to such time, the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced; or (3) on or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock of such corporation not owned by the interested stockholder.
Varex believes these provisions will protect its stockholders from coercive or otherwise unfair takeover tactics by requiring potential acquirers to negotiate with Varex’s board of directors and by providing Varex’s board of directors with more time to assess any acquisition proposal. These provisions are not intended to make Varex immune from takeovers. However, these provisions will apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that Varex’s board of directors determines is not in the best interests of Varex and Varex’s stockholders. These provisions may also prevent or discourage attempts to remove and replace incumbent directors.
Potential indemnification liabilities to Varian could materially and adversely affect Varex’s business, financial condition, results of operations, and cash flows.
Varex entered into a Separation and Distribution Agreement when it spun off from Varian. The agreement provides for, among other things, indemnification obligations designed to make Varex financially responsible for any Varex liabilities; the failure of Varex to pay, perform, or otherwise promptly discharge any Varex liabilities or contracts in accordance with their respective terms; any guarantee, indemnification obligation, surety bond or other credit support agreement, arrangement, commitment, or understanding by Varian for the benefit of Varex, unless related to Varian liabilities; any breach by Varex of the Separation and Distribution Agreement or any of the ancillary agreements; any action by Varex in contravention of its Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws; and, any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information contained in the Registration Statement on Form 10 (as amended or supplemented) or any other disclosure document that describes the separation, the distribution, Varex and its subsidiaries, or the transactions contemplated by the Separation and Distribution Agreement, subject to certain exceptions. If Varex is required to indemnify Varian under the circumstances set forth in the Separation and Distribution Agreement, Varex may be subject to substantial liabilities.
In connection with Varex’s spin-off from Varian, Varian has agreed to indemnify Varex for certain liabilities. However, there can be no assurance that the indemnity will be sufficient to insure Varex against the full amount of such liabilities or that Varian’s ability to satisfy its indemnification obligation will not be impaired in the future.
Pursuant to the Separation and Distribution Agreement and certain other agreements with Varian, Varian agreed to indemnify Varex for certain liabilities. However, third parties could also seek to hold Varex responsible for any of the liabilities that Varian retained, and there can be no assurance that the indemnity from Varian will be sufficient to protect Varex against the full amount of such liabilities or that Varian will be able to fully satisfy its indemnification obligations. In addition, Varian’s insurers may attempt to

53

deny coverage to Varex for liabilities associated with certain occurrences of indemnified liabilities prior to the separation. Moreover, even if Varex ultimately succeeds in recovering from Varian or such insurance providers any amounts for which Varex is held liable, Varex may be temporarily required to bear these losses. Each of these risks could negatively affect Varex’s business, financial position, results of operations, and/or cash flows.
Potential liabilities may arise due to fraudulent transfer considerations, which could materially and adversely affect Varex’s financial condition and its results of operations.
In connection with the spin-off, Varian completed several corporate restructuring transactions, which, along with the separation and distribution, may be subject to federal and state fraudulent conveyance and transfer laws. If, under these laws, a court were to determine that, at the time of the separation and distribution, any entity involved in these restructuring transactions or the separation and distribution:
•
was insolvent;
•
was rendered insolvent by reason of the separation and distribution;
•
had remaining assets constituting unreasonably small capital; or,
•
intended to incur, or believed it would incur, debts beyond its ability to pay these debts as they matured,
then the court could void the separation and distribution, in whole or in part, as a fraudulent conveyance or transfer. The court could then require Varex’s stockholders to return to Varian some or all of the shares of Varex common stock issued in the distribution or require Varian or Varex, as the case may be, to fund liabilities of the other company for the benefit of creditors. The measure of insolvency will vary depending upon the jurisdiction whose law is being applied. Generally, however, an entity would be considered insolvent if the fair value of its assets was less than the amount of its liabilities or if it incurred debt beyond its ability to repay the debt as it matures.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.


54

Item 6. Exhibits

(a) Exhibits required to be filed by Item 601 of Regulation S-K:
Exhibit
No.
 
Description
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101.INS*
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
104*
 
Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101)
 
 
 
*
 
Filed herewith.

55

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



 
 
 
VAREX IMAGING CORPORATION
 
 
 
 
 
 
 
 
Date:
February 18, 2020
By:
/s/ CLARENCE R. VERHOEF
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President and Chief Financial Officer
 
 
 
(Duly Authorized Officer and Principal Financial Officer)


56
 EX-31.1 2 varexq120exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Sunny S. Sanyal, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Varex Imaging Corporation (the “registrant”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:    
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated:
February 18, 2020
By:
/s/ Sunny S. Sanyal
 
 
 
Sunny S. Sanyal
 
 
 
President, Chief Executive Officer
 
 
 
 



 EX-31.2 3 varexq120exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence R. Verhoef, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Varex Imaging Corporation (the “registrant”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:    
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated:
February 18, 2020
By:
/s/ Clarence R. Verhoef
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President, Chief Financial Officer
 
 
 
 



 EX-32.1 4 varexq120exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varex Imaging Corporation (the “Company”), on Form 10-Q for the quarter ended January 3, 2020 (the “Report”), I, Sunny S. Sanyal, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

1.
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:
February 18, 2020
By:
/s/ Sunny S. Sanyal
 
 
 
Sunny S. Sanyal
 
 
 
President, Chief Executive Officer
 
 
 
 








 EX-32.2 5 varexq120exhibit322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varex Imaging Corporation (the “Company”), on Form 10-Q for the quarter ended January 3, 2020 (the “Report”), I, Clarence R. Verhoef, Senior Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

1.
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:
February 18, 2020
By:
/s/ Clarence R. Verhoef
 
 
 
Clarence R. Verhoef
 
 
 
Senior Vice President, Chief Financial Officer
 
 
 
 



 EX-101.SCH 6 var-20200103.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2111100 - Disclosure - BORROWINGS link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - BORROWINGS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - BORROWINGS - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - BORROWINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - BUSINESS COMBINATION - Intangibles Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - EMPLOYEE STOCK PLANS link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - EMPLOYEE STOCK PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - NET (LOSS) EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - NET (LOSS) EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - RESTRUCTURING link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - RESTRUCTURING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - RESTRUCTURING - Summary of Restructuring Cost Incurred (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - RESTRUCTURING (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - REVENUE RECOGNITION - Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - SEGMENT INFORMATION - Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - TAXES ON EARNINGS link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - TAXES ON EARNINGS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - TAXES ON EARNINGS - Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - TAXES ON EARNINGS (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 var-20200103_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 var-20200103_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 var-20200103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivatives designated as cash flow hedges Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued liabilities and other current liabilities Accrued Liabilities [Member] Other long-term liabilities Other Current Liabilities [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap Contracts Interest Rate Swap [Member] Cross Currency Swap Contracts Cross Currency Interest Rate Contract [Member] Derivative [Line Items] Derivative [Line Items] Derivative assets fair value, gross Derivative Asset, Fair Value, Gross Asset Derivative liabilities fair value, gross Derivative Liability, Fair Value, Gross Liability Derivative assets and liabilities, net Derivative, Fair Value, Net Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Operating lease assets Operating Lease, Right-of-Use Asset Finance lease, right-of-use asset Finance Lease, Right-of-Use Asset Operating lease liability Operating Lease, Liability Present value of lease liabilities Finance Lease, Liability Decrease to retained earnings upon adoption of new accounting guidance Retained Earnings (Accumulated Deficit) Statement of Financial Position [Abstract] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock, par value per share (in USD per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares, issued (in shares) Common Stock, Shares, Issued Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Direct Conversion AB Direct Conversion AB [Member] Direct Conversion AB [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Net cash paid Payments to Acquire Businesses, Gross Debt assumed in acquisition Noncash or Part Noncash Acquisition, Debt Assumed Deferred consideration Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned Deferred consideration, value of common stock (in shares) Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration Restructuring and Related Activities [Abstract] Summary of Restructuring Costs Incurred Restructuring and Related Costs [Table Text Block] Summary of Cash and Cash Equivalents and Restricted Cash Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Summary of Customers with a Significant Portion of Revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Scenario, Forecast Forecast [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Fixed Cost Commitments Fixed Cost Commitments [Member] Fixed Cost Commitments [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] dpiX Holding dpiX Holding [Member] dpiX Holding [Member] VEC Imaging GmbH & Co. KG VEC Imaging GmbH & Co. KG [Member] VEC Imaging GmbH & Co. KG [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Varian Equity Method Investee [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Number of consortium members Equity Method Investments, Number of Full Ownership Members Equity Method Investments, Number of Full Ownership Members (Loss) Income from equity method investments Income (Loss) from Equity Method Investments Equity method investments Equity Method Investments Purchases from related party Related Party Transaction, Purchases from Related Party Accounts payable, related parties Accounts Payable, Related Parties Percentage of manufacturing capacity Percentage Of Manufacturing Capacity The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to. Percentage of fixed costs Percentage Of Fixed Costs The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay. Payments to acquire equity method investments Payments to Acquire Equity Method Investments Earnings Per Share [Abstract] Net earnings attributable to Varex Net Income (Loss) Attributable to Parent Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Dilutive effect of potential common shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Earnings per share, basic (in USD per share) Earnings Per Share, Basic Earnings per share, diluted (in USD per share) Earnings Per Share, Diluted Anti-dilutive employee shared based awards, excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue from Contract with Customer Revenue from Contract with Customer Benchmark [Member] Accounts Receivable Accounts Receivable [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Canon Medical Systems Corporation Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Backlog Order or Production Backlog [Member] Trade names Trade Names [Member] Developed technology Developed Technology Rights [Member] Customer relationships Customer Relationships [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process research and development In Process Research and Development [Member] Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Estimated Weighted Average Useful Life (In Years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Income Tax Disclosure [Abstract] TAXES ON EARNINGS Income Tax Disclosure [Text Block] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenues Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Allocated share-based compensation expense Share-based Payment Arrangement, Expense Leases [Abstract] Operating Leases Operating Leases [Abstract] Operating Leases [Abstract] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Finance Leases Finance Leases [Abstract] Finance Leases [Abstract] Weighted average remaining lease term Finance Lease, Weighted Average Remaining Lease Term Weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Medical Medical [Member] Medical [Member] Industrial Industrial [Member] Industrial [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of reportable operating segments Number of Operating Segments Revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Gross margin Gross Profit Total operating expenses Operating Expenses Interest and other income (expenses), net Nonoperating Income (Expense) Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Taxes on earnings Income Tax Expense (Benefit) Net (loss) earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net (loss) earnings attributable to Varex Noncontrolling Interest [Abstract] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Table Text Block] Statement of Comprehensive Income [Abstract] Net (loss) earnings Other comprehensive (loss) earnings, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized (loss)/gain on interest rate swap contracts Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Unrealized (loss)/gain on interest rate swap contracts Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other comprehensive (loss) earnings, net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive (loss) earnings Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: Comprehensive earnings attributable to noncontrolling interests Comprehensive (loss) earnings attributable to Varex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Interest Rate Derivatives Schedule of Interest Rate Derivatives [Table Text Block] Schedule of Net Investment Hedges Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Number of Instruments Derivative, Number of Instruments Held Notional Value Derivative, Notional Amount FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Total operating lease costs Operating Lease, Cost Total finance lease costs Lease, Cost, Finance Lease Costs Lease, Cost, Finance Lease Costs Operating cash flows from operating leases Operating Lease, Payments Financing cash flows from finance leases Finance Lease, Principal Payments Total cash paid for amounts included in the measurement of lease liabilities Cash Paid For Operating And Finance Leases Cash Paid For Operating And Finance Leases Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Second Revolving Credit Facility [Member] Second Revolving Credit Facility [Member] Second Revolving Credit Facility [Member] Revolving Credit Facility May 2017 Revolving Credit Facility May 2017 [Member] Revolving Credit Facility May 2017 [Member] Debt Repayment Period [Axis] Debt Repayment Period [Axis] Debt Repayment Period [Axis] Debt Repayment Period [Domain] Debt Repayment Period [Domain] [Domain] for Debt Repayment Period [Axis] Debt Instrument, Repayment, Period One Debt Instrument, Repayment, Period One [Member] Debt Instrument, Repayment, Period One [Member] Debt Instrument, Repayment, Period Two Debt Instrument, Repayment, Period Two [Member] Debt Instrument, Repayment, Period Two [Member] Debt Instrument, Repayment, Period Three Debt Instrument, Repayment, Period Three [Member] Debt Instrument, Repayment, Period Three [Member] Debt Instrument, Repayment, Period Four Debt Instrument, Repayment, Period Four [Member] Debt Instrument, Repayment, Period Four [Member] Debt Instrument, Repayment, Period Five Debt Instrument, Repayment, Period Five [Member] Debt Instrument, Repayment, Period Five [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Federal Funds Effective Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Base Rate Base Rate [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Secured Debt Secured Debt [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Debt instrument, term Debt Instrument, Term Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Repayment percentage Debt Instrument, Periodic Payment, Percentage Debt Instrument, Periodic Payment, Percentage Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Used capacity, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Subsequent Events Subsequent Events, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Fiscal Year Fiscal Period, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Loss Contingencies Commitments and Contingencies, Policy [Policy Text Block] Product Warranty Standard Product Warranty, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Change in Contract with Customer, Asset [Abstract] Change in Contract with Customer, Asset [Abstract] Balance at September 28, 2019 Contract with Customer, Asset, after Allowance for Credit Loss Costs recovered from product returns during the period Contract with Customer, Asset, Credit Loss Expense (Reversal) Contract asset from shipments of products, subject to return during the period Contract with Customer, Asset, Shipments Contract with Customer, Asset, Shipments Balance at January 3, 2020 Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Balance at September 28, 2019 Contract with Customer, Liability Release of refund liability included in beginning of year refund liability Contract with Customer, Liability, Revenue Recognized Additions to refund liabilities Contract With Customer, Liability, Additions Contract With Customer, Liability, Additions Balance at January 3, 2020 REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Noncontrolling Interest Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares [Rollforward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options, outstanding, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, canceled, forfeited and expired in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Options, exercises in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options, outstanding, ending balance (in shares) Options, exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Price range Exercise Price Range [Abstract] Exercise Price Range [Abstract] Outstanding at period beginning and ending (in USD per share) Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Canceled, expired or forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price Exercisable at January 3, 2020 (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, outstanding, weighted average exercise price, beginning (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, grants in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, canceled, forfeited and expired in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options, exercises in period, weighted average exercise price (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, outstanding, weighted average exercise price, ending (in USD per share) Options, exercisable, weighted average exercise price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options, outstanding, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options, exercisable, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options, outstanding, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Options, exercisable, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share price (in USD per share) Share Price Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Smaller Reporting Company Entity Small Business Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date NET (LOSS) EARNINGS PER SHARE Earnings Per Share [Text Block] Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] FAIR VALUE Fair Value Disclosures [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Reliable Healthcare Imaging Technology Reliable Healthcare Imaging Technology [Member] Reliable Healthcare Imaging Technology [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Other Debt Other Debt [Member] Other Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Current maturities of long-term debt Long-term Debt, Current Maturities [Abstract] Current maturities of long-term debt Long-term Debt, Current Maturities Weighted-Average Interest Rate Short-term Debt, Weighted Average Interest Rate, over Time Change in current portion of Term Facility Proceeds from (Repayments of) Lines of Credit Change in current portion of other long-term debt Proceeds from (Repayments of) Other Debt Change in current maturities of long-term debt Proceeds From (Repayments Of) Long-Term Debt, Current Maturities Proceeds From (Repayments Of) Long-Term Debt, Current Maturities Non-current maturities of long-term debt: Maturities of Long-term Debt [Abstract] Long-term debt excluding current maturities, gross Long-term Debt Excluding Current Maturities, Gross Long-term Debt Excluding Current Maturities, Gross Debt issuance costs Debt Issuance Costs, Net Non-current maturities of long-term debt Long-term Debt, Excluding Current Maturities Weighted-Average Interest Rate Long-term Debt, Weighted Average Interest Rate, over Time Change in revolving credit facility Proceeds From (Repayments Of) Long Term Line Of Credit Proceeds From (Repayments Of) Long Term Line Of Credit Change in long-term portion of other debt Proceeds from (Repayments of) Other Long-term Debt Change in debt issuance costs Amortization Of Debt Issuance Costs And Costs Written Off Due to Reduction Of Available Funds For Revolving Credit Facility Amortization Of Debt Issuance Costs And Costs Written Off Due to Reduction Of Available Funds For Revolving Credit Facility Change in maturities of long-term debt Proceeds From (Repayments Of) Long-Term Debt, Excluding Current Maturities Proceeds From (Repayments Of) Long-Term Debt, Excluding Current Maturities Total debt outstanding, net Long-term Debt Change in total debt outstanding, net Proceeds From (Repayments Of) Debt, Net Of Issuance Costs Proceeds From (Repayments Of) Debt, Net Of Issuance Costs RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Disaggregation of Revenue by Geographic Location Disaggregation of Revenue [Table Text Block] Summary of Contract Asset and Liabilities Contract with Customer, Asset and Liability [Table Text Block] Schedule of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Effective tax rate percent Effective Income Tax Rate Reconciliation, Percent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Acquired existing technology Patents, licenses and other Intellectual Property [Member] Customer contracts and supplier relationship Customer Contracts and Supplier Relationships [Member] Customer Contracts and Supplier Relationships [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total intangible assets with finite lives, net carrying amount Finite-Lived Intangible Assets, Net In-process research and development with indefinite lives Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Amortization of intangible assets Amortization of Intangible Assets Identifiable assets Assets Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Allocation of the purchase consideration: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Goodwill Goodwill Intangible assets Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued liabilities and other current liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities Current maturities of long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Deferred revenues Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Net assets acquired, less noncontrolling interest Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Deferred consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Total consideration Business Combination, Consideration Transferred Inventory Disclosure [Abstract] INVENTORIES Inventory Disclosure [Text Block] BUSINESS COMBINATION Business Combination Disclosure [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Balance at September 27, 2019 Balance at January 3, 2020 Assets Assets [Abstract] Liabilities Liabilities [Abstract] Operating lease liabilities (current) Operating Lease, Liability, Current Finance lease liabilities (current) Finance Lease, Liability, Current Operating lease liabilities (non-current) Operating Lease, Liability, Noncurrent Finance lease liabilities (non-current) Finance Lease, Liability, Noncurrent Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Americas Americas [Member] EMEA EMEA [Member] APAC Asia Pacific [Member] UNITED STATES UNITED STATES Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Tax expense (benefit) Deferred tax liabilities of undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] EMPLOYEE STOCK PLANS Share-based Payment Arrangement [Text Block] Product Warranty Liability [Table] Product Warranty Liability [Table] Product Warranty Liability [Line Items] Product Warranty Liability [Line Items] Warranty term Warranty Term Warranty Term Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Accrued product warranty, at beginning of period Standard Product Warranty Accrual Charged to cost of revenues Standard Product Warranty Accrual, Increase for Warranties Issued Product warranty expenditures Standard Product Warranty Accrual, Decrease for Payments Accrued product warranty, at end of period Leases Lessee, Operating Leases [Text Block] Leases Lessee, Finance Leases [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Joint Venture In Saudi Arabia Joint Venture In Saudi Arabia [Member] Joint Venture In Saudi Arabia [Member] MeVis Medical Solutions AG (MeVis) MeVis Medical Solutions AG (MeVis) [Member] MeVis Medical Solutions AG (MeVis) [Member] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Majority voting rights, percent Noncontrolling Interest, Ownership Percentage by Parent Noncontrolling interest, ownership percentage by noncontrolling owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Annual recurring compensation (in euros per share) Business Acquisition, Annual Recurring Compensation Business Acquisition, Annual Recurring Compensation Temporary equity, redemption price per share (in euros per share) Temporary Equity, Redemption Price Per Share Temporary equity, shares outstanding (in shares) Temporary Equity, Shares Outstanding Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Balance at beginning of period, September 27, 2019 Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Net earnings attributable to noncontrolling interests Temporary Equity, Net Income Other, including foreign currency remeasurement Temporary Equity, Other Changes Balance at end of period, January 3, 2020 Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Balance at beginning of period, September 27, 2019 Stockholders' Equity Attributable to Noncontrolling Interest Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Other, including foreign currency remeasurement Noncontrolling Interest, Other Changes Noncontrolling Interest, Other Changes Balance at end of period, January 3, 2020 Position [Axis] Position [Axis] Position [Domain] Position [Domain] Buy contracts Long [Member] Sell contract Short [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Japanese yen Japan, Yen Swiss franc Switzerland, Francs Chinese renminbi China, Yuan Renminbi Euro Euro Member Countries, Euro Foreign Exchange Contract Foreign Exchange Contract [Member] Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Severance costs Severance Costs Total restructuring charges Restructuring Costs and Asset Impairment Charges Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash Cash and cash equivalents and restricted cash as reported per statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents BORROWINGS Debt Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted stock units, nonvested, beginning balance, number of shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted stock units, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units, vested in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted stock units, canceled or expired in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted stock units, nonvested, ending balance, number of shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restricted stock units, nonvested, beginning of period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted stock units, grants in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted stock units, vested in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Restricted stock units, canceled or expired, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Restricted stock units, nonvested, end of period, weighted average grant date fair value (in USD per share) Interest expense Interest Expense [Member] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Current assets: Assets, Current [Abstract] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization Property, plant and equipment, net Property, Plant and Equipment, Net Intangible assets, net Investments in privately-held companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Other assets Other Assets, Noncurrent Total assets Liabilities, redeemable noncontrolling interests and equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities and other current liabilities Accrued Liabilities, Current Current operating lease liabilities Deferred revenues Contract with Customer, Liability, Current Total current liabilities Liabilities, Current Long-term debt, net Deferred tax liabilities Deferred Income Tax Liabilities, Net Operating lease liabilities Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Redeemable noncontrolling interests Redeemable Noncontrolling Interest, Equity, Carrying Amount Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued Preferred Stock, Value, Outstanding Common stock, $.01 par value: 150,000,000 shares authorized, 38,494,349 issued and outstanding as of January 3, 2020 ; 38,371,305 issued and outstanding as of September 27, 2019 Common Stock, Value, Outstanding Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Total Varex equity Stockholders' Equity Attributable to Parent Noncontrolling interests Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities, redeemable noncontrolling interests and equity Liabilities and Equity RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2020 remaining Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total future lease payments Lessee, Operating Lease, Liability, Payments, Due Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability, Payment, Due [Abstract] Finance Lease, Liability, Payment, Due [Abstract] 2020 remaining Finance Lease, Liability, Payments, Remainder of Fiscal Year 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total future lease payments Finance Lease, Liability, Payment, Due Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Cash equivalents - Money market funds Cash and Cash Equivalents, Fair Value Disclosure Derivative assets Derivative Asset Total assets measured at fair value Assets, Fair Value Disclosure Liabilities: Derivative liabilities Derivative Liability Deferred consideration Business Combination, Contingent Consideration, Liability Total liabilities measured at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Long-term debt, fair value Long-term Debt, Fair Value Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Santa Clara Facility Relocation Santa Clara Facility Relocation [Member] Santa Clara Facility Relocation [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring charges Restructuring and related costs expected remaining Restructuring and Related Cost, Expected Cost Remaining Schedule of Supplemental Balance Sheet Information, Weighted Average Remaining Lease Terms and Discount Rates Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Schedule of Lease Cost and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Schedule of Finance Lease Liability Maturities Finance Lease, Liability, Maturity [Table Text Block] Schedule of Operating Lease Liability Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Retained Earnings Retained Earnings [Member] Total Varex Equity Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares, outstanding, beginning balance (in shares) Stockholders' equity, beginning balance Cumulative effect of accounting changes Cumulative Effect of New Accounting Principle in Period of Adoption Net earnings Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Common stock issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Unrealized loss on interest rate swap contracts, net of tax Currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax Other Stockholders' Equity, Other Common stock, shares, outstanding, ending balance (in shares) Stockholders' equity, ending balance REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Lease renewal term Lessee, Operating Lease, Renewal Term Operating lease payments due in 2019, under topic 840 Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating lease payments due in 2020, under topic 840 Operating Leases, Future Minimum Payments, Due in Two Years Operating lease payments due in 2021, under topic 840 Operating Leases, Future Minimum Payments, Due in Three Years Operating lease payments due in 2022, under topic 840 Operating Leases, Future Minimum Payments, Due in Four Years Operating lease payments due in 2023, under topic 840 Operating Leases, Future Minimum Payments, Due in Five Years Operating lease payments due thereafter, under topic 840 Operating Leases, Future Minimum Payments, Due Thereafter Income Statement [Abstract] Cost of revenues Cost of Goods and Services Sold Gross margin Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Operating earnings Operating Income (Loss) Interest expense Interest Expense Other expense, net Other Nonoperating Income (Expense) Interest and other expense, net (Loss) earnings before taxes Net (loss) earnings per common share attributable to Varex Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average common shares outstanding, diluted (in shares) Schedule of Debt Schedule of Debt [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Depreciation Depreciation Deferred taxes Deferred Income Tax Expense (Benefit) Income from equity method investments Amortization of deferred loan costs Amortization of Debt Issuance Costs Other, net Other Noncash Income (Expense) Changes in assets and liabilities, net of effects of acquisition: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities and other current and long-term operating liabilities Increase (Decrease) in Accrued Liabilities Deferred revenues Increase (Decrease) in Contract with Customer, Liability Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Contributions and advances to joint ventures Payments to Acquire Interest in Joint Venture Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Borrowings under credit agreements Proceeds from Long-term Lines of Credit Repayments of borrowing under credit agreements Repayments of Long-term Lines of Credit Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from shares issued under employee stock purchase plan Proceeds from Stock Plans Other financing activities Proceeds from (Payments for) Other Financing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effects of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents and restricted cash at beginning of period Cash and cash equivalents and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income tax Income Taxes Paid Supplemental non-cash activities: Noncash Investing and Financing Items [Abstract] Purchases of property, plant and equipment financed through accounts payable Fair Value of Assets Acquired SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Raw materials and parts Inventory, Raw Materials and Supplies, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventories SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] EX-101.PRE 10 var-20200103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 logoa34.jpg begin 644 logoa34.jpg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�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end XML 12 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Assets (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Segment Reporting Information [Line Items]    
Identifiable assets $ 1,068.4 $ 1,038.9
Medical | Operating Segments    
Segment Reporting Information [Line Items]    
Identifiable assets 830.8 794.3
Industrial | Operating Segments    
Segment Reporting Information [Line Items]    
Identifiable assets $ 237.6 $ 244.6
XML 13 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
Jan. 03, 2020
USD ($)
€ / shares
shares
Jan. 03, 2020
€ / shares
Apr. 30, 2019
Apr. 29, 2019
Sep. 28, 2018
Apr. 30, 2015
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]              
Balance at beginning of period, September 27, 2019 $ 3.3            
Net earnings attributable to noncontrolling interests 0.0            
Other, including foreign currency remeasurement 0.0            
Balance at end of period, January 3, 2020 3.3            
Direct Conversion AB              
Noncontrolling Interest [Line Items]              
Percentage of voting interests acquired       98.20% 98.20%    
MeVis Medical Solutions AG (MeVis)              
Noncontrolling Interest [Line Items]              
Percentage of voting interests acquired             73.50%
Annual recurring compensation (in euros per share) | € / shares   € 0.95          
Temporary equity, redemption price per share (in euros per share) | € / shares     € 19.77        
Temporary equity, shares outstanding (in shares) | shares   0.5          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Balance at beginning of period, September 27, 2019 10.5            
Net earnings attributable to noncontrolling interests 0.1            
Other, including foreign currency remeasurement 0.1            
Balance at end of period, January 3, 2020 $ 10.5 € 10.7          
Joint Venture In Saudi Arabia              
Noncontrolling Interest [Line Items]              
Majority voting rights, percent           75.00%  
Noncontrolling interest, ownership percentage by noncontrolling owners           25.00%  
MeVis Medical Solutions AG (MeVis)              
Noncontrolling Interest [Line Items]              
Noncontrolling interest, ownership percentage by noncontrolling owners   26.30%          
XML 14 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)
shares in Thousands
 3 Months Ended
Jan. 03, 2020
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Restricted stock units, nonvested, beginning balance, number of shares (in shares) | shares 678
Restricted stock units, grants in period (in shares) | shares 3
Restricted stock units, vested in period (in shares) | shares (2)
Restricted stock units, canceled or expired in period (in shares) | shares (8)
Restricted stock units, nonvested, ending balance, number of shares (in shares) | shares 671
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Restricted stock units, nonvested, beginning of period, weighted average grant date fair value (in USD per share) | $ / shares $ 33.18
Restricted stock units, grants in period, weighted average grant date fair value (in USD per share) | $ / shares 26.78
Restricted stock units, vested in period, weighted average grant date fair value (in USD per share) | $ / shares 30.21
Restricted stock units, canceled or expired, weighted average grant date fair value (in USD per share) | $ / shares 33.49
Restricted stock units, nonvested, end of period, weighted average grant date fair value (in USD per share) | $ / shares $ 33.16
XML 15 varex10q2020q1_htm.xml IDEA: XBRL DOCUMENT 0001681622 2019-09-28 2020-01-03 0001681622 2020-02-11 0001681622 2018-09-29 2018-12-28 0001681622 2020-01-03 0001681622 2019-09-27 0001681622 2018-09-28 0001681622 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 0001681622 us-gaap:ParentMember 2018-12-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2018-12-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 2018-12-28 0001681622 us-gaap:ParentMember 2018-09-29 2018-12-28 0001681622 us-gaap:RetainedEarningsMember 2018-09-29 2018-12-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 2018-12-28 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-29 2018-12-28 0001681622 2018-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2018-12-28 0001681622 us-gaap:CommonStockMember 2018-09-29 2018-12-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-28 0001681622 us-gaap:ParentMember 2018-09-28 0001681622 us-gaap:RetainedEarningsMember 2018-12-28 0001681622 us-gaap:NoncontrollingInterestMember 2018-09-28 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-28 2020-01-03 0001681622 us-gaap:CommonStockMember 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-28 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-27 0001681622 us-gaap:AdditionalPaidInCapitalMember 2019-09-28 2020-01-03 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-27 0001681622 us-gaap:RetainedEarningsMember 2019-09-28 0001681622 2019-09-28 0001681622 us-gaap:RetainedEarningsMember 2020-01-03 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2019-09-27 0001681622 us-gaap:NoncontrollingInterestMember 2019-09-28 2020-01-03 0001681622 us-gaap:AdditionalPaidInCapitalMember 2020-01-03 0001681622 us-gaap:RetainedEarningsMember 2019-09-27 0001681622 us-gaap:CommonStockMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2020-01-03 0001681622 us-gaap:NoncontrollingInterestMember 2020-01-03 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-03 0001681622 us-gaap:RetainedEarningsMember 2019-09-28 2020-01-03 0001681622 us-gaap:ParentMember 2019-09-27 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2018-12-28 0001681622 srt:MinimumMember 2019-09-28 2020-01-03 0001681622 us-gaap:AccountingStandardsUpdate201602Member 2019-09-28 0001681622 srt:MaximumMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-09-28 2020-01-03 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-09-29 2019-09-27 0001681622 srt:AsiaPacificMember 2019-09-28 2020-01-03 0001681622 us-gaap:EMEAMember 2018-09-29 2018-12-28 0001681622 srt:AsiaPacificMember 2018-09-29 2018-12-28 0001681622 srt:AmericasMember 2019-09-28 2020-01-03 0001681622 us-gaap:EMEAMember 2019-09-28 2020-01-03 0001681622 srt:AmericasMember 2018-09-29 2018-12-28 0001681622 country:US 2018-09-29 2018-12-28 0001681622 country:US 2019-09-28 2020-01-03 0001681622 2020-01-04 2019-09-27 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:TradeNamesMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:DevelopedTechnologyRightsMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:InProcessResearchAndDevelopmentMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:OrderOrProductionBacklogMember 2019-04-29 0001681622 var:DirectConversionABMember us-gaap:CustomerRelationshipsMember 2019-04-29 0001681622 var:DirectConversionABMember 2019-04-29 2019-04-29 0001681622 var:ReliableHealthcareImagingTechnologyMember 2019-09-28 2020-01-03 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-27 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2020-01-03 0001681622 var:VECImagingGmbHCo.KGMember 2020-01-03 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-30 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2013-10-01 2013-10-31 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2018-09-29 2018-12-28 0001681622 var:VECImagingGmbHCo.KGMember 2018-11-01 2020-01-03 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2019-09-28 2020-01-03 0001681622 var:DpiXHoldingMember srt:ScenarioForecastMember var:FixedCostCommitmentsMember us-gaap:EquityMethodInvesteeMember 2020-01-01 2020-12-31 0001681622 var:VECImagingGmbHCo.KGMember 2019-09-27 0001681622 var:VECImagingGmbHCo.KGMember srt:ScenarioForecastMember 2020-02-18 2020-02-18 0001681622 srt:MinimumMember var:SantaClaraFacilityRelocationMember 2020-01-03 0001681622 var:SantaClaraFacilityRelocationMember 2019-09-28 2020-01-03 0001681622 var:SantaClaraFacilityRelocationMember 2018-09-29 2018-12-28 0001681622 srt:MaximumMember var:SantaClaraFacilityRelocationMember 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2018-12-28 0001681622 us-gaap:CrossCurrencyInterestRateContractMember 2019-09-28 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-29 2018-12-28 0001681622 us-gaap:InterestRateSwapMember 2019-09-28 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:CashFlowHedgingMember 2019-09-28 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-03 0001681622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-27 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:JPY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-01-03 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 currency:CHF us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-01-03 0001681622 us-gaap:FairValueInputsLevel2Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel3Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member 2019-09-27 0001681622 us-gaap:FairValueInputsLevel1Member 2020-01-03 0001681622 us-gaap:FairValueInputsLevel3Member 2020-01-03 0001681622 us-gaap:FairValueInputsLevel2Member 2020-01-03 0001681622 var:IndustrialMember 2019-09-27 0001681622 var:MedicalMember 2020-01-03 0001681622 var:MedicalMember 2019-09-27 0001681622 var:IndustrialMember 2020-01-03 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2020-01-03 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2019-09-27 0001681622 us-gaap:IntellectualPropertyMember 2020-01-03 0001681622 us-gaap:DevelopedTechnologyRightsMember 2020-01-03 0001681622 us-gaap:DevelopedTechnologyRightsMember 2019-09-27 0001681622 var:OtherDebtMember 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-28 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2018-09-29 2019-09-27 0001681622 us-gaap:SecuredDebtMember 2019-09-28 2020-01-03 0001681622 var:OtherDebtMember 2019-09-28 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2018-09-29 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2020-01-03 0001681622 us-gaap:SecuredDebtMember 2019-09-27 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2019-09-27 0001681622 var:OtherDebtMember 2019-09-27 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodOneMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:LondonInterbankOfferedRateLIBORMember 2017-05-01 2017-05-01 0001681622 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodThreeMember 2017-05-01 2017-05-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2019-10-01 0001681622 var:RevolvingCreditFacilityMay2017Member 2018-10-03 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:BaseRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member 2017-05-01 0001681622 us-gaap:RevolvingCreditFacilityMember 2020-01-03 0001681622 us-gaap:RevolvingCreditFacilityMember var:RevolvingCreditFacilityMay2017Member us-gaap:FederalFundsEffectiveSwapRateMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:RevolvingCreditFacilityMay2017Member var:DebtInstrumentRepaymentPeriodFiveMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:SecondRevolvingCreditFacilityMember var:DebtInstrumentRepaymentPeriodTwoMember 2017-05-01 2017-05-01 0001681622 us-gaap:SecuredDebtMember var:SecondRevolvingCreditFacilityMember var:DebtInstrumentRepaymentPeriodFourMember 2017-05-01 2017-05-01 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2020-01-03 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2020-01-03 0001681622 var:JointVentureInSaudiArabiaMember 2018-09-28 0001681622 var:DirectConversionABMember 2019-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-28 2020-01-03 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2019-09-27 0001681622 us-gaap:CostOfSalesMember 2019-09-28 2020-01-03 0001681622 us-gaap:CostOfSalesMember 2018-09-29 2018-12-28 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-09-28 2020-01-03 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-09-29 2018-12-28 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2019-09-28 2020-01-03 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-29 2018-12-28 0001681622 srt:MaximumMember 2019-09-27 0001681622 srt:MaximumMember 2020-01-03 0001681622 srt:MinimumMember 2020-01-03 0001681622 srt:MinimumMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2018-09-29 2018-12-28 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-28 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-28 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2018-09-29 2018-12-28 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:MedicalMember 2019-09-27 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2020-01-03 0001681622 us-gaap:OperatingSegmentsMember var:IndustrialMember 2019-09-27 var:derivative iso4217:USD iso4217:USD shares pure var:member shares iso4217:EUR shares var:segment false --10-02 Q1 2020 0001681622 0.01 0.01 150000000 150000000 38371305 38494349 38371305 38494349 0.01 0.01 20000000 20000000 0 0 0.075 0.05 37.60 22.63 37.60 22.63 37.60 22.63 37.10 22.84 22.84 22.84 10-Q true 2020-01-03 false 001-37860 VAREX IMAGING CORPORATION DE 81-3434516 1678 S. Pioneer Road Salt Lake City UT 84104 801 972-5000 Common Stock VREX NASDAQ Yes Yes Large Accelerated Filer false false false 38500000 200100000 185700000 139000000.0 125700000 61100000 60000000.0 21700000 18800000 34800000 30800000 56500000 49600000 4600000 10400000 5400000 5100000 -400000 -1200000 -5800000 -6300000 -1200000 4100000 0 1100000 -1200000 3000000.0 100000 0 -1300000 3000000.0 -0.03 0.08 -0.03 0.08 38500000 38100000 38500000 38300000 -1200000 3000000.0 0 -2300000 -900000 0 -900000 -2300000 -2100000 700000 100000 0 -2200000 700000 30000000.0 29900000 122900000 141000000.0 269100000 248200000 18200000 19300000 440200000 438400000 146200000 142300000 290800000 290800000 81800000 86300000 54900000 53600000 25100000 29400000 27500000 1068400000 1038900000 73200000 58200000 70900000 75700000 6700000 30400000 30700000 9700000 10500000 190900000 175100000 350900000 364400000 8900000 8200000 19200000 36600000 32500000 606500000 580200000 10700000 10500000 0 0 400000 400000 377600000 371800000 -2600000 -1700000 72500000 74400000 447900000 444900000 3300000 3300000 451200000 448200000 1068400000 1038900000 -1200000 3000000.0 3200000 2600000 5200000 9800000 4500000 3700000 500000 -2500000 700000 800000 600000 600000 0 -100000 -18500000 -20600000 21100000 22000000.0 -3700000 -3700000 15400000 -500000 -4800000 3100000 -800000 -1400000 23000000.0 20000000.0 8100000 3400000 1200000 0 1300000 0 -10600000 -3400000 3000000.0 4000000.0 17800000 19000000.0 1100000 0 1800000 1900000 -100000 0 -12000000.0 -13100000 -300000 -400000 100000 3100000 31300000 53400000 31400000 56500000 5000000.0 3000000.0 500000 600000 800000 1800000 38400000 400000 371800000 -1700000 74400000 444900000 3300000 448200000 -600000 -600000 -600000 -1300000 -1300000 0 -1300000 1100000 1100000 1100000 100000 1800000 1800000 1800000 3200000 3200000 3200000 900000 900000 900000 300000 300000 300000 38500000 400000 377600000 -2600000 72500000 447900000 3300000 451200000 38000000.0 400000 357600000 5800000 62400000 426200000 2100000 428300000 -4100000 -4100000 -4100000 3000000.0 3000000.0 -200000 2800000 100000 1900000 1900000 1900000 2600000 2600000 2600000 -2300000 -2300000 -2300000 38100000 400000 362100000 3500000 61300000 427300000 1900000 429200000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary imaging systems, to independent service companies, distributors and directly to end-users for replacement purposes.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also designs, manufacturers, sells and services industrial products, which include Linatron</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 and is listed on the NASDAQ Global Select Market under the ticker “VREX.”</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principle of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited. These condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods.</span></div><span style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> included in the Company’s Form 10-K, which was filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">December 20, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;">, in the Company’s Annual Report on Form 10-K for fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span>.<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fiscal Year</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> is the 53-week period ending </span><span style="font-family:inherit;font-size:10pt;">October 2, 2020</span><span style="font-family:inherit;font-size:10pt;">. Fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was the 52-week period that ended on </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">.  The fiscal quarters ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;"> were 14-week and 13-week periods, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents and restricted cash as reported per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, as follows:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canon Medical Systems Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:2px;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.8%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:2px;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.3%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canon Medical Systems Corporation accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>14.5%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>10.1%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company warrants most of its products for a specific period of time, usually </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>24</span></span><span style="font-family:inherit;font-size:10pt;"> months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, the Company bases warranty </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimates on historical experience for similar products and adds a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the changes in the Company’s accrued product warranty:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Charged to cost of revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represents the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate ("IBR"). The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases ("Topic 842"), referred to as ASC 842. The purpose of ASC 842 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and is effective for the Company in fiscal year 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases ("Topic 842"): Targeted Improvements. Under this method, the Company applied the new leasing rules on </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;">, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 28, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Also, the Company applied the hindsight practical expedient. Furthermore, as a lessee the Company elected to combine lease and non-lease components for the majority of its leases, which means that the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. The only asset class that did not combine lease and non-lease components were vehicle leases. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant impact of the standards for the Company relate to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$26.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and corresponding operating lease liabilities and finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. This includes the recording of the Company’s existing capital leases as finance leases at transition. The cumulative impact of adoption was a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> decrease to retained earnings. Refer to Note </span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases, </span><span style="font-family:inherit;font-size:10pt;">for a detailed impact of adopting this standard and its impact on the consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">, which provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disclosures. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Effective </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company adopted ASU 2018-02 and it did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standards or Updates Not Yet Effective</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12 which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021 and must be applied on a modified retrospective basis. The Company is evaluating the potential impact of this standard to its condensed consolidated financial statements.</span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited. These condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods.</span></div> <span style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> included in the Company’s Form 10-K, which was filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">December 20, 2019</span>. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> reportable operating segments, Medical and Industrial, which align with how its Chief Executive Officer, who has been identified as the Company's Chief Operating Decision Maker ("CODM"), views and measures the Company’s business performance. See Note </span><span style="font-family:inherit;font-size:10pt;">16</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information</span><span style="font-family:inherit;font-size:10pt;">, for further information on the Company’s segments.</span></div> 2 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fiscal Year</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> is the 53-week period ending </span><span style="font-family:inherit;font-size:10pt;">October 2, 2020</span><span style="font-family:inherit;font-size:10pt;">. Fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was the 52-week period that ended on </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">.  The fiscal quarters ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;"> were 14-week and 13-week periods, respectively.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</span></div>Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Beginning of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents and restricted cash as reported per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>53.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29900000 30000000.0 51900000 55100000 1400000 1400000 1500000 1400000 31300000 31400000 53400000 56500000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.</span></div>Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, as follows:<div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:69%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canon Medical Systems Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:2px;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.8%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:2px;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.3%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.188 0.183 0.145 0.101 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision.</span></div> <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Warranty</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company warrants most of its products for a specific period of time, usually </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>24</span></span><span style="font-family:inherit;font-size:10pt;"> months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, the Company bases warranty </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimates on historical experience for similar products and adds a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div> P12M P24M <div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the changes in the Company’s accrued product warranty:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Charged to cost of revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product warranty expenditures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued product warranty, at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8100000 7300000 4100000 2000000.0 3200000 2700000 9000000.0 6600000 <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div>The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represents the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate ("IBR"). The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that <div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases ("Topic 842"), referred to as ASC 842. The purpose of ASC 842 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and is effective for the Company in fiscal year 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases ("Topic 842"): Targeted Improvements. Under this method, the Company applied the new leasing rules on </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;">, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 28, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Also, the Company applied the hindsight practical expedient. Furthermore, as a lessee the Company elected to combine lease and non-lease components for the majority of its leases, which means that the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. The only asset class that did not combine lease and non-lease components were vehicle leases. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant impact of the standards for the Company relate to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$26.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and corresponding operating lease liabilities and finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. This includes the recording of the Company’s existing capital leases as finance leases at transition. The cumulative impact of adoption was a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> decrease to retained earnings. Refer to Note </span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases, </span><span style="font-family:inherit;font-size:10pt;">for a detailed impact of adopting this standard and its impact on the consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">, which provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disclosures. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Effective </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company adopted ASU 2018-02 and it did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standards or Updates Not Yet Effective</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU 2019-12 which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021 and must be applied on a modified retrospective basis. The Company is evaluating the potential impact of this standard to its condensed consolidated financial statements.</span></div> 26800000 600000 27500000 600000 -300000 REVENUE RECOGNITION<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transaction price and allocation to performance obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction , to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contracts and performance obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table disaggregates the Company’s revenue by geographic region:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Americas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EMEA</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>65.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">APAC</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>64.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue in the United States of America was </span><span style="font-family:inherit;font-size:10pt;"><span>$68.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$67.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note </span><span style="font-family:inherit;font-size:10pt;">16</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information</span><span style="font-family:inherit;font-size:10pt;">, for the disaggregation of the Company’s revenue based on reportable operating segments.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Balances</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities and other current liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contract Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs recovered from product returns during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contract asset from shipments of products, subject to return during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Refund Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Release of refund liability included in beginning of year refund liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to refund liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Remaining Performance Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, total remaining performance obligations amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$268.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company expects to recognize the remaining performance obligations over the next </span><span style="font-family:inherit;font-size:10pt;"><span>12 months</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs to Obtain or Fulfill a Customer Contract</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.</span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table disaggregates the Company’s revenue by geographic region:</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Americas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>68.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">EMEA</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>65.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">APAC</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>64.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 70300000 68400000 65200000 62600000 64600000 54700000 200100000 185700000 68900000 67200000 The following table summarizes the changes in the contract assets and refund liabilities for the three months ended <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contract Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs recovered from product returns during the period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Contract asset from shipments of products, subject to return during the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Refund Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 28, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Release of refund liability included in beginning of year refund liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additions to refund liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 23700000 800000 1600000 24500000 26400000 900000 1700000 27200000 268300000 P12M LEASES<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2019, the Company adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement. The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>six years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, our incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:33%;"/><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current) </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued liabilities and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs (a)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a) </sup></span><span style="font-family:inherit;font-size:10pt;">Includes variable and short-term lease expense, which were immaterial for the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total future lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">At </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and therea</span><span style="font-family:inherit;font-size:10pt;">fter, as follows: </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span>, respectively. LEASES<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2019, the Company adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement. The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>six years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, our incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:33%;"/><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current) </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued liabilities and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs (a)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a) </sup></span><span style="font-family:inherit;font-size:10pt;">Includes variable and short-term lease expense, which were immaterial for the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total future lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">At </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and therea</span><span style="font-family:inherit;font-size:10pt;">fter, as follows: </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span>, respectively. P1Y P5Y P6Y <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:33%;"/><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current) </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued liabilities and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 25100000 600000 6700000 200000 19200000 400000 P5Y2M12D P3Y 0.042 0.038 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs (a)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total finance lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a) </sup></span><span style="font-family:inherit;font-size:10pt;">Includes variable and short-term lease expense, which were immaterial for the three months ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2100000 100000 2000000.0 100000 2100000 <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total future lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal years:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total future lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5800000 200000 6500000 200000 5600000 100000 3300000 100000 2500000 0 5300000 0 29000000.0 600000 3200000 0 25800000 600000 7500000 5400000 4700000 1800000 900000 200000 BUSINESS COMBINATION <div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">April 29, 2019</span><span style="font-family:inherit;font-size:10pt;">, Varex completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for </span><span style="font-family:inherit;font-size:10pt;"><span>$69.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, net of cash acquired, the assumption of Direct Conversion's debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and deferred consideration equal to </span><span style="font-family:inherit;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.</span></div><div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary purchase price allocation:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Total liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired, less noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of January 3, 2020, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Weighted Average <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the prior year period.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first quarter of fiscal year 2020, the Company made a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> acquisition to enhance our X-ray tube development and manufacturing operations.</span></div> 0.982 69500000 4500000 9900000 300000 <div style="line-height:120%;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary purchase price allocation:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allocation of the purchase consideration:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Total liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired, less noncontrolling interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2400000 5700000 700000 900000 47200000 32900000 89800000 1000000.0 1500000 1000000.0 900000 3500000 1100000 9000000.0 1400000 79400000 69500000 9900000 79400000 <div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Weighted Average <br/>Useful Life<br/>(In Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Backlog</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">indefinite</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 200000 P1Y 2500000 P5Y 18400000 P10Y 2800000 9000000.0 P10Y 32900000 1200000 RELATED PARTY TRANSACTIONS<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment in Privately-Held Companies</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> ownership interest in dpiX Holding LLC (“dpiX Holding”), a </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;">-member consortium that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated. During the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded (loss) and income on the equity investment in dpiX Holding of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.7) million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Income and loss on the equity investment in dpiX Holding is included in other expense, net in the condensed consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding was </span><span style="font-family:inherit;font-size:10pt;"><span>$48.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$48.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company purchased glass transistor arrays from dpiX totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. These purchases of glass transistor arrays are included as a component of inventories on the condensed consolidated balance sheets or cost of revenues in the condensed consolidated statements of earnings.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had accounts payable to dpiX totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had no remaining fixed cost commitments related to the agreement remaining for calendar year 2019. In January 2020, the fixed cost commitment was determined and approved by the dpiX board of directors to be </span><span style="font-family:inherit;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for calendar year 2020. The amended agreement will continue unless the ownership structure of dpiX changes as provided in the amended agreement.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$48.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and fixed cost commitments.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has made contributions totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and has committed to contribute an additional $</span><span style="font-family:inherit;font-size:10pt;"><span>1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as milestones are achieved, and to provide certain full-time employees to support prototyping and manufacturing activities in exchange for a </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in VEC. The Company's investment in VEC was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively .</span></div> 0.40 4 -900000 700000 48500000 48100000 5900000 2800000 3400000 3600000 0.50 0.50 12700000 48500000 4200000 1100000 0.50 0.50 3000000.0 2000000.0 RESTRUCTURING<div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of September 2020 and all activities related to the closure of the facility to be complete by the end of December 2020. In connection with the relocation of the glass production and site closure the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to incur an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$7.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of restructuring charges through December 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, which predominately relate to the Company's Medical segment:</span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:213px;"/><td style="width:258px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:107px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:107px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Restructuring Charges in Consolidated Statements of Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Severance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 800000 5100000 7300000 11300000 Below is a detail of restructuring charges incurred during the <span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, which predominately relate to the Company's Medical segment:</span><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:720px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:213px;"/><td style="width:258px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:107px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:107px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Restructuring Charges in Consolidated Statements of Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accelerated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Severance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total restructuring charges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 300000 4200000 500000 900000 800000 5100000 FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivatives Designated as Hedging Instruments - Cash Flow Hedges</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as hedging instruments:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain (Loss) Recognized in OCI on Derivative<br/>Three months ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain (Loss) Reclassified from Accumulated OCI into Income<br/>Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects that approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:10pt;"> of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. The following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the </span><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">accompanying consolidated balance sheets where the instruments are recorded:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivative Assets and Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:none;font-weight:bold;">Derivatives designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:none;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivatives Designated as Hedging Instruments - Net Investment Hedges</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as net investment hedging instruments:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:18%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain (Loss) Recognized in OCI on Derivative<br/>Three months ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivative Assets and Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Balance Sheet Hedges</span></div><div style="line-height:120%;padding-top:12px;padding-left:4px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s foreign currency management objective is to mitigate the potential impact of currency fluctuations on the value of its U.S. dollar cash flows and to reduce the variability of certain cash flows at the subsidiary level. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The Company does not and does not intend to use derivative financial instruments for speculative or trading purposes.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the notional amounts of outstanding foreign currency contracts as of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value of Derivatives not Designated as Hedging Instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Buy contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Sell contract</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Chinese renminbi</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6 253100000 0 -2500000 0 400000 <span style="font-family:inherit;font-size:10pt;"><br/></span>he following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the <span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">accompanying consolidated balance sheets where the instruments are recorded:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivative Assets and Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;text-decoration:none;font-weight:bold;">Derivatives designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:none;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued liabilities and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -300000 -300000 0 -200000 -500000 -500000 -500000 4 77700000 he following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:18%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain (Loss) Recognized in OCI on Derivative<br/>Three months ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivative Assets and Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance sheet location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> -800000 0 400000 0 1300000 0 -2200000 0 -900000 0 he following table shows the notional amounts of outstanding foreign currency contracts as of <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value of Derivatives not Designated as Hedging Instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Buy contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Sell contract</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Swiss franc</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Chinese renminbi</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Euro</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>s of <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as hedging instruments:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest Rate Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>253.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div>s of <span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had the following outstanding derivatives designated as net investment hedging instruments:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for number of instruments)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cross Currency Swap Contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>77.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 2300000 0 0 -1000000.0 1700000 0 0 -3400000 4000000.0 -4400000 FAIR VALUE<div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets/Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the outstanding borrowings under the Company's credit agreement were </span><span style="font-family:inherit;font-size:10pt;"><span>$381.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of deferred loan costs, which approximated its fair value. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company determined the following levels of inputs at fair value for the following assets or liabilities: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at January 3, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">September 27, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company determined the following levels of inputs at fair value for the following assets or liabilities: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash equivalents - Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred Consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 4700000 0 4700000 0 1300000 0 1300000 0 6000000.0 0 6000000.0 0 2700000 0 2700000 9700000 0 0 9700000 9700000 2700000 0 12400000 381300000 0 8800000 0 8800000 0 8800000 0 8800000 0 700000 0 700000 8900000 0 0 8900000 8900000 700000 0 9600000 INVENTORIES<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s inventories:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Raw materials and parts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s inventories:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Raw materials and parts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>160.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 184200000 160100000 27600000 27900000 57300000 60200000 269100000 248200000 GOODWILL AND INTANGIBLE ASSETS<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflect goodwill by reportable operating segment:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Industrial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the condensed consolidated balance sheets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired existing technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Patents, licenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets with finite lives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>79.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process R&amp;D with indefinite lives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span>, respectively. <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflect goodwill by reportable operating segment:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Industrial</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>173.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>290.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 173000000.0 117800000 290800000 173000000.0 117800000 290800000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the condensed consolidated balance sheets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquired existing technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>74.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Patents, licenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets with finite lives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>79.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>83.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In-process R&amp;D with indefinite lives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(58.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>140.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(54.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>86.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 74100000 30800000 43300000 74100000 28400000 45700000 12700000 8700000 4000000.0 12700000 8400000 4300000 50700000 19000000.0 31700000 50700000 17200000 33500000 137500000 58500000 79000000.0 137500000 54000000.0 83500000 2800000 2800000 2800000 2800000 140300000 58500000 81800000 140300000 54000000.0 86300000 4500000 3700000 BORROWINGS<div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's short-term and long-term debt:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$ Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current maturities of long-term debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current maturities of long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>301.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>350.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>381.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>395.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Existing Credit Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 1, 2017 Varex entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a term of </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is subsequently amended. The Company reduced the Revolving Credit Facility to </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> on October 3, 2018 and to </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> on October 1, 2019. At </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$73.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Revolving Credit Facility available for borrowings, subject to covenants contained in the Credit Agreement. The Term Facility will be repaid over </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, with </span><span style="font-family:inherit;font-size:10pt;"><span>5.0%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments during each of the first two years of the term thereof, </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments during the third and fourth years of the term thereof, and </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;">The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> or the LIBOR rate for a one-month period plus </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;">). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span><span style="font-family:inherit;font-size:10pt;"> (for LIBOR rate loans) and </span><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of </span><span style="font-family:inherit;font-size:10pt;"><span>0.125%</span></span><span style="font-family:inherit;font-size:10pt;">, and a fee on unused commitments which ranges from </span><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.40%</span></span>. <div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's short-term and long-term debt:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$ Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except for percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current maturities of long-term debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current maturities of long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revolving credit facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Term facility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>301.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current maturities of long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>350.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>364.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>381.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>395.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29400000 0.053 29400000 0.056 0 1000000.0 1300000 -300000 30400000 30700000 -300000 52000000.0 0.053 59000000.0 0.056 -7000000.0 301100000 0.053 308600000 0.056 -7500000 2600000 2500000 100000 4800000 5700000 900000 350900000 364400000 -13500000 381300000 395100000 -13800000 200000000 P5Y 400000000 150000000 125000000 73000000.0 P5Y 0.050 0.075 0.10 0.0050 0.0100 0.0175 0.0275 0.0075 0.0175 0.00125 0.0025 0.0040 REDEEMABLE NONCONTROLLING INTERESTS &amp; <span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">NONCONTROLLING INTERESTS</span><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In </span><span style="font-family:inherit;font-size:10pt;">April 2019, a subsidiary of Varex completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;"><span>98.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In September 2018, the Company entered into a partnership in Saudi Arabia. </span><span style="font-family:inherit;font-size:10pt;">The Company has majority voting rights with an approximate </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2015, the Company completed the acquisition of </span><span style="font-family:inherit;font-size:10pt;"><span>73.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of the then outstanding shares of MeVis, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of </span><span style="font-family:inherit;font-size:10pt;"><span>€0.95</span></span><span style="font-family:inherit;font-size:10pt;"> per MeVis share starting from January 1, 2015; and (2) a put right for their MeVis shares at </span><span style="font-family:inherit;font-size:10pt;"><span>€19.77</span></span><span style="font-family:inherit;font-size:10pt;"> per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, noncontrolling shareholders together held approximately </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of MeVis, representing </span><span style="font-family:inherit;font-size:10pt;"><span>26.3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable Noncontrolling Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interest</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Balance at beginning of period, September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, including foreign currency remeasurement</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Balance at end of period, January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.982 0.75 0.25 0.735 0.95 19.77 500000 0.263 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable Noncontrolling Interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interest</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Balance at beginning of period, September 27, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, including foreign currency remeasurement</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Balance at end of period, January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10500000 3300000 100000 0 100000 0 10700000 3300000 NET (LOSS) EARNINGS PER SHARE<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net (loss) earnings per common share is computed by dividing the net (loss) earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net (loss) earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:22px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dilutive effect of potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anti-dilutive shared based awards, excluded</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company excludes potentially dilutive common shares (consisting of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to (loss) earnings per share. Because the Company incurred a net loss for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span>, none of the potentially dilutive common shares were included in the diluted share calculation for that period as they would have been anti-dilutive. <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions, except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:22px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Dilutive effect of potential common shares</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings per share attributable to Varex - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-bottom:1px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Anti-dilutive shared based awards, excluded</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1300000 3000000.0 38500000 38100000 0 200000 38500000 38300000 -0.03 0.08 -0.03 0.08 1700000 2100000 EMPLOYEE STOCK PLANS<div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized in the condensed consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the effect of recording the share-based compensation expense (which includes the option component of the employee stock purchase plan shares):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options under Varex’s 2017 Omnibus Stock Plan and 2017 Employee Stock Purchase Plan for the Company’s employees:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Outstanding</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts and the remaining term)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled, expired or forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.84 - $37.10</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.84 - $22.84</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,735.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercisable at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,735.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of </span><span style="font-family:inherit;font-size:8pt;"><span>$30.00</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">January 3, 2020</span><span style="font-family:inherit;font-size:8pt;">, the last trading date of the Company's </span><span style="font-family:inherit;font-size:8pt;">first</span><span style="font-family:inherit;font-size:8pt;"> quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for restricted stock units under Varex’s 2017 Omnibus Stock Plan for the Company’s employees:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant-Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>671</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the effect of recording the share-based compensation expense (which includes the option component of the employee stock purchase plan shares):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cost of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total share-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 300000 300000 600000 500000 2300000 1800000 3200000 2600000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for stock options under Varex’s 2017 Omnibus Stock Plan and 2017 Employee Stock Purchase Plan for the Company’s employees:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Outstanding</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts and the remaining term)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled, expired or forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.84 - $37.10</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.84 - $22.84</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Outstanding at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,735.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercisable at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$22.63 - $37.60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,735.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of </span><span style="font-family:inherit;font-size:8pt;"><span>$30.00</span></span><span style="font-family:inherit;font-size:8pt;"> as of </span><span style="font-family:inherit;font-size:8pt;">January 3, 2020</span><span style="font-family:inherit;font-size:8pt;">, the last trading date of the Company's </span><span style="font-family:inherit;font-size:8pt;">first</span><span style="font-family:inherit;font-size:8pt;"> quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.</span></div> 2269000 30.60 0 0 19000 30.99 49000 22.84 2201000 30.77 P3Y11M1D 1735000.0 1500000 30.04 P3Y4M2D 1735000.0 30.00 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for restricted stock units under Varex’s 2017 Omnibus Stock Plan for the Company’s employees:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant-Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at September 27, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Canceled or expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at January 3, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>671</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>33.16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 678000 33.18 3000 26.78 2000 30.21 8000 33.49 671000 33.16 TAXES ON EARNINGS<div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated effective tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized an income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 28, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, for effective rates of </span><span style="font-family:inherit;font-size:10pt;"><span>0.9%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>26.8%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's effective tax rate for the </span><span style="font-family:inherit;font-size:10pt;">three months ended January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">, decreased primarily due to losses in certain jurisdictions for which no benefit can be recorded due to full valuation allowance positions and a nearly equivalent overall pre-tax book loss. </span></div><span style="font-family:inherit;font-size:10pt;">As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are indefinitely reinvested outside the U.S. The Company is maintaining this prior assertion for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">January 3, 2020</span><span style="font-family:inherit;font-size:10pt;">. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span>. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend. <div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Estimated effective tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.009 0.268 0.0 1100000 0.009 0.268 100000 SEGMENT INFORMATION<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Segments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to the Company’s segments is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>155.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>143.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross margin</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total gross margin</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other income (expenses), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s total assets by its reportable segments:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Identifiable assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>830.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>794.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>244.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,068.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2 <div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to the Company’s segments is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 28, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>155.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>143.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>41.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>200.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross margin</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>45.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total gross margin</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>61.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other income (expenses), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings before taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Taxes on earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less: Net earnings attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net earnings attributable to Varex</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 155600000 143900000 44500000 41800000 200100000 185700000 43800000 45100000 17300000 14900000 61100000 60000000.0 56500000 49600000 -5800000 -6300000 -1200000 4100000 0 1100000 -1200000 3000000.0 100000 0 -1300000 3000000.0 <div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s total assets by its reportable segments:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(In millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">January 3, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 27, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Identifiable assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>830.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>794.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Industrial</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>237.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>244.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,068.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 830800000 794300000 237600000 244600000 1068400000 1038900000 XML 16 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details)
$ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
Reliable Healthcare Imaging Technology  
Business Acquisition [Line Items]  
Net cash paid $ 1.2
XML 17 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details)
$ in Millions
Jan. 03, 2020
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
2020 remaining $ 5.8
2021 6.5
2022 5.6
2023 3.3
2024 2.5
Thereafter 5.3
Total future lease payments 29.0
Less: imputed interest (3.2)
Present value of lease liabilities 25.8
Finance Lease, Liability, Payment, Due [Abstract]  
2020 remaining 0.2
2021 0.2
2022 0.1
2023 0.1
2024 0.0
Thereafter 0.0
Total future lease payments 0.6
Less: imputed interest 0.0
Present value of lease liabilities $ 0.6
XML 18 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Jan. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table reflect goodwill by reportable operating segment:
(In millions)
Medical
 
Industrial
 
Total
Balance at September 27, 2019
$
173.0

 
$
117.8

 
$
290.8

Balance at January 3, 2020
$
173.0

 
$
117.8

 
$
290.8
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]
The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the condensed consolidated balance sheets:
 
January 3, 2020
 
September 27, 2019
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(30.8
)
 
$
43.3

 
$
74.1

 
$
(28.4
)
 
$
45.7

Patents, licenses and other
12.7

 
(8.7
)
 
4.0

 
12.7

 
(8.4
)
 
4.3

Customer contracts and supplier relationship
50.7

 
(19.0
)
 
31.7

 
50.7

 
(17.2
)
 
33.5

Total intangible assets with finite lives
137.5

 
(58.5
)
 
79.0

 
137.5

 
(54.0
)
 
83.5

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
2.8

 
0.0

 
2.8

Total intangible assets
$
140.3

 
$
(58.5
)
 
$
81.8

 
$
140.3

 
$
(54.0
)
 
$
86.3

 
 
 
 
 
 
 
 
 
 
 
 
XML 19 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 20 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS (Tables)
 3 Months Ended
Jan. 03, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
The table below summarizes the effect of recording the share-based compensation expense (which includes the option component of the employee stock purchase plan shares):
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Cost of revenues
$
0.3

 
$
0.3

Research and development
0.6

 
0.5

Selling, general and administrative 
2.3

 
1.8

Total share-based compensation expense
$
3.2

 
$
2.6
Schedule of Share-based Compensation, Stock Options, Activity
The following table summarizes the activity for stock options under Varex’s 2017 Omnibus Stock Plan and 2017 Employee Stock Purchase Plan for the Company’s employees:
 
Options Outstanding
(In thousands, except per share amounts and the remaining term)
Options
 
Price Range
 
Weighted Average Exercise Price
 
Weighted Average Remaining Term (in years)
 
Aggregate Intrinsic Value(1)
Outstanding at September 27, 2019
2,269

 
$22.63 - $37.60

 
$
30.60

 
 
 
 
Granted
—

 
—

 
—

 
 
 
 
Canceled, expired or forfeited
(19
)
 
$22.84 - $37.10

 
30.99

 
 
 
 
Exercised
(49
)
 
$22.84 - $22.84

 
22.84

 
 
 
 
Outstanding at January 3, 2020
2,201

 
$22.63 - $37.60

 
$
30.77

 
3.92
 
$
1,735.0

 
 
 
 
 
 
 
 
 
 
Exercisable at January 3, 2020
1,500

 
$22.63 - $37.60

 
$
30.04

 
3.34
 
$
1,735.0

(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $30.00 as of January 3, 2020, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
The following table summarizes the activity for restricted stock units under Varex’s 2017 Omnibus Stock Plan for the Company’s employees:
(In thousands, except per share amounts)
Number of Shares

Weighted Average Grant-Date Fair Value
Balance at September 27, 2019
678


$
33.18

Granted
3


26.78

Vested
(2
)

30.21

Canceled or expired
(8
)

33.49

Balance at January 3, 2020
671


$
33.16
XML 21 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
 3 Months Ended
Jan. 03, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
The Company records all derivatives on the consolidated balance sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective.    The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. The Company does not offset fair value amounts recognized for derivative instruments in its consolidated balance sheets for presentation purposes.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Cash Flow Hedges
The Company uses interest rate swap contracts as cash flow hedges to manage its exposure to fluctuations in LIBOR interest rates. Interest rate swap contracts hedging variable rate debt effectively fix the LIBOR component of its interest rate for a specific period of time.
As of January 3, 2020, the Company had the following outstanding derivatives designated as hedging instruments:
(In millions, except for number of instruments)
 
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
 
6

 
$
253.1

The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for cash flow hedges:
 
Amount of Gain (Loss) Recognized in OCI on Derivative
Three months ended
 
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income
 
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income
Three months ended
(In millions)
January 3, 2020
 
December 28, 2018
 
 
January 3, 2020
 
December 28, 2018
Interest Rate Swap Contracts
$
—

 
$
(2.5
)
 
Interest expense
 
$
—

 
$
0.4


The Company expects that approximately $(0.3) million of the accumulated other comprehensive (loss) income related to cash flow hedges will be realized in pre-tax earnings over the next 12 months, but the amount will vary depending on interest rates.
These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. The following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the
accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as cash flow hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Interest rate swap contracts
 
Accrued liabilities and other current liabilities
 
$
(0.3
)
 
$
—

Interest rate swap contracts
 
Other long-term liabilities
 
(0.2
)
 
(0.5
)
 
 
 
 
$
(0.5
)
 
$
(0.5
)

Derivatives Designated as Hedging Instruments - Net Investment Hedges
The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive (loss) income along with the foreign currency translation adjustments on those investments. As of January 3, 2020, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7

The following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain (Loss) Recognized in OCI on Derivative
Three months ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
January 3, 2020
 
December 28, 2018
 
 
January 3, 2020
 
December 28, 2018
Cross Currency Swap Contracts
$
(0.8
)
 
$
—

 
Interest expense
 
$
0.4

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as net investment hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Cross Currency Swap Contracts
 
Other current assets
 
$
1.3

 
$
—

Cross Currency Swap Contracts
 
Other long-term liabilities
 
(2.2
)
 
—

 
 
 
 
$
(0.9
)
 
$
—

Balance Sheet Hedges
The Company’s foreign currency management objective is to mitigate the potential impact of currency fluctuations on the value of its U.S. dollar cash flows and to reduce the variability of certain cash flows at the subsidiary level. These forward contracts are not designated for hedge accounting treatment, therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense). The Company does not and does not intend to use derivative financial instruments for speculative or trading purposes.
The following table shows the notional amounts of outstanding foreign currency contracts as of January 3, 2020:
 
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions)
Buy contracts
 
Sell contract
Japanese yen
$
2.3

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.7

 
—

Euro
—

 
(3.4
)
 
$
4.0

 
$
(4.4
)
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES
 3 Months Ended
Jan. 03, 2020
Leases [Abstract]  
Leases LEASES
On September 28, 2019, the Company adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement. The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of one year to approximately five years, some of which may include options to extend the leases for up to six years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, our incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease.
The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
January 3, 2020
(In millions)
Balance Sheet Location
 
Operating Leases
 
Finance Leases
Assets
 
 
 
 
 
Operating lease right-of-use assets
Operating lease assets
 
$
25.1

 
$
—

Finance lease right-of-use assets
Property, plant and equipment, net
 
$
—

 
$
0.6

Liabilities
 
 
 
 
 
Operating lease liabilities (current)
Current operating lease liabilities
 
$
6.7

 
$
—

Finance lease liabilities (current)
Accrued liabilities and other current liabilities
 
$
—

 
$
0.2

Operating lease liabilities (non-current)
Operating lease liabilities
 
$
19.2

 
$
—

Finance lease liabilities (non-current)
Other long-term liabilities
 
$
—

 
$
0.4

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:
 
January 3, 2020
 
Operating Leases
 
Finance Leases
Weighted average remaining lease term (in years)
5.2

 
3.0

Weighted average discount rate
4.2
%
 
3.8
%

The following table provides information related to the Company’s operating and finance leases:
(In millions)
Three Months Ended January 3, 2020
Total operating lease costs (a)
$
2.1

 
 
Total finance lease costs
$
0.1

 
 
Operating cash flows from operating leases
$
2.0

Financing cash flows from finance leases
0.1

Total cash paid for amounts included in the measurement of lease liabilities
$
2.1

(a) Includes variable and short-term lease expense, which were immaterial for the three months ended January 3, 2020.


As of January 3, 2020, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:
(In millions)
 
 
 
Fiscal years:
Operating Leases
 
Finance Leases
2020 remaining
$
5.8

 
$
0.2

2021
6.5

 
0.2

2022
5.6

 
0.1

2023
3.3

 
0.1

2024
2.5

 
—

Thereafter
5.3

 
—

Total future lease payments
$
29.0

 
$
0.6

Less: imputed interest
(3.2
)
 
—

Present value of lease liabilities
25.8

 
0.6



At September 27, 2019, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as follows: $7.5 million, $5.4 million, $4.7 million, $1.8 million, $0.9 million, and $0.2 million, respectively.
Leases LEASES
On September 28, 2019, the Company adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. The determination of whether an arrangement is, or contains, a lease is performed at the inception of the arrangement. The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles and certain equipment. The Company's lease agreements do not contain any material residual value guarantees, variable lease costs, bargain purchase options or restrictive covenants. The Company does not have any lease transactions with related parties. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of one year to approximately five years, some of which may include options to extend the leases for up to six years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, our incremental borrowing rate is based on a credit-adjusted risk-free rate, which best approximates a secured rate over a similar term of lease.
The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
January 3, 2020
(In millions)
Balance Sheet Location
 
Operating Leases
 
Finance Leases
Assets
 
 
 
 
 
Operating lease right-of-use assets
Operating lease assets
 
$
25.1

 
$
—

Finance lease right-of-use assets
Property, plant and equipment, net
 
$
—

 
$
0.6

Liabilities
 
 
 
 
 
Operating lease liabilities (current)
Current operating lease liabilities
 
$
6.7

 
$
—

Finance lease liabilities (current)
Accrued liabilities and other current liabilities
 
$
—

 
$
0.2

Operating lease liabilities (non-current)
Operating lease liabilities
 
$
19.2

 
$
—

Finance lease liabilities (non-current)
Other long-term liabilities
 
$
—

 
$
0.4

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:
 
January 3, 2020
 
Operating Leases
 
Finance Leases
Weighted average remaining lease term (in years)
5.2

 
3.0

Weighted average discount rate
4.2
%
 
3.8
%

The following table provides information related to the Company’s operating and finance leases:
(In millions)
Three Months Ended January 3, 2020
Total operating lease costs (a)
$
2.1

 
 
Total finance lease costs
$
0.1

 
 
Operating cash flows from operating leases
$
2.0

Financing cash flows from finance leases
0.1

Total cash paid for amounts included in the measurement of lease liabilities
$
2.1

(a) Includes variable and short-term lease expense, which were immaterial for the three months ended January 3, 2020.


As of January 3, 2020, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:
(In millions)
 
 
 
Fiscal years:
Operating Leases
 
Finance Leases
2020 remaining
$
5.8

 
$
0.2

2021
6.5

 
0.2

2022
5.6

 
0.1

2023
3.3

 
0.1

2024
2.5

 
—

Thereafter
5.3

 
—

Total future lease payments
$
29.0

 
$
0.6

Less: imputed interest
(3.2
)
 
—

Present value of lease liabilities
25.8

 
0.6



At September 27, 2019, the Company was committed to minimum rentals under non-cancelable operating leases (including rent escalation clauses) for fiscal years 2020 through 2024 and thereafter, as follows: $7.5 million, $5.4 million, $4.7 million, $1.8 million, $0.9 million, and $0.2 million, respectively.
XML 23 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS
 3 Months Ended
Jan. 03, 2020
Debt Disclosure [Abstract]  
BORROWINGS BORROWINGS
The following table summarizes the Company's short-term and long-term debt:
 
January 3, 2020
 
September 27, 2019
 
$ Change
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
 
 
Current maturities of long-term debt
 
 
 
 
 
 
 
 
 
Term facility
$
29.4

 
5.3
%
 
$
29.4

 
5.6
%
 
$
—

Other debt
1.0

 
 
 
1.3

 
 
 
(0.3
)
Total current maturities of long-term debt
$
30.4

 
 
 
$
30.7

 
 
 
$
(0.3
)
 
 
 
 
 
 
 
 
 
 
Non-current maturities of long-term debt:
 
 
 
 
 
 
 
 
 
Revolving credit facility
$
52.0

 
5.3
%
 
$
59.0

 
5.6
%
 
$
(7.0
)
Term facility
301.1

 
5.3
%
 
308.6

 
5.6
%
 
(7.5
)
Other debt
2.6

 
 
 
2.5

 
 
 
0.1

Debt issuance costs
(4.8
)
 
 
 
(5.7
)
 
 
 
0.9

Non-current maturities of long-term debt
350.9

 
 
 
364.4

 
 
 
(13.5
)
Total long-term debt, net
$
381.3

 
 
 
$
395.1

 
 
 
$
(13.8
)

Existing Credit Facility
On May 1, 2017 Varex entered into a new secured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of up to $200 million with a term of five years, and a secured term facility (the “Term Facility” and together with the Revolving Credit Facility, the “Credit Agreement”) in an aggregate principal amount of $400 million, which is subsequently amended. The Company reduced the Revolving Credit Facility to $150 million on October 3, 2018 and to $125 million on October 1, 2019. At January 3, 2020, the Company had $73.0 million of the Revolving Credit Facility available for borrowings, subject to covenants contained in the Credit Agreement. The Term Facility will be repaid over five years, with 5.0% payable in quarterly installments during each of the first two years of the term thereof, 7.5% payable in quarterly installments during the third and fourth years of the term thereof, and 10% payable in quarterly installments in the fifth year of the term thereof, with the remaining amount due at maturity. Both the Term Facility and Revolving Credit Facility expire on May 1, 2022.
The Credit Agreement contains various customary restrictive covenants that limits, among other things, the incurrence of indebtedness by Varex and its subsidiaries, the grant or incurrence of liens by Varex and its subsidiaries, the entry into sale and leaseback transactions by Varex and its subsidiaries, and the entry into certain fundamental change transactions by Varex and its subsidiaries. It also contains customary events of default and certain financial covenants. The Company agreed to maintain financial covenants, which include maximum consolidated total leverage ratio, maximum senior secured leverage ratio, maximum capital expenditures and a minimum consolidated fixed charge coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement as of January 3, 2020.
The Credit Agreement is secured by the stock and assets of Varex’s material subsidiaries. The Credit Agreement has several borrowing and interest rate options including the following indices: (a) LIBOR rate, or (b) the base rate (equal to the greater of the prime rate, the federal funds rate plus 0.50% or the LIBOR rate for a one-month period plus 1.00%). Loans under the Credit Agreement bear interest at a rate per annum using the applicable indices plus a varying interest rate margin of between 1.75% and 2.75% (for LIBOR rate loans) and 0.75%-1.75% (for base rate loans). The Credit Agreement also provides for fees applicable to amounts available to be drawn under outstanding letters of credit of 0.125%, and a fee on unused commitments which ranges from 0.25% to 0.40%.
XML 24 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 193 435 1 false 72 0 false 8 false false R1.htm 0001000 - Document - Cover Sheet http://www.varex.com/role/Cover Cover Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) Sheet http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited) Sheet http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited) Statements 3 false false R4.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 4 false false R5.htm 1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) Sheet http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2102100 - Disclosure - REVENUE RECOGNITION Sheet http://www.varex.com/role/RevenueRecognition REVENUE RECOGNITION Notes 9 false false R10.htm 2103100 - Disclosure - LEASES Sheet http://www.varex.com/role/Leases LEASES Notes 10 false false R11.htm 2104100 - Disclosure - BUSINESS COMBINATION Sheet http://www.varex.com/role/BusinessCombination BUSINESS COMBINATION Notes 11 false false R12.htm 2105100 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.varex.com/role/RelatedPartyTransactions RELATED-PARTY TRANSACTIONS Notes 12 false false R13.htm 2106100 - Disclosure - RESTRUCTURING Sheet http://www.varex.com/role/Restructuring RESTRUCTURING Notes 13 false false R14.htm 2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivities FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Notes 14 false false R15.htm 2108100 - Disclosure - FAIR VALUE Sheet http://www.varex.com/role/FairValue FAIR VALUE Notes 15 false false R16.htm 2109100 - Disclosure - INVENTORIES Sheet http://www.varex.com/role/Inventories INVENTORIES Notes 16 false false R17.htm 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.varex.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 17 false false R18.htm 2111100 - Disclosure - BORROWINGS Sheet http://www.varex.com/role/Borrowings BORROWINGS Notes 18 false false R19.htm 2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Sheet http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS Notes 19 false false R20.htm 2113100 - Disclosure - NET (LOSS) EARNINGS PER SHARE Sheet http://www.varex.com/role/NetLossEarningsPerShare NET (LOSS) EARNINGS PER SHARE Notes 20 false false R21.htm 2114100 - Disclosure - EMPLOYEE STOCK PLANS Sheet http://www.varex.com/role/EmployeeStockPlans EMPLOYEE STOCK PLANS Notes 21 false false R22.htm 2115100 - Disclosure - TAXES ON EARNINGS Sheet http://www.varex.com/role/TaxesOnEarnings TAXES ON EARNINGS Notes 22 false false R23.htm 2116100 - Disclosure - SEGMENT INFORMATION Sheet http://www.varex.com/role/SegmentInformation SEGMENT INFORMATION Notes 23 false false R24.htm 2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.varex.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 2302301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.varex.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.varex.com/role/RevenueRecognition 26 false false R27.htm 2303301 - Disclosure - LEASES (Tables) Sheet http://www.varex.com/role/LeasesTables LEASES (Tables) Tables http://www.varex.com/role/Leases 27 false false R28.htm 2304301 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://www.varex.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) Tables http://www.varex.com/role/BusinessCombination 28 false false R29.htm 2306301 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.varex.com/role/RestructuringTables RESTRUCTURING (Tables) Tables http://www.varex.com/role/Restructuring 29 false false R30.htm 2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesTables FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Tables http://www.varex.com/role/FinancialDerivativesAndHedgingActivities 30 false false R31.htm 2308301 - Disclosure - FAIR VALUE (Tables) Sheet http://www.varex.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.varex.com/role/FairValue 31 false false R32.htm 2309301 - Disclosure - INVENTORIES (Tables) Sheet http://www.varex.com/role/InventoriesTables INVENTORIES (Tables) Tables http://www.varex.com/role/Inventories 32 false false R33.htm 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.varex.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.varex.com/role/GoodwillAndIntangibleAssets 33 false false R34.htm 2311301 - Disclosure - BORROWINGS (Tables) Sheet http://www.varex.com/role/BorrowingsTables BORROWINGS (Tables) Tables http://www.varex.com/role/Borrowings 34 false false R35.htm 2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) Sheet http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables) Tables http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests 35 false false R36.htm 2313301 - Disclosure - NET (LOSS) EARNINGS PER SHARE (Tables) Sheet http://www.varex.com/role/NetLossEarningsPerShareTables NET (LOSS) EARNINGS PER SHARE (Tables) Tables http://www.varex.com/role/NetLossEarningsPerShare 36 false false R37.htm 2314301 - Disclosure - EMPLOYEE STOCK PLANS (Tables) Sheet http://www.varex.com/role/EmployeeStockPlansTables EMPLOYEE STOCK PLANS (Tables) Tables http://www.varex.com/role/EmployeeStockPlans 37 false false R38.htm 2315301 - Disclosure - TAXES ON EARNINGS (Tables) Sheet http://www.varex.com/role/TaxesOnEarningsTables TAXES ON EARNINGS (Tables) Tables http://www.varex.com/role/TaxesOnEarnings 38 false false R39.htm 2316301 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.varex.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://www.varex.com/role/SegmentInformation 39 false false R40.htm 2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Details 40 false false R41.htm 2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) Details 41 false false R42.htm 2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) Details 42 false false R43.htm 2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Details 43 false false R44.htm 2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details) Sheet http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details) Details 44 false false R45.htm 2402402 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) Sheet http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails REVENUE RECOGNITION - Disaggregation of Revenue (Details) Details 45 false false R46.htm 2402403 - Disclosure - REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details) Sheet http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details) Details 46 false false R47.htm 2402404 - Disclosure - REVENUE RECOGNITION - Performance Obligation (Details) Sheet http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails REVENUE RECOGNITION - Performance Obligation (Details) Details 47 false false R48.htm 2403402 - Disclosure - LEASES - Narrative (Details) Sheet http://www.varex.com/role/LeasesNarrativeDetails LEASES - Narrative (Details) Details 48 false false R49.htm 2403403 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) Sheet http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) Details 49 false false R50.htm 2403404 - Disclosure - LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details) Sheet http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details) Details 50 false false R51.htm 2403405 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) Sheet http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) Details 51 false false R52.htm 2403406 - Disclosure - LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details) Sheet http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details) Details 52 false false R53.htm 2404403 - Disclosure - BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details) Sheet http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details) Details 53 false false R54.htm 2404404 - Disclosure - BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details) Sheet http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details) Details 54 false false R55.htm 2404405 - Disclosure - BUSINESS COMBINATION - Intangibles Acquired (Details) Sheet http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails BUSINESS COMBINATION - Intangibles Acquired (Details) Details 55 false false R56.htm 2404406 - Disclosure - BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details) Sheet http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details) Details 56 false false R57.htm 2405401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details) Sheet http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details) Details 57 false false R58.htm 2406402 - Disclosure - RESTRUCTURING - Narrative (Details) Sheet http://www.varex.com/role/RestructuringNarrativeDetails RESTRUCTURING - Narrative (Details) Details 58 false false R59.htm 2406403 - Disclosure - RESTRUCTURING - Summary of Restructuring Cost Incurred (Details) Sheet http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails RESTRUCTURING - Summary of Restructuring Cost Incurred (Details) Details 59 false false R60.htm 2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) Details 60 false false R61.htm 2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) Details 61 false false R62.htm 2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) Details 62 false false R63.htm 2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details) Details 63 false false R64.htm 2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details) Sheet http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details) Details 64 false false R65.htm 2408402 - Disclosure - FAIR VALUE (Details) Sheet http://www.varex.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.varex.com/role/FairValueTables 65 false false R66.htm 2409402 - Disclosure - INVENTORIES (Details) Sheet http://www.varex.com/role/InventoriesDetails INVENTORIES (Details) Details http://www.varex.com/role/InventoriesTables 66 false false R67.htm 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) Sheet http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) Details 67 false false R68.htm 2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 68 false false R69.htm 2411402 - Disclosure - BORROWINGS - Schedule of Debt (Details) Sheet http://www.varex.com/role/BorrowingsScheduleOfDebtDetails BORROWINGS - Schedule of Debt (Details) Details 69 false false R70.htm 2411403 - Disclosure - BORROWINGS - Narrative (Details) Sheet http://www.varex.com/role/BorrowingsNarrativeDetails BORROWINGS - Narrative (Details) Details 70 false false R71.htm 2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details) Sheet http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details) Details 71 false false R72.htm 2413402 - Disclosure - NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details) Sheet http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details) Details http://www.varex.com/role/NetLossEarningsPerShareTables 72 false false R73.htm 2414402 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Sheet http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Details 73 false false R74.htm 2414403 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Sheet http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Details 74 false false R75.htm 2414404 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Sheet http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Details 75 false false R76.htm 2415402 - Disclosure - TAXES ON EARNINGS - Reconciliation (Details) Sheet http://www.varex.com/role/TaxesOnEarningsReconciliationDetails TAXES ON EARNINGS - Reconciliation (Details) Details 76 false false R77.htm 2415403 - Disclosure - TAXES ON EARNINGS - Narrative (Details) Sheet http://www.varex.com/role/TaxesOnEarningsNarrativeDetails TAXES ON EARNINGS - Narrative (Details) Details 77 false false R78.htm 2416402 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details) Sheet http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails SEGMENT INFORMATION - Income Statement Information (Details) Details 78 false false R79.htm 2416403 - Disclosure - SEGMENT INFORMATION - Assets (Details) Sheet http://www.varex.com/role/SegmentInformationAssetsDetails SEGMENT INFORMATION - Assets (Details) Details 79 false false R9999.htm Uncategorized Items - varex10q2020q1.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - varex10q2020q1.htm Cover 80 false false All Reports Book All Reports varex10q2020q1.htm var-20200103.xsd var-20200103_cal.xml var-20200103_def.xml var-20200103_lab.xml var-20200103_pre.xml varexq120exhibit311.htm varexq120exhibit312.htm varexq120exhibit321.htm varexq120exhibit322.htm logoa34.jpg http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 25 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION (Tables)
 3 Months Ended
Jan. 03, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Geographic Location
The following table disaggregates the Company’s revenue by geographic region:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Americas
$
70.3

 
$
68.4

EMEA
65.2

 
62.6

APAC
64.6

 
54.7

 
$
200.1

 
$
185.7
Summary of Contract Asset and Liabilities The following table summarizes the changes in the contract assets and refund liabilities for the three months ended January 3, 2020:
(In millions)
Contract Assets
Balance at September 28, 2019
$
23.7

Costs recovered from product returns during the period
(0.8
)
Contract asset from shipments of products, subject to return during the period
1.6

Balance at January 3, 2020
$
24.5

(In millions)
Refund Liabilities
Balance at September 28, 2019
$
26.4

Release of refund liability included in beginning of year refund liability
(0.9
)
Additions to refund liabilities
1.7

Balance at January 3, 2020
$
27.2
EXCEL 26 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

,N"M$PP=?$1X1SE%!@+GT$#@^*$;NSVU$XC8/?YE8_4)2_.(H#=_ M./[;[%45S8G MMX@H$VH.QY@99>9P?$X?> [[IT3V_J3['S/B*OM'Q-70HOZKA.*^L?X>/\$K6O[789J$PG/>]! M8K,2#?^>,^(VOH-]#PW;E=#3]V:6MTN0S4TJ_*E #OKY_8PE: #0&Q=X'\^( M9&.Z;0CZL_"6*5?2-N7A,.MVB16SY\I!R[4']GH=E] FR(X&9>G"TS<& Q$'PR$';UA7?. ]6R4Q^+/\V, :-5TUR[TA-3Y771K<#Z# ) M9TUSWGD8B\^@!AL'RIE!QZZ+S $[],7!*J, M1)&5FH=GJY@3TW.6(Z^TEZT28JJ3N(S\<.UYB;PM5H%@C"**(5\>Y=!^'[<[ M/UGT#&C=A<>C+22>SZ5,"JOT'M(R@625SYDT*%\3!9+9()NU(N :KVB>;\HT M9XTCD]U=QJ_L2RG,VFQOD&526?2"X5FIVQ-%K;UTH[>9?*HO^J< M!MJT[R!.8"'L3+&?7D_H.]A25^?; @R7BG286TM&3;+4Y!Y40\T(I8PMDNQ M[W");#294C !J#G," WJJO4!VNK/CU@ )R)92#<#,N1RI_=A7OD+,UA;UIWP MGA\(X$&'_V]IS7C,58LN1WHYC4V9+)8W=F^Y'5V5;).TZ^_6'?/#2O'QL[5. M%QURUKF&^CYD^V5(;*P]VO!.@'X)SW[CF'FM(#'PRSPQB/THK;;LHT6R3*DB M,5\*38]-XA7E I.0"\1'OBB^3VR@ONY4 !8H@8W&ZQKU)XIR,=5UPY(G+L4? M74HU$];F\O 0U#L6&TX,WA\R99?1EFI)8_00!V>JO%LG>)X+:]ME#1AEL MJN)*)7G,EOYQ-G3? DEQ'V3+B0\D@I\KL6!\T,.!!*@4$ON_;\&H^01R\383 M2I(C%@"_39TD4QH>&_OH_=5\C?B_A-N3JZ0!E1J0+9-#TDU,;@"] P(MO'/0 MCJZS>+EQEQZ0H=HUH"0=[IIJBRV!CMCV3 $MC-S,[)K6@7LCI)@7@Q[@%A,. MWB-[+TSA8-!(X5+!9>_17_LX"34G=)D(X%J''CB45^A!M[#\7,->$PNPR$P$ M-(]8"VKT*"2*H]Q=YYS$/0"?PJ^N0%!FLFZ"5Y:)1!4 M05@#),"F-E(/6;!()C5FPC]L2A9LN^1M"^%KN$1#IW\H"&J^"3^6\$+(TZ>K MK]#Z5FNE- RQ":ONRBOE6$'I")1'-+$[))MH',,]$ WR^"&-JP[+!C(RQ?RT M-B[ODAY6..0*RNYO(L=B9WJD6XV'8B_I MGIJUV3X?Z^@'TJRJX/ #*%>F\@>%:OI[DJCEE,<5N)5F_@BZZ['ECR6"L]8S MR8_)YY2J@6(UCW0R?^$DYJG%O>(8'1C\._*>M@0I2P"Q7+TG L(5>R]UDORM8?@ MM%YF%K,#1W!'8%;LH$4?P+VI0^O$ VU9N;R[OA]8ZP>=6EJI$$Y2!DN/$_K= M0F6K1^M5QG= GCP*D@1#&>$[&$J+$O.:D16"Y6U'GZQL1JVW> X:>(/!'* M;:MHU"!_&"=+ DL9?^$\%5M]%\7VE,[Z4O"<9JF)"F.L+[\MFC?7)=^?'/VITSX_)JE3YD]' M#BB9R^'2B?-A,(_9!K;?.R"R+@5N4\SVJ=<0Q0)(1]WS]NEIV!/L VZBCT @ MQTKV91.+Q(/#K0EQ (4"N7'LC ^N1TS2CI:0%Q*.]'8YE52:= '7)6FNQ/$: MC%F;ML-:!Y\0W]M/9>PHST>%2WB,L7?2[F^0P-KB%Z E4+-N7*DME;M&KHD& MD;5H^D&[6SU<4M:,6@V>6UR*/:KDA7Y FUL35DEHG! :T3V?@H[ J@3>XO%W M$8WZ735Z08XRXZ[Q';.W 09=D?.']]'^]>UX?! -!Z,;KZ-I:1]<*'-GL"H9D?>8&13%:$J1>FE MU1.6U61+"8*P8"X)R39DL<$@.0E6,5621"JF:R29:I!'@[W%[[KB3' 4$#$& MY=,E&F"]0 :8)(I>:/^@\A<2YL^PF%8"@VN70^KYQ0A_1UR_-UDL> MEJ;5@&H,:\* H=TZ,VMKN@N8JEJ8V@F:T9(CM<,SA3_.7MN*&4:EG0%,\] = M1VS$5)!FPJ4]9$D>PR=Z@CNAL%JX]&;M\?97;U^.D=Q"_\L.TH$KR,VLQIX) MLTP5-E*SM^G,."'FZT(=QNJT2LK]\2;Q3/ ^#Z@EZ/6'':OCKR*1O1.4:2WK M6KB\F(XOH1?O'JA1N?\^WEW?_CH<1N/[VXN_1G?7@VH1%KH6#YE$[KA6)ZC= M9,JCOYLOS+K6^98]?$?-76A)>"CA*KH_3U0V\2P^BM2&2*QZ7=.O,,[; Z*I M$0QM,2B,LR9+Q=8!I:8"<00\R> MZMK(JJVKA+=)CW(H3J(Q3?Z6UTC@!E]V2E,WSU(ZF^9LPJ9\YPT%;]PNEL"] M"^GT;AZS$D^_#S#);C7/VV?=#@V"?[]()=&&(-MDW"IHB\" M6+.K>XH^)UCH64+09_M=RJN%QL^.I/%N!YL^/[=3AJ>._*?X#_Y_,('PH,#H M.]WZT8.^WF^?4[QSZ[1_#**/],@*=K6M;NNXTZEOJW.$:M.1:@L7%PG7@S#H-/E>V7?IU8"F+;C6$=9%6$9[2H87L@NYM=-Y.D'YM$ MP9&$6B13X2&?EFC\>BTORUTSO-QK:N8U3&T'=K4C:]+H(V->C@J#H8-^>(D[ MK#)C-D>PGYQB6&V_WX;[R3"*/MI^X/O/+)7N4P0QJ )=RRJ00QAFL7_& <; M #:$O9^<=J6?2L[&_>#OPW%T>V.M"]7,#5+2[N',[10L6VFP[O+>?EV[@H[. MXHOGGAS1&.SX$Z[3&?SCQ[I9*2U>&OT27^,J'1Q)UPF@\/TGS?6,3W9_/PQO MRFQ3@-8D(3"@/\)95O8QAT(GERH%$3R.=CQ!J81%6 MITMX I)#"N/Y2D%F*N >VG8('Q@_DSNT>=E%&1G0EQV"&,7\BIGH+367 $ZP MXN*B"-LOI"*6A>J,?$ &]P-C M?D[O/,>C%! *SQ!A7KTSRQ$58V[,0VR44B MJ5(:7+?.6)(G:O*$<9X:71I56*S"83=!']*T"#KC.KE9'DP#7S8E19LR(57Q M8LZ*USJ7'S2*89V87(3M\]X2P(:IX%.&L2H^N1-J&&/-9GKW"-:>:[:X&+LE M*%.S^&N64UN&"AV@!^LA,IQD6B'+EK[O=7(SMN*JY]AC%GJ#K6%)SYG,:CZR M8L?QMXH"/OSP<7AS'UW=O+\=?1Q@*=/*(YS-!?8R,W90V M5C34I6?JL@_%U?A:JR]3EIRTD4978 M5IX8VZVMV_0$%% WA(NG-)FA'#UA6\SM; :#R/$09K1!&$6%M'AQ>_D1!!+A M.2P@V+ MG6A;%TPT1#XN)GFZ,LLS-@2"@PGJ+@@63]%2!8"0-5(9*=_)WE3\21>(BCGH M#'L5GB+&1N>B0HT@>\SCU9/8QV?S=09K-LE6\(4TC\,!C8,> XG!:C9 H?9+ M;$C2[)]@"58O4C.+'LT/8ZI+Q\5K*"I+GSJWSM%#GH&.8(>]<99F\FIJ\JH\.F%/X; >&CK]D<$YE,I1;Z@4(?#IM"'YZS_$M1FM4-)YW& MC\L,R][9E_ 98'<+Z35>8YPR/F!!J<7;B$8@KJZ@1PG=F#PWD#2X,A<.XV$] M^?+BQR[;$]^XDG&>J%/$ZE9F'RQ>@)LLHMOA1[7,=!.CK)JCEYJA'Q86* :4 M#L.MW-1K" 3%/HSU;D5?$2, #G[^$O(W?QAA6#8R*3X:R*H:9T@5:1@'E\ZW M<-R)J7F-!%*P*R'+33D7-%+.7QA$?7H(!RHOS/4]CR=2_,(#:%)IPZ\_SO9. M4,>7M%[V&5879LG2>+8,CK9!L0#=CRJ+F09:F#7\F+F('%30\ DA';S!9"E/R*8]IP M-'EA&@.3V$J1*#1_7'S-TS5F1!];HY.R)H6 M:"FIA!S?2VQ?L/8R#W:3L9[34JI9X)44"2 AX8?-@GO48'/*#Q;WU0HJSX(_ M^.*=DBQ_C V7D8J"4LR)&1S00*$B$BNU"UQ\'.:,I"#>8>Z.%\GHH&:Y]+R: MT"*)D49!8<.NW0)N\2W8.;W.=;N+W7YDI ISZ^Q%W6-,L<1\Y'[[7!__(TPM M/G(V>&7K[W4ZE.G8/6=0,+=L@6%.7 M6CY!NP(_X(01ZYPY/L&AG<.X;>",RT8/X.Z* \[3W#_FA- 3\C[;L)$'KD4* MN@"Z.[N48XX)\/?T1::T6P=)U?5]N?(6NK.OX>2^_0%!.*]WI.]@$@SIK-1@ M*P\O$OX72I+? _K!:#.S-%;9ZHXPSOI<>^KT',$!%>^@3Z 81W8FFN,ARR M>G=.SMIL_^[TS]KG%07IT\>/@]&OT>W[:'SUX>;J_=7% /2EP<7%[:>;>PSP MO[N]OKI 0)3].RPU @>W@J/'P'5PPN]409F*@>ZI"I):Y\BL#U_.L3XR1D&7 MDF=:-'I":QMP)NL5*JL\N110DM<0+8-[:$GAJ9, MU06F@13D,3>E7\>N]"N[]TW_-;55%0JG)./B&-Q=AI?I2AEET,:=2*4U&ML M+C>@'=OYA\'@SO3>-M""(.HO13EQ<:8MN0%?LZCFRB<(0H?\W8IT+ 16GX&> MELC3=72H]X*K*<6)3@0$9'MR=QE?;48/)8Z0+@Q.;Z4JJ"M'5T^/KYRN,;-X M5+RTI:HM?;*D]V2B(! AC+/LEO]<+X-*D-M[M]B(J-LY_*NQ]&$2X"Q% [\=%= L@US;(HS,KBKF?OYGB2391.J)3DK)=;%B^$(%6-T3L0/P*,$A8+Y-()T<6H8#5:JD^M6IPXNM$*/%3<0@[);XI*X 1RW&(.,(MW-K! .&DQ 0_QE]@ M'_??H%'H#8@77]-$X(XE,+;^OK76%J_D^CC!,&&0U;LG4L^G[5',H B]4N!.?V%]F?'85 M[A/^+@HKWK_.-5-_L2&W0NIA@ 8X+'B3FO,>YF6JQNE9VJU.L:&\&K0),=H MH'"+8V0&?-JYYBC;RJ+3M1RDFR1M^WA.+<)>3W.6#9:1*C BSI!0)4&-O5PK M[9A+$')TAHV8+-0N5DN,N\@ 1'"LD340$,D1UB@MONST$,+VU0"%D2W,CL6J"8LF:/S;+VR 8CB56#CG, )<3:ZV]J6E ZTVJ#K, .Y:>F$G6B: M/2\1=<5ASYCY&%=H0:E;UC-.146S]4,Y6\\=%;"OA2)P.'I)PD;1J@U_J4(% M7%*]AGATW]D#]UQ0,17#HJS]5G*LG8D4CV=LRW+R@F&,M:#B$;7(0V@-G">' M['.R3]302)*67'S>T B\P(3S]/M/7>H=MWW3/2GQ*&2O]Z:' M(:?B)*L'&[)/P\U:SEFFH=C& \S)H29();<^.OHJ+8QP MV((N;2D';!%N5B_(D%TZ+;E8XHV&=[XW[80DP]M/A-TVN+>U0WDPUC M('99U)W4.V9!T2\QY@"4+]M^#\!U'M-([ M,A%54OD+,3815B,7DQ#R;MC>1V2KI5MI#."85&XR#99"9&^76Z)V&!<0QO)L MYJ5+$Z>,<^_)@[34O*A,X$Y2]$IAV\+J5(C0-L\=VKA35ORI1)4,S0BUQ "1 M]2,HE4F$9P!':J)R2FC3B<:XP Z*C9%SZYG]$*AE>IWJ4G-P$O0.KW/PIQFL M3,%26ZDFY%8RF)HJ;4WQ=P6J[XS5[%Q.15UT@PF $O@GOJM( \_LX''$C E% M-C5Q-IEPK$ -EC6@<;71&D0 BF84_JWR0!*)G8LRBC0-;*8$-R_N!3@BQ\W) M$4X"H<-U8M0*D/6S"0JF,Z,#3FL4A G#(0ZF&1EI!\Z:"XQB"7]/E([%C^N'QE+"@!CN)QG6 M#0BSOR:EJR?W&[J]6H(X_I"38@[Z]PFOEU,_:L?R+L,Z"(BC\.;]8/SNS8&8 MU>J?YF%'^V\&XT]O$!JU33T==GJMZ#HA'(/!.8"1NAN,-VU,0V)T9MZ8A()]U)NAQXG%7O'5\#%X7*?\ !,JDUA',#/<:C>O MP2J>?(E95EQA5*:](Z8IL:$5%@@I74JK.=IJ)^T81-="TL6(5QH@FIAFV3S- M@O2&,XL$ZR*T_5$^BW7 \'"6"?#)47:%_&IZ66[ )^5L MMZ"1E'$!#1-P<9)-;9I7"=\DQ?MW"G7I7.ZT.>:4802! .OABT4UFP0_B8! MI.C!I+N!-Y6;F:93(J4=%X1.XM<$IFVZ$:FD;SC1=N:K2FJM/& %Q90W3((S/#3F4QFR*3-!- MXT"9PR4;GL)D&4K'\7#],7G605;[V2\L'N3X928NEV TH?G='X4G&&#OIV%5 M@>;><<,=>%BAE% )^JKS4#G6(R"PLC5QX8^,[?Z6@S)Q20D,JIAERIEU_I=T&$2\X5@NUC+QOV0/!3HR MX(8M!/O$RFDP?G+_FX#U;37>3:4U6L]@HUEAXQ*IXO!J\'"++@R"IX+O3@M: M:[PA?;$/C<.>$.JY3G<002V$;Y/PJ1ML.YVI7@+S[ARC/#DB$1JUG)Y"B)09 MR^ 4U'N67T>]WZL,(MFK* W$76T@^_/#;D_H$_1SD ]FJPI'SW"C)R_.#:9*HFUDE%FW#\RRR:^%\JS MKW#($FLS[G0\XHU;?'K8.3*83O,X9PT4>].]RTIS[)M&)X,QZT):";I;EFYF MXS)98?%$YW@M'7HMW/VV#\LR7* OFJK8?<;[:+H)&L-N)=18.O7K/L?*O8QI MV5)YJ*P4R K8DK4U[T@F5*MS"YETPS[(/.VT"D2_$98"IT#+ +\#=;E1?"]Y MK4&"51:A*FV='';[K>C-1Y]@!(W[VCI7G2U)589NOV'!!YL2NVLA\7MB^V>7 M@J,&UK*Y_)8X0?57$GLE4&S.&\FC$5,A(\*\$-JN6BK:1*T,E\ W(2>8,9QVKW M392,1,R16(C1^I!8K1$%65!+ILP_0#AP],MFUFUDZO) M2ZC9_D=9/I; I?O MJ99V)6QY3$'?I)M>F" ^F,8Q$1L"_UHBB 0&K0OD?;R) M=FSTA; J70[VSJ&@2T9)I1Z[AD"2L#_^Y7*!^/)4S)=LRNOXDLUU6DK M7M?[IVH"AP?,.7$@M76BN7$&&?>9? MAM%H>'$+G):2Z)MXZF5:&&0EG^Q1N/N0V-3C:TD@WV5OIZ[-AGCAW/7QZ/I M@.YL^6-VE?,JD$6<,GP;I=4,/PX'T)L^ Y5K86X4TWS^ZT6@7Z>C@8;Y*?%/<>8^A;(L6\3$=CRME0 ?JM M30!Y9$HDF#PF4(1]HB"+45UL=]TAL+!EA1Z-GT&2;LTN_4,18$;X=M9J 56? M)OS)&SZGDB/$]?A>6I6/%]@+B7 MS'A0F%IQ1A@7[=3UWD\\6@\'H@EN7XQ"![:BZR9#.]X[IXU#KV_77&ZAP5ZL MG=)KJH#+Q@JV%P/:G<@2/_11A+O5&09/Y M#.&RXFP\SD5ZQ7L$I55<*VS,/^^[*%M!=K;Q#E+UW?B P%B[\I3O;N)G]BCC MV2VK4EET<1KGM]LC25&,,34O!)ZCCNV='J0RI*0_2,QLF%(8F WKC@1."*=V M99Q=""+A;"NN0C6_+$%?-B41O:7IPIK:7R&85 T%:NL]0G0*1O31%CD.WHZ^ M+>9OBU4\2?[C#1VW_&ORYL\UB'9^F>1PJS?[$:V7.]3D=1E8!JKC6$?D&PD[ M2;84V%"Y7H22N_E@TES<803-E[+/D562M>B$JDC3AQZ5FT;"@0]]*J@A'XZH MV+3A7O=NJ%BKVG[-M,[AIA+5P5D*8A?HF.N&8 )2 2"R]:%$S3'-2=ZY,Q57 M%[EW3$7H*\J-)H]@?78AD#^_^S2^NAF.Q]'%[<=W5S>#C=J1I^]:C&,">QU8 M3*WO$/>!--E*AT;@>=]B,X MZ39_*T*LBSNI9^SB.2MWLT@A'7K:DT1:OBA"R)L?C-O@"$15A+/PD\*B?L\B M91@U9R(&>="QS]MG;O"F#C$A0W2B[Y$E]KM4[7RG',DN<,>)!N.L .NK:A8[^+)EWGV*)R\BV72IDFTC!?(%F'/<-<(>AY%OV3R MM&0O2Q?0].ET(D-2912:V'L8)>7I"%J6O$H>K*J.-* M9[EJAQK?CSY=W'\:H7E_!ZO^*#'8?KCY;&VX$I]3A8]3*0)*H^(H%H$V5 UP M0>7"N:V\:N@_")[7A) D4ZYSPPBG.M2KT0Z\@Z7K6K'Y8'7LY*(+[8 8>PX( M"P:TDR&4@;]PH?"\300.KK$B LKO8RK;O)P8T7>7 @@=$DO.+1!.W9YA'VNI*83LY]U:=XQ;Y2R-?XD1T:U \75)$D)?Z;3C MYQ3A1'&C[7=R25X\I?0:3 LV^2$ERY5Y9KC.,_="G^XOI!N4%O>/Z&,]'+Y+ M_9P&(K97)TPMR-1;C"=9C+1I,;PT7U>72SVOP=S5FH;[8F&ZT.H%"Q6OK*&S MB$[(R-.'N__WF>:2#&062_J_;M87!&UV8:@YF#8ZX4Y/:RSHOIR@UDV1=OA2 MB$'54#J6[ M8(IY==D+7$MW2K_':K;?$?@T<_0V]K!1;NVP>ZI#$NY>^,>F#;XA4[*ES9]I ME79AJD&U!YNX9Z#=$U MT?D^?95&[BC.P%1H:N-#5CVA:((;V%E]P!"]_6NJLS7RBD?=7EPQJ).=E98& MZ#WHH/95"7#UW]Z73H>FA!HMVM KJGJ?4/#R03C WZ^CUWKV=O!P;^1->\8= M57,Z7,FE#@42**-(D321%U7"=?ZJ15R@\03VG>VOIK)Q$3VF%%PI8:CH]N%Z M<4A3LQFZQ"@>@2Q+'!60$T! &W5"&U4@3$\R%))YRB*YT!KVV=X%,9&Q*9W2 M1,-HFJ&-Z/SN(_3_'[Y=>R!_ _/>3&VW=?:3O:CK25>[--' GGN>66W/&"AL MVQ79>7 UBCX/KC\-&R5CIZ.VO"654$**-QM95$""DJS6@F$=BSK@HG&AO$-0 M7APBP"6'&I(Y&8L@MS;L:<09WS;,E%#4[7 HWLV" 7.R#A4S6%$)!2G^H,*X M5%-/*3!V4)9?_(I0Z7*%\?Q4O!2:-<:'I&)U*"NV=JYTI)1^%8Y9U+EU?3+_ MVSK#U2%[(QVK 0?U?92B GCF&8\4E?EMD#6EZ(15SQ3%DM MX^;>LH=%!VP=HKZ:O$AI@P@]U[[[Z\CS#/)G=6)EHQWF;-_[VS,(-FRZ;OV$ ME G_LYK_6]UUD\.N%XRX1R-N,(R=5FJSX7=5RU[CV,\YU"3HL]NKVM7T41P8 MK-G_/H7_?0K_^Q3^CJKZVNR'%_=W ]N/ER]NQY&@_%X>+_; M"AL/YRL"GKVMHGYMSMGM+9Z)VC_KLQMK#V ME0QK,D!Q O.4L?=";Y<.JI%D1_/#IH007]FM!E]M9>9<@^+"3%!L*SK% M>: GAV:W\.$?T(1QXKK\=N5YW(M.C^B@[?>-;>6H3RJN^;YW9FS_%&H0EXS] M.H<+*H@UZ.*5O']&X?#H*#"?C^ASW[DJE0=%LK\(RE%[,*-C9*O[7?:L]]$S M(=^<3<-9BKZ1]E7W.TC>,#^\1G90$_).RI?'5$/9]B> MK/YT*7F/SMW*S?4HP*5#_^J_FP:$A4S8\6:& )='EPZH^X$' C]@,9"*S_1V M-+K]A8JM[N87>_@-5\8?"ATV1AJ%%S:QTU'80S\GYOLU>C& ;V(J=OR8%-9J M:3SJA\:C[CL;=GMJIT@1*A(^BR<<=4214$<4./63^W!"'\S5SJ(4O8P.-!2V MQ5PO\1:[=$LY6$?\SZDS^-^X:-6-[[_%)(]LSEGBG!2IYG",L8AF#L?G]('G ML']*U.5/NM_!V!9^OM\YPV0*>GS_5$7%T*@QY:)'OM\NT1:EK"K?\?X1U[$Y MIL./EJQ=)Q3UC_'Q_@GZ%/>['(\C,ICWH(F1[I])XM@YAV#C.V=5?\9H>#D< M?AR@6'!S>W-Q>W,_NKV^1AQ1Y^-NK"!%5:8BSBH,= M]25G ]#OJM%[*56M.DF(SQ<,.MR-F^%]M']].QX?N K6=\-1-/YY,&HVKFKV M:F,S[E"W>J*R@VC(F4@VQ1Q#*,,&!F047^+9\X29Y7K!1=LDU&?)T2A@CW.>S+@X82@ B' M5"9',S%S!,%U\D7%^P(;$HHY^"%)CXV!6OC_45,H8(?BPH]WBMS"J"!7-F_K M*N&1[)&5;6,8=_.>CVG%;E>"8DYFK!T3C,,P GF5 6^IV4Q <1C4D(Z)U04) MFNEVL82#5,@H[G"[;-4F1[C\HPT.QZ<"" B'#28O46@_=WZK6,4^6>RS=1$O MIQL8IZKX82+_4;XYL&UR@/J(Y.9*<.GP&PC,J0UCWY#?=Q]D]0Q,3B\* CG" MPD_$0+G?/? F4F^*Z+5Z)R (]( :^L"/]K D7H=E6/CW R8ZPSA":YIUDN*= M/4^H/H/%9(2%GB6$0P]*'G(T:/SL2!KO=K#I\W,[97CJR'^*_^#_!Q,(CQN, MOM.M'_WI*=#Y.5FO6J?]8[B%I$?.GZFVU6T==SKU;76.4-@X4FWAXA)TC5W^ MU"X_VQ!M=#23.N>;;QER9?,YF,$.86::"*S$_V M\K<]4/D-NVXFB"(6A]3W,42%L\&,)X [X2^Q-D/QP[BE0N?@#5U3\Z]AFSLP MQ!V9GXY/'/."5U@8L9+#2Z0AY479;"<].44[2K_?AGO4L*(^)G_#]Y\3PFW9 M)Y,1R'U=RXP8%Y;9T?X96Y2 Q6PPKIZ<=J6?RI5X/_C[C+4]47>+_7:KXOTL5_VZEBFN@_@-579PA%!!IJ!@: MTQD8>COJR,2+>N;A+IZ-!3U_TY!?A6OF MI@-O?AI?1OM[2(AX_F5/J_5*5VW+AS84S)O\4-2T#1!>OVVQC"O(+]-'-?KT MTFQZ[G [(%8XQF[/8__5961L(SKC%O.&7$!F()O+#-*X_G&-P4U7.);041H\ MCG4#6\H-4AGN6?NL4[EZ$=ZK^JU-N!W9;.'*BW AU30'?+/Z[:MVLX(G]FKJ M_B@5(/ 9 \=;;982*F"G_S$"IHKU=-#&55GCU\*"U1CKFY#!FHI2U0*$O6I< MGCF[LCJ@U2_6BZTEL5P2_28:M(^CZ:'FA'!F964,\;>Z,=AR6;^)@%Y16.!F-[P?WP_%NV#G:F[-'P@_MV%"@1C]^L53'+AQ 7\< M(EV%,CN#GQTZVKIO?H@.FNTJBROJO,U"%\M9<:N'THK&AH8ZGM$ M8J'U&<-/Q2R>&.=#G)<1F9'^,?B6%O_S+>WG8:=[V*F$ZO^XCC>RF&WKT7+H MVJ5MO?"F54^_ AUX&-W@Q'90M_[=?3+\OF:E[P&)Z^':_GQ^5L?Z/%"YJL'@H;0(=U3,U(ZP^FA=HM]N3[6<#<,+ M/,#8%8FOVG'O=\)[)+92N]=Z!UXM/>^,Z5@U5E2'4F/EVP#76'63!KD']8$.5@Q736C%'YB&,7K=,;9&;]2E%AE51UV8?4P5T$,JWZ% M>N&I'K#P^SC\*)FS/_/G))Z73Q.,-KE:Q(\< V>3G.IX_A;;Q2[M5NTIUX/[ MX>7AW6!T_VMT/QK('Q)+UZJ.^3 MAW;4/=MH]+N=E' )=8DD*[) G=5P05:]&B.R-PV&+_.G&$W*3 M?;7W9HV[D^,_[A!C!S$VE\4.!AA!09)8&Y))D8U""U+,W&'+5%9YNDK_'OV< MS2G$[?_%"((TKO"884-KK2A[7@+WP+2V9F??$<;952]IZ[FFU,2\3->+B+>G M@('4;U330*K^*[FF1$0W<36$7=1@[+>(OBWO\1JQVQ=6%O%RC88LP8J,5_&D MQH)Y7+L(?DNS]!N)$35ZR^?AA3VG'Q8//TN&ST76CO[ZH=*J,8V4F;EW=B>( M,0P(B"!KH1LRF6 $))#%:[JO;>$]S8VT1. )BY0[AQ_^O][.MJ>-(PC ?^6D M1BV5SH A0*M*E5R*JU00(AGR):JJHSY24F(C&S>-Y!_?VYU]G]G9W>/@"Q_P MWNS;[-OLS+-9"NA36Y]D$,0\5^W&(-S-$H9.@@J*:M]M99KJ]+Y9-=54QZ-U MXSH"YE8WH%W-"S_T"^,^"@N!:\;F&CUGJ8O/'ED'O<'2<@TLM\?N,T)_Q=.N MQWNE-U$DTA6M.2485Z_B-*_5WW'EW%"A M@9W;*EZ( .:YK5ZA_16')!NN)]4RZ@3S3,42DM'!64K-O/T-ZWA-4BIK%\I8 M:^=$] *YF >NFO_02.J%=KQ"/&JL#0DMW99H_9:GSF572C6)OI7U7E[O*BD9 M4-HQ^<6K6#+8$ 2RL(4R=,V6O;9LS%,=+E:+Y.!?L:,]+:SV3>:?-FH7$5,\ MH@8E#3#$?"SQ1([/_?--R;F.'#3MQP)X:G!]9KZCD6C2G9E81 M9O65=U$=^ MD1+C:B=;BL-3EM6.E_2<*U+Q>3E?E_%64L&!O3!1%U6C.M.;2+0W/41F0V"3 M>GAZY<[!ZFXC>(38$V7\M80S#82."R1/U&6O_[1@=AD3R^01R^WUHIO;[N52 MZ"XF_ER1'/Y3%?#?3:3@4&.\:=B>\Q#X_+Z(_;332)>8GTKK /1324.@?BJ] M8.SC7;J#]F=_3-0C3,O4(TR:JD>8GJJ'BZLM/M$ AP[M;'.P=,EYD36(TZ@W M9!YWJ'1YRU;:A)Z9$A M^M##Z!5;-&B 79@LX-<15Y<.Q([N5H=D%R9(D.M&]N4MX>)^"Q[NN4N;^9;W MCV>C*9'U X(K\(95!P@5UQ#SY8J[.Y%6I^A$MAO#C8>Q2,K/@F"&G/F&N=T\HN[U M!B[I=+E9)8IZ0D5 IO4R=B>4[@R8R)UB4_ZNUQ+#I"34TA,*;OZJV[9E&G5_ M=WQPU*,ZR?[,$#!MYQ(U-94L<(NRD-8=:3(J&>]%436\QG:+N3)Q?J%QD^4*AL^_TS-E?!!9F][JLA)K/!F_Y@@!;HU?19 M>63,])>+=H@Y+&?UDS=?+Y/75,R??%9CTC]F -;M*$J,M1LJ1*8N<0"E&XW9QUZT[^\L=F:V%.12$:\Z^:W:D;^A MS?K)(;7<3Q:+C?16T>\6>1!+X3W>;KJ3E(60B?DQI4=7[6(_?\$9]PVD=2$)""80#)T(I& MYG5P3!WO>?SSJ,+HI[<>H?E7A] LK.@(_"RORGQOTW?@8" "'&:@/J0A:L^9 M8R4)L"Z?=-/H*W1&R4%G+E)4Q M,HKN6"9-4S]+2^'5OH5YO*3JK<.=9=(GH,!YQ?L2QLWZB%BW]T11A#[912Z[ M\Y+YE C/[N1!U(PJ)H_: 8(K M5DFWQ(A8\_NEV)^NF9C/S$:S\>7Z\FBCT!0.$#N4K>*\J_'81)R+@/.>[?JD M(FB>5D6'O-.M$)"B\\J=^ CV*;FJ 9&64@M0[CZ=6\VI=HJ1PSA7M5,L\:0 MARB>FS;& L\00"_A) K:9<[ ?ZF3=W31]D[,KQ+'ZP$&LCI>N$[><.?T^'>S ML,/\[5)Z:(L.H[<5T:.)TT@.N[H6YP$M$6TR:O&8BLH$[UBC9ZE85MQVI%@8 M%'H@87HY="G6PTAVFM??Q?1LVR'7#$>9:')X%9+#.0I7@7HY1A$TVTLE >R] M\S@HGAM$K$;4+)"K@2^=?ZBT+YT_H>F7;2W=QA?9&@1HAZNFV37_)MN6EJ#6:.= M&V.G-GF@^8< U8^T669FT,8]P#N4=3O"GV:I]YD18BRY6DR_,6Y^)N =Z1)% M>,<[2UV2F2U)Q&>03!MW)*0[KJ_+($$_Q[9IL$IO*UQ2W*H&D)Z3_+RY:5$% MS^Y)>SSIP'X*_H=BP)T9(QV"UVHJK0 ,P$Y <.L5US44N5F//C;-PY]6-$B^ MO.WD6K%&ZIL%R+R\C4E\UTAW(NVT@2=8Q9TUFH53[JW7CS__#U!+ P04 M" "I@%)0Y&KU<6L" !@#0 #0 'AL+W-T>6QE!#!3*G_G.$6488:*,Y%CKB.)D PI MO92I4^02H[@P28PZ8]>=.0P1#D.?E^R&J0)$HN0J@+/.!6S^M8AQ $=O1B/W MS+T_O3IIS%,([+Z/<0"]V5OH_#'Q_N3UMU*HJU? 7GNA862+\'07X:VR ]'9 M;K1/X0ZESY^1_OGC<;MX']PF?[&K_)/J _%+(^XT'1'ZB>!]8TR@=>CJB&&P M1#2 UXB2A20F*T&,T)5UCXTC$E1(H'1':CK/>(H'&_;LRC1KH\,(%[*N;2O8 MST6S?1!H5P:04-H!CJ%UA'Z.E,*2W^A%O;EV_A8"C3U?Y9HPE6CEC:>P3Z@O MNLA"R!C+KHP'6U?H4YP8'$G2S%R5R!T35$HP;<0$I8*CFJ'-: PM&V%*[\PW M^6NRH5TEP.XQC\2%P%"TICYU8_9/S:V1U]6L]KKL9"]=D).E4!]*?1Q>KTWK MX%N)$U+5ZRKI +0ZRG.Z>D])RAFVAWFVH+=GP=!';1V0"4D>M)YIE4@[L(1@ MB:4BT;KGNT3Y'%>J;:'SVCFB2. /(H[>7$,D)>'#SGYUXQ.,V2L33(;&PO=V]R:V)O;VLN>&ULQ9M+#B#G\>LSX'7?54722M7Z\.LN:M%LFN.0K1% M/E/G@97JE:D;5:53 M^80EI[:ZR?)6U$[2BF5=G>ZR\G U429LG]5-&W77[H\LLC(KLI]BUZ\UQ^K; MQZK.?E9EF^116E=YWG^KV]%_25ZA^;WE5M1ME@X.;)-MF$C6JXDYER>\SYIL MF^59^^-JTG_.Q43^BAGX&7T<'I M-L?LKIFP,BG$U611W8NZ(Y87<'*YCQW(EBN5BQ7T J2*0ZADA_U4!I(9 :F>!O+8]VU]P!B!U!%(_(^0@ MD@8":9RSN34 :2*0YCDA=0!I(9 6+62T6:WL\#,+;ECD+GWWQEW8?LSLQ2+8 M^+$+("\1R$M:R)#?T8!ZW(Q[!?GJ.==1S6IKK M3>3Z/(KD_;:Z=GW[CS@IJ$2(+1)RK[O[IVL[C#^S.+3]R%YT@(/H8091B!42 M\B@.-XMX$[K^$D)AQE"(E7$CF]%?N+;''!ZZM[));WG$;-]A'[FSA(^G@CE# M(9;&C>V&[-;V-AP288)0B WA^K++B(/0'3Z>F X48A\L@\#YY'I>WWRN']O^ MTKWV.+.CB,<#2LP'"K$0KH,P##[)1V! A'7^"GGO[W"^LKM0^8$O71J'@>=) MPBZ(/(28F H48A?X/&877A!%;QBW0[^+(%OSD$4?[1 ^%BJF")58$7RU]H+/ MG,LL)%C\S=8RJ8/MK&**4(D5$=O_R+XM\'^'#X*AM06Q&2*^E(5.+&^WFR!< M_:E5%?.#2NP'-'T;9.LJY@>5V \X)LS754P:*K$T1O),=A$G$J)Y QDQBZC$ M%GE(.4>Q,&VHU-H8R3U'(3&3J.0F 2G>*!TF$)58(&BN-QS#P!2B$2OD*=<; MBZ"&&40C-@A(^D;9,(EHQ!+!LS\X^*.A0U3$0GE*_T8CB$E$(Y8(F@<.GP], M(AJQ1- \D%U 3,PC&K%'QC+!T2;'K*(16^592CA*B"E%(U;*2&XXRHB)12,6 M"YY]P8%('1.+3BP6'-. F)AD=&+)X)@FQ,1\HU,7+2BF!3$QW^AG+6 N(28Z M*4+NGN>5P90Y69,<#K4X0$S,/?H9"I@IBTY%D=0_6 4Q,??HQ.X9QUR+NC]; M"3$Q^^C$]OFOU)HR/ZGKI)NL9A>.:),L'_3M.N8?G=@_OQDC>;+=*1>LVC-/ M)(U@878X0DQ,0?JK3)3\@?E)2,)6[)@-9Q4Q!1G$"AK%#.Y$U_KE 2;I!J8@ M@UA!*.9PCA93D$&LH-$Q@2FSTZ\GR=)"3$Q!!G7),X[Y&%N(B2G((%;0"YAN MV2;E(=M"3'1FGEA!:*,/[TU,00:Y@EZ:C^QC"C$Q!1G$"AJ.6#TS$<3$+&2\ MZL :R#CV+!3-X$G'+&2<=81M\-H(9B&3>H0-Q83UFHE9R"2V$(X)ZS43LY!) M;"$<$]9K)F8A\YPS_8-ZS<0L9+[:3/]H+FQBZC%?;\Y_' Y]&>R"8@RX2$XY)+!PP3#W,@AVQ;0>#K"8F')-8. /,YU4D? 40$XY%+!Q\ M9!TVNH4)QR(6#CZR/H68F' L8N&,CJS+N_28U&*ZA3F;A0G'(A;.2YAME7Z1 MQ23$Q(1C$0OG!B]@]SVIQB5GHLK?0K#^X^?!^)_99*7:^O$0C MMZ=)GJYKUBWZ5_%4W>A>Q]N?\GPAMP6E5R7=]OX&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'/%VD%NVS 0A>&K&#I : [)H5+$6763;=L+"#9M&;$E0631Y/95O:D*)'I= M&$\;"X8%SK_Z+%!\^I8N33GW76[/0]Z\72]=WE5M*<,78_*^3=PJ\W8Q MO_KQ-;1_2_XSOC\?S/GWM]S^OJ2L?5/P=4)F/@V0Y2.A! M;CG(T8/\PM=;@-["UUN WL+76X#>PM=; M@-["U]L!O1U?;P?T=GR]'=#;K;!7@C9+^'H[H+?CZ^V WHZOMP-Z.[[>#NCM M^'H[H+?CZ^V WHZOMP=Z>[[>'NCM^7I[H+?GZ^V!WGZ%O6ZTV >@=^'HKT%OY>BO06_EZ*]!;^7HK MT%OY>BO06_EZ*]!;5SAK@@Z;\/56H+?R]5:@M_+U5J"W\O6.0._(USL"O2-? M[PCTCGR](] [\O6.0._(USL"O2-?[PCTCBN<%42'!?EZ1Z!WY.L=@=Z1KW<- M]*[Y>M?7Z\ M/K?>5BZ$H6]<[OW$[J?V1=/U4\,ZTK"L25T?TH>RH%I]/98NJ5S;5J6:*O:* M"2]OG,_+?=_O*<:^I3=%\[M=WU#KF[NQW%*G$,FUJ2/*XU"GSD5J?^383_NG MO+KT2Z+=7$YH7G?$2:MTY+[:N&E]:7^V%_^WA8OI]ZX7^+B2V'][WU M\^40(#DD2 X%DD.#Y# @.2Q(CBN0'!]!D !D;V-0&UL4$L! A0#% @ J(!24(3%P<+N *P( !$ M ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% @ J(!24)E< MG",0!@ G"< !, ( !M@( 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " "H@%)0#HVDNC # V#P & @ 'W M" >&PO=V]R:W-H965T&UL4$L! A0#% @ J(!24);Q M&PO=V]R:W-H965T M&UL4$L! A0#% @ J8!24" ?-.(L @ , < !@ M ( !6!< 'AL+W=O% M& @ %\'@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ J8!24""F)+JS 0 T@, !@ ( !YR( 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24,^3'V*U 0 T@, !D M ( !GRH 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ J8!24'(ZZWFT 0 T@, !D ( !8C 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!2 M4,$\O=BT 0 T@, !D ( !(S8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24(!6E*JS 0 T@, M !D ( !YCL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24)VU21]( @ / @ !D M ( !IT$ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ J8!24+M;5ZW< 0 04 !D ( !+$@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24*;[ M&$O1 0 G 0 !D ( !*$X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24$!D"U+% 0 -P0 !D M ( !&50 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ J8!24.>$V]FW 0 T@, !D ( ! M[ED 'AL+W=O&PO=V]R:W-H965T%= !X;"]W;W)K&UL4$L! A0#% M @ J8!24 ,=6\?& 0 -P0 !D ( !SU\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24+0Q1#<5 M @ )@8 !D ( !$V8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24#0'9<:$ @ T0@ !D M ( !D6T 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ J8!24*OW8$%J @ 9 @ !D ( !QG0 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MJ8!24"U_,V_U 0 9@4 !D ( !E'L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24,#U;>L$ P M> P !D ( !J8( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24)TMQO\X P C X !D M ( !A(H 'AL+W=O_[S\" !'!P &0 @ 'SC0 >&PO=V]R:W-H M965T&UL4$L! M A0#% @ J8!24/4KN-3C 0 2P4 !D ( !II( 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!2 M4#3K1$G( 0 %@0 !D ( !+9H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24$HP1Z3\ 0 =P4 M !D ( !VJ( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24#'.MTRB P @Q !D M ( !WZH 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ J8!24"QWK+-B @ H < !D ( !.;8 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24%8Q M]0=< @ NP< !D ( !";\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ J8!24 +&X6,8 P 8PP !D M ( !X<4 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ J8!24+,)^V8X? #OH! !0 ( ! MK,T 'AL+W-H87)E9%-T&UL4$L! A0#% @ J8!24.1J]7%K M @ 8 T T ( !%DH! 'AL+W-T>6QE&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ J8!24%+:4AR! @ U2\ !H M ( !WU(! 'AL+U]R96QS+W=OR^$D @ EBX !, ( !F%4! %M#;VYT96YT A7U1Y<&5S72YX;6Q02P4& %D 60!A& [5 XML 27 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS
 3 Months Ended
Jan. 03, 2020
Income Tax Disclosure [Abstract]  
TAXES ON EARNINGS TAXES ON EARNINGS
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Estimated effective tax rate
0.9
%
 
26.8
%

The Company recognized an income tax benefit of $0.0 million and an income tax expense of $1.1 million for the three months ended January 3, 2020 and December 28, 2018, respectively, for effective rates of 0.9% and 26.8%, respectively.
The Company's effective tax rate for the three months ended January 3, 2020, decreased primarily due to losses in certain jurisdictions for which no benefit can be recorded due to full valuation allowance positions and a nearly equivalent overall pre-tax book loss.
As a result of the changes to the U.S. taxation of foreign earnings included in U.S. Tax Reform, the Company reevaluated its previous indefinite reinvestment assertion with respect to these earnings during fiscal year 2018, which resulted in the Company revoking its assertion for current and future earnings for all countries, while maintaining the assertion that historic earnings are indefinitely reinvested outside the U.S. The Company is maintaining this prior assertion for the quarter ended January 3, 2020. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable U.S. tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for U.S. State income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend.

XML 28 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details) - Designated as Hedging Instrument - Foreign Exchange Contract
$ in Millions
Jan. 03, 2020
USD ($)
Buy contracts  
Derivative [Line Items]  
Notional Value $ 4.0
Buy contracts | Japanese yen  
Derivative [Line Items]  
Notional Value 2.3
Buy contracts | Swiss franc  
Derivative [Line Items]  
Notional Value 0.0
Buy contracts | Chinese renminbi  
Derivative [Line Items]  
Notional Value 1.7
Buy contracts | Euro  
Derivative [Line Items]  
Notional Value 0.0
Sell contract  
Derivative [Line Items]  
Notional Value (4.4)
Sell contract | Japanese yen  
Derivative [Line Items]  
Notional Value 0.0
Sell contract | Swiss franc  
Derivative [Line Items]  
Notional Value (1.0)
Sell contract | Chinese renminbi  
Derivative [Line Items]  
Notional Value 0.0
Sell contract | Euro  
Derivative [Line Items]  
Notional Value $ (3.4)
XML 29 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument
$ in Millions
Jan. 03, 2020
USD ($)
derivative
Interest Rate Swap Contracts  
Derivative [Line Items]  
Number of Instruments | derivative 6
Notional Value | $ $ 253.1
Cross Currency Swap Contracts  
Derivative [Line Items]  
Number of Instruments | derivative 4
Notional Value | $ $ 77.7
XML 30 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Sep. 27, 2019
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, gross $ 137.5   $ 137.5
Accumulated amortization (58.5)   (54.0)
Total intangible assets with finite lives, net carrying amount 79.0   83.5
In-process research and development with indefinite lives 2.8   2.8
Total intangible assets, gross 140.3   140.3
Total intangible assets, net 81.8   86.3
Amortization of intangible assets 4.5 $ 3.7  
Acquired existing technology      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, gross 74.1   74.1
Accumulated amortization (30.8)   (28.4)
Total intangible assets with finite lives, net carrying amount 43.3   45.7
Patents, licenses and other      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, gross 12.7   12.7
Accumulated amortization (8.7)   (8.4)
Total intangible assets with finite lives, net carrying amount 4.0   4.3
Customer contracts and supplier relationship      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, gross 50.7   50.7
Accumulated amortization (19.0)   (17.2)
Total intangible assets with finite lives, net carrying amount $ 31.7   $ 33.5
XML 31 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Jan. 03, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Varex Imaging Corporation (the “Company,” “Varex” or “Varex Imaging”) designs, manufactures, sells and services a broad range of Medical products, which include X-ray imaging components, including X-ray tubes, digital detectors and accessories, high voltage connectors, image processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys, for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, computed tomography, oncology and computer-aided detection. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary imaging systems, to independent service companies, distributors and directly to end-users for replacement purposes.
The Company also designs, manufacturers, sells and services industrial products, which include Linatron® X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection systems. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
Varex Imaging Corporation was incorporated in Delaware on July 18, 2016 and is listed on the NASDAQ Global Select Market under the ticker “VREX.”
Basis of Presentation and Principle of Consolidation
The accompanying condensed consolidated financial statements are unaudited. These condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods.
These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements for the fiscal years ended 2019, 2018 and 2017 included in the Company’s Form 10-K, which was filed with the SEC on December 20, 2019. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2019.
Fiscal Year
The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2020 is the 53-week period ending October 2, 2020. Fiscal year 2019 was the 52-week period that ended on September 27, 2019.  The fiscal quarters ended January 3, 2020 and December 28, 2018 were 14-week and 13-week periods, respectively.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates
include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
Restricted Cash
Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet. Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended January 3, 2020
 
Three Months Ended December 28, 2018
 
Beginning of Period
 
End of Period
 
Beginning of Period
 
End of Period
Cash and cash equivalents
$
29.9

 
$
30.0

 
$
51.9

 
$
55.1

Restricted cash
1.4

 
1.4

 
1.5

 
1.4

Cash and cash equivalents and restricted cash as reported per statement of cash flows
$
31.3

 
$
31.4

 
$
53.4

 
$
56.5


Concentration of Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, as follows:
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Canon Medical Systems Corporation
18.8%
 
18.3%

Canon Medical Systems Corporation accounted for 14.5% and 10.1% of the Company’s accounts receivable as of January 3, 2020 and September 27, 2019, respectively.
Loss Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision.
Product Warranty
The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, the Company bases warranty
estimates on historical experience for similar products and adds a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
The following table reflects the changes in the Company’s accrued product warranty:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Accrued product warranty, at beginning of period
$
8.1

 
$
7.3

Charged to cost of revenues
4.1

 
2.0

Product warranty expenditures
(3.2
)
 
(2.7
)
Accrued product warranty, at end of period
$
9.0

 
$
6.6


Leases
The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represents the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate ("IBR"). The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases ("Topic 842"), referred to as ASC 842. The purpose of ASC 842 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and is effective for the Company in fiscal year 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases ("Topic 842"): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 28, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840.
Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 28, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Also, the Company applied the hindsight practical expedient. Furthermore, as a lessee the Company elected to combine lease and non-lease components for the majority of its leases, which means that the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. The only asset class that did not combine lease and non-lease components were vehicle leases.
The most significant impact of the standards for the Company relate to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $26.8 million and $0.6 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $27.5 million and $0.6 million, respectively. This includes the recording of the Company’s existing capital leases as finance leases at transition. The cumulative impact of adoption was a $0.3 million decrease to retained earnings. Refer to Note 3, Leases, for a detailed impact of adopting this standard and its impact on the consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional
disclosures. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Effective September 28, 2019, the Company adopted ASU 2018-02 and it did not have a material effect on the Company’s financial statements and related disclosures.
Recent Accounting Standards or Updates Not Yet Effective
In December 2019, the FASB issued ASU 2019-12 which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021 and must be applied on a modified retrospective basis. The Company is evaluating the potential impact of this standard to its condensed consolidated financial statements.
XML 32 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Movement in Standard Product Warranty Accrual [Roll Forward]    
Accrued product warranty, at beginning of period $ 8.1 $ 7.3
Charged to cost of revenues 4.1 2.0
Product warranty expenditures (3.2) (2.7)
Accrued product warranty, at end of period $ 9.0 $ 6.6
Minimum    
Product Warranty Liability [Line Items]    
Warranty term 12 months  
Maximum    
Product Warranty Liability [Line Items]    
Warranty term 24 months  
XML 33 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Performance Obligation (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Revenue from Contract with Customer [Abstract]    
Remaining performance obligation $ 268.3  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-04    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligation, expected timing of satisfaction, period   12 months
XML 34 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Current assets:    
Cash and cash equivalents $ 30.0 $ 29.9
Accounts receivable, net 122.9 141.0
Inventories 269.1 248.2
Prepaid expenses and other current assets 18.2 19.3
Total current assets 440.2 438.4
Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization 146.2  
Property, plant and equipment, net   142.3
Goodwill 290.8 290.8
Intangible assets, net 81.8 86.3
Investments in privately-held companies 54.9 53.6
Operating lease assets 25.1  
Other assets 29.4 27.5
Total assets 1,068.4 1,038.9
Current liabilities:    
Accounts payable 73.2 58.2
Accrued liabilities and other current liabilities 70.9 75.7
Current operating lease liabilities 6.7  
Current maturities of long-term debt 30.4 30.7
Deferred revenues 9.7 10.5
Total current liabilities 190.9 175.1
Long-term debt, net 350.9 364.4
Deferred tax liabilities 8.9 8.2
Operating lease liabilities 19.2  
Other long-term liabilities 36.6 32.5
Total liabilities 606.5 580.2
Commitments and contingencies
Redeemable noncontrolling interests 10.7 10.5
Equity:    
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued 0.0 0.0
Common stock, $.01 par value: 150,000,000 shares authorized, 38,494,349 issued and outstanding as of January 3, 2020 ; 38,371,305 issued and outstanding as of September 27, 2019 0.4 0.4
Additional paid-in capital 377.6 371.8
Accumulated other comprehensive loss (2.6) (1.7)
Retained earnings 72.5 74.4
Total Varex equity 447.9 444.9
Noncontrolling interests 3.3 3.3
Total equity 451.2 448.2
Total liabilities, redeemable noncontrolling interests and equity $ 1,068.4 $ 1,038.9
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES (Tables)
 3 Months Ended
Jan. 03, 2020
Leases [Abstract]  
Schedule of Supplemental Balance Sheet Information, Weighted Average Remaining Lease Terms and Discount Rates
The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
January 3, 2020
(In millions)
Balance Sheet Location
 
Operating Leases
 
Finance Leases
Assets
 
 
 
 
 
Operating lease right-of-use assets
Operating lease assets
 
$
25.1

 
$
—

Finance lease right-of-use assets
Property, plant and equipment, net
 
$
—

 
$
0.6

Liabilities
 
 
 
 
 
Operating lease liabilities (current)
Current operating lease liabilities
 
$
6.7

 
$
—

Finance lease liabilities (current)
Accrued liabilities and other current liabilities
 
$
—

 
$
0.2

Operating lease liabilities (non-current)
Operating lease liabilities
 
$
19.2

 
$
—

Finance lease liabilities (non-current)
Other long-term liabilities
 
$
—

 
$
0.4

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:
 
January 3, 2020
 
Operating Leases
 
Finance Leases
Weighted average remaining lease term (in years)
5.2

 
3.0

Weighted average discount rate
4.2
%
 
3.8
%
Schedule of Lease Cost and Supplemental Cash Flow Information
(In millions)
Three Months Ended January 3, 2020
Total operating lease costs (a)
$
2.1

 
 
Total finance lease costs
$
0.1

 
 
Operating cash flows from operating leases
$
2.0

Financing cash flows from finance leases
0.1

Total cash paid for amounts included in the measurement of lease liabilities
$
2.1

(a) Includes variable and short-term lease expense, which were immaterial for the three months ended January 3, 2020.
Schedule of Finance Lease Liability Maturities January 3, 2020, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:
(In millions)
 
 
 
Fiscal years:
Operating Leases
 
Finance Leases
2020 remaining
$
5.8

 
$
0.2

2021
6.5

 
0.2

2022
5.6

 
0.1

2023
3.3

 
0.1

2024
2.5

 
—

Thereafter
5.3

 
—

Total future lease payments
$
29.0

 
$
0.6

Less: imputed interest
(3.2
)
 
—

Present value of lease liabilities
25.8

 
0.6
Schedule of Operating Lease Liability Maturities January 3, 2020, maturities of operating lease and finance lease liabilities for each of the following five years and a total thereafter were as follows:
(In millions)
 
 
 
Fiscal years:
Operating Leases
 
Finance Leases
2020 remaining
$
5.8

 
$
0.2

2021
6.5

 
0.2

2022
5.6

 
0.1

2023
3.3

 
0.1

2024
2.5

 
—

Thereafter
5.3

 
—

Total future lease payments
$
29.0

 
$
0.6

Less: imputed interest
(3.2
)
 
—

Present value of lease liabilities
25.8

 
0.6
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION
 3 Months Ended
Jan. 03, 2020
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company has two reportable operating segments Medical and Industrial. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, who is also its CODM, evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross margin. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
The Medical segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy and computer-aided detection. The Company provides a broad range of X-ray imaging components for Medical customers including X-ray tubes, digital flat panel detectors, generators, high voltage connectors, image-processing software and workstations, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, ionization chambers and buckys. The Company’s X-ray imaging components are primarily sold to imaging system OEM customers that incorporate them into their medical diagnostic, radiation therapy, dental, veterinary and industrial imaging systems. The Company also sells its X-ray imaging components to independent service companies, distributors and directly to end-users for replacement purposes.
The Industrial segment designs, manufactures, sells and services products for use in the security and industrial inspection applications, such as airport security, cargo screening at ports and borders and nondestructive examination in a variety of applications. The products include Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high voltage connectors and image processing software that we generally sell to OEM customers that incorporate these products into their inspection systems.
Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
Information related to the Company’s segments is as follows:

Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Revenues
 
 
 
Medical
$
155.6


$
143.9

Industrial
44.5


41.8

Total revenues
$
200.1


$
185.7

Gross margin
 
 
 
Medical
$
43.8

 
$
45.1

Industrial
17.3

 
14.9

Total gross margin
$
61.1

 
$
60.0

Total operating expenses
56.5

 
49.6

Interest and other income (expenses), net
(5.8
)
 
(6.3
)
Earnings before taxes
(1.2
)
 
4.1

Taxes on earnings
—

 
1.1

Net earnings
(1.2
)
 
3.0

Less: Net earnings attributable to noncontrolling interests
0.1

 
—

Net earnings attributable to Varex
$
(1.3
)
 
$
3.0


The following table summarizes the Company’s total assets by its reportable segments:
(In millions)
January 3, 2020
 
September 27, 2019
Identifiable assets
 
 
 
Medical
$
830.8


$
794.3

Industrial
237.6


244.6

Total reportable segments
$
1,068.4


$
1,038.9
XML 37 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS - Schedule of Debt (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2020
Sep. 27, 2019
Current maturities of long-term debt    
Current maturities of long-term debt $ 30.4 $ 30.7
Change in current maturities of long-term debt (0.3)  
Non-current maturities of long-term debt:    
Debt issuance costs (4.8) (5.7)
Non-current maturities of long-term debt 350.9 364.4
Change in debt issuance costs 0.9  
Change in maturities of long-term debt (13.5)  
Total debt outstanding, net 381.3 395.1
Change in total debt outstanding, net (13.8)  
Secured Debt    
Current maturities of long-term debt    
Current maturities of long-term debt $ 29.4 $ 29.4
Weighted-Average Interest Rate 5.30% 5.60%
Change in current portion of Term Facility $ 0.0  
Non-current maturities of long-term debt:    
Long-term debt excluding current maturities, gross $ 301.1 $ 308.6
Weighted-Average Interest Rate 5.30% 5.60%
Change in revolving credit facility $ (7.5)  
Other Debt    
Current maturities of long-term debt    
Current maturities of long-term debt 1.0 $ 1.3
Change in current portion of other long-term debt (0.3)  
Non-current maturities of long-term debt:    
Long-term debt excluding current maturities, gross 2.6 2.5
Change in long-term portion of other debt 0.1  
Revolving Credit Facility May 2017 | Revolving Credit Facility    
Non-current maturities of long-term debt:    
Long-term debt excluding current maturities, gross $ 52.0 $ 59.0
Weighted-Average Interest Rate 5.30% 5.60%
Change in revolving credit facility $ (7.0)  
XML 38 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Assets:    
Cash equivalents - Money market funds $ 4.7 $ 8.8
Derivative assets 1.3  
Total assets measured at fair value 6.0 8.8
Liabilities:    
Derivative liabilities 2.7 0.7
Deferred consideration 9.7 8.9
Total liabilities measured at fair value 12.4 9.6
Long-term debt, fair value 381.3  
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)    
Assets:    
Cash equivalents - Money market funds 0.0 0.0
Derivative assets 0.0  
Total assets measured at fair value 0.0 0.0
Liabilities:    
Derivative liabilities 0.0 0.0
Deferred consideration 9.7 8.9
Total liabilities measured at fair value 9.7 8.9
Significant Other Observable Inputs (Level 2)    
Assets:    
Cash equivalents - Money market funds 4.7 8.8
Derivative assets 1.3  
Total assets measured at fair value 6.0 8.8
Liabilities:    
Derivative liabilities 2.7 0.7
Deferred consideration 0.0 0.0
Total liabilities measured at fair value 2.7 0.7
Significant Unobservable Inputs (Level 3)    
Assets:    
Cash equivalents - Money market funds 0.0 0.0
Derivative assets 0.0  
Total assets measured at fair value 0.0 0.0
Liabilities:    
Derivative liabilities 0.0 0.0
Deferred consideration 0.0 0.0
Total liabilities measured at fair value $ 0.0 $ 0.0
XML 39 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Cross Currency Swap Contracts    
Derivative [Line Items]    
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax $ (0.8)  
Interest Rate Swap Contracts    
Derivative [Line Items]    
Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended 0.0  
Designated as Hedging Instrument | Derivatives designated as cash flow hedges | Cross Currency Swap Contracts    
Derivative [Line Items]    
Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended   $ 0.0
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended   0.0
Designated as Hedging Instrument | Derivatives designated as cash flow hedges | Interest Rate Swap Contracts    
Derivative [Line Items]    
Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended   (2.5)
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended   $ 0.4
Interest expense | Cross Currency Swap Contracts    
Derivative [Line Items]    
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax 0.4  
Interest expense | Interest Rate Swap Contracts    
Derivative [Line Items]    
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended $ 0.0  
XML 40 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Jan. 03, 2020
Sep. 27, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value (in USD per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value per share (in USD per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares, issued (in shares) 38,494,349 38,371,305
Common stock, shares, outstanding (in shares) 38,494,349 38,371,305
XML 41 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover - shares
shares in Millions
 3 Months Ended
Jan. 03, 2020
Feb. 11, 2020
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jan. 03, 2020  
Document Transition Report false  
Entity File Number 001-37860  
Entity Registrant Name VAREX IMAGING CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-3434516  
Entity Address, Address Line One 1678 S. Pioneer Road  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84104  
City Area Code 801  
Local Phone Number 972-5000  
Title of 12(b) Security Common Stock  
Trading Symbol VREX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   38.5
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001681622  
Current Fiscal Year End Date --10-02  
XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (4,100,000)
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (600,000)
Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (600,000)
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (4,100,000)
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (600,000)
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (4,100,000)
XML 44 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION
 3 Months Ended
Jan. 03, 2020
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.
The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray tubes, digital detectors and image-processing tools and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X ray imaging and sells its Linatron ® X-ray accelerators together with its imaging processing software and image detection products to OEM customers that incorporate them into their inspection systems. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
Transaction price and allocation to performance obligations
Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction , to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available.
The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. ASC 606-10-55-23 requires that for sales with a right of return, revenue is reduced for expected returns, a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding contract liability and contract asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately.

Contracts and performance obligations
The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Revenue recognition
Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
Service revenue is generally recognized over time as the services are rendered to the customer based on the extent of progress towards completion of the performance obligation. The Company recognizes service revenue over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.
The following table disaggregates the Company’s revenue by geographic region:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Americas
$
70.3

 
$
68.4

EMEA
65.2

 
62.6

APAC
64.6

 
54.7

 
$
200.1

 
$
185.7


Revenue in the United States of America was $68.9 million and $67.2 million for the three months ended January 3, 2020 and December 28, 2018, respectively.
Refer to Note 16, Segment Information, for the disaggregation of the Company’s revenue based on reportable operating segments.
Contract Balances
Contract assets are included within the prepaid expenses and other current assets, and other assets balances. Contract liabilities, which also includes refund obligations are included within the accrued liabilities and other current liabilities, deferred revenues, and other long-term liabilities balances. The following table summarizes the changes in the contract assets and refund liabilities for the three months ended January 3, 2020:
(In millions)
Contract Assets
Balance at September 28, 2019
$
23.7

Costs recovered from product returns during the period
(0.8
)
Contract asset from shipments of products, subject to return during the period
1.6

Balance at January 3, 2020
$
24.5

(In millions)
Refund Liabilities
Balance at September 28, 2019
$
26.4

Release of refund liability included in beginning of year refund liability
(0.9
)
Additions to refund liabilities
1.7

Balance at January 3, 2020
$
27.2


Remaining Performance Obligations
Remaining performance obligations represent the transaction price of firm orders for which revenue has not yet been recognized. As of January 3, 2020, total remaining performance obligations amounted to $268.3 million. The Company expects to recognize the remaining performance obligations over the next 12 months.
Costs to Obtain or Fulfill a Customer Contract
The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
XML 45 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) - Customer Concentration Risk - Canon Medical Systems Corporation
 3 Months Ended 12 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Sep. 27, 2019
Revenue from Contract with Customer      
Concentration Risk [Line Items]      
Concentration risk, percentage 18.80% 18.30%  
Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.50%   10.10%
XML 46 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details)
$ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
Change in Contract with Customer, Asset [Abstract]  
Balance at September 28, 2019 $ 23.7
Costs recovered from product returns during the period (0.8)
Contract asset from shipments of products, subject to return during the period 1.6
Balance at January 3, 2020 24.5
Change in Contract with Customer, Liability [Abstract]  
Balance at September 28, 2019 26.4
Release of refund liability included in beginning of year refund liability (0.9)
Additions to refund liabilities 1.7
Balance at January 3, 2020 $ 27.2
ZIP 47 0001681622-20-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001681622-20-000005-xbrl.zip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

@7.\^*K8<:Y MGR0GY/[Z9U>R@PG)-9D" MY3ITIB:25M*^_G8EN_?3R?E@]->%1R(3"W)Q??QY.""56KW^97]0KY^,3LBG MT6^?R<%>HTE&BB::&RX3*NIU[ZQ"*I$Q::=>G\UF>[/]/:DF]=%E'9MO#KJ.W;WH1HP'\?=/[J58C)]+/8I88XBM�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end XML 48 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS - Narrative (Details) - USD ($)
May 01, 2017
Jan. 03, 2020
Oct. 01, 2019
Oct. 03, 2018
Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Available borrowing capacity   $ 73,000,000.0    
Second Revolving Credit Facility [Member] | Debt Instrument, Repayment, Period Two | Secured Debt        
Line of Credit Facility [Line Items]        
Repayment percentage 5.00%      
Second Revolving Credit Facility [Member] | Debt Instrument, Repayment, Period Four | Secured Debt        
Line of Credit Facility [Line Items]        
Repayment percentage 7.50%      
Revolving Credit Facility May 2017        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity     $ 125,000,000 $ 150,000,000
Revolving Credit Facility May 2017 | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity $ 200,000,000      
Debt instrument, term 5 years      
Used capacity, commitment fee percentage 0.125%      
Revolving Credit Facility May 2017 | Secured Debt        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity $ 400,000,000      
Debt instrument, term 5 years      
Revolving Credit Facility May 2017 | Federal Funds Effective Swap Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 0.50%      
Revolving Credit Facility May 2017 | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 1.00%      
Revolving Credit Facility May 2017 | Minimum | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Unused capacity, commitment fee percentage 0.25%      
Revolving Credit Facility May 2017 | Minimum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 1.75%      
Revolving Credit Facility May 2017 | Minimum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 0.75%      
Revolving Credit Facility May 2017 | Maximum | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Unused capacity, commitment fee percentage 0.40%      
Revolving Credit Facility May 2017 | Maximum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 2.75%      
Revolving Credit Facility May 2017 | Maximum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 1.75%      
Revolving Credit Facility May 2017 | Debt Instrument, Repayment, Period One | Secured Debt        
Line of Credit Facility [Line Items]        
Repayment percentage 5.00%      
Revolving Credit Facility May 2017 | Debt Instrument, Repayment, Period Three | Secured Debt        
Line of Credit Facility [Line Items]        
Repayment percentage 7.50%      
Revolving Credit Facility May 2017 | Debt Instrument, Repayment, Period Five | Secured Debt        
Line of Credit Facility [Line Items]        
Repayment percentage 10.00%      

XML 49 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands
 3 Months Ended
Jan. 03, 2020
Sep. 27, 2019
Number of Shares [Rollforward]    
Options, outstanding, beginning balance (in shares) 2,269  
Options, grants in period (in shares) 0  
Options, canceled, forfeited and expired in period (in shares) (19)  
Options, exercises in period (in shares) (49)  
Options, outstanding, ending balance (in shares) 2,201  
Options, exercisable (in shares) 1,500  
Weighted Average Exercise Price    
Options, outstanding, weighted average exercise price, beginning (in USD per share) $ 30.60  
Options, grants in period, weighted average exercise price (in USD per share) 0  
Options, canceled, forfeited and expired in period, weighted average exercise price (in USD per share) 30.99  
Options, exercises in period, weighted average exercise price (in USD per share) 22.84  
Options, outstanding, weighted average exercise price, ending (in USD per share) 30.77  
Options, exercisable, weighted average exercise price (in USD per share) $ 30.04  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]    
Options, outstanding, weighted average remaining contractual term (in years) 3 years 11 months 1 day  
Options, exercisable, weighted average remaining contractual term (in years) 3 years 4 months 2 days  
Options, outstanding, intrinsic value $ 1,735,000.0  
Options, exercisable, intrinsic value $ 1,735,000.0  
Share price (in USD per share) $ 30.00  
Minimum    
Price range    
Outstanding at period beginning and ending (in USD per share) 22.63 $ 22.63
Canceled, expired or forfeited (in USD per share) 22.84  
Exercised (in USD per share) 22.84  
Exercisable at January 3, 2020 (in USD per share) 22.63  
Maximum    
Price range    
Outstanding at period beginning and ending (in USD per share) 37.60 $ 37.60
Canceled, expired or forfeited (in USD per share) 37.10  
Exercised (in USD per share) 22.84  
Exercisable at January 3, 2020 (in USD per share) $ 37.60  
XML 50 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION - Income Statement Information (Details)
$ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
segment
Dec. 28, 2018
USD ($)
Segment Reporting Information [Line Items]    
Number of reportable operating segments | segment 2  
Revenues, net $ 200.1 $ 185.7
Gross margin 61.1 60.0
Total operating expenses 56.5 49.6
Interest and other income (expenses), net (5.8) (6.3)
Earnings before taxes (1.2) 4.1
Taxes on earnings 0.0 1.1
Net (loss) earnings (1.2) 3.0
Less: Net earnings attributable to noncontrolling interests 0.1 0.0
Net (loss) earnings attributable to Varex (1.3) 3.0
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues, net 155.6 143.9
Gross margin 43.8 45.1
Operating Segments | Industrial    
Segment Reporting Information [Line Items]    
Revenues, net 44.5 41.8
Gross margin $ 17.3 $ 14.9
XML 51 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended 14 Months Ended
Feb. 18, 2020
USD ($)
Oct. 31, 2013
Jan. 03, 2020
USD ($)
member
Dec. 28, 2018
USD ($)
Dec. 31, 2020
USD ($)
Jan. 03, 2020
USD ($)
member
Sep. 27, 2019
USD ($)
Nov. 30, 2018
Related Party Transaction [Line Items]                
(Loss) Income from equity method investments     $ (0.7) $ (0.8)        
dpiX Holding | Varian                
Related Party Transaction [Line Items]                
Equity method investment, ownership percentage     40.00%     40.00%    
Number of consortium members | member     4     4    
(Loss) Income from equity method investments     $ 0.9 (0.7)        
Equity method investments     48.5     $ 48.5 $ 48.1  
Purchases from related party     5.9 $ 2.8        
Accounts payable, related parties     3.4     3.4 3.6  
Percentage of manufacturing capacity   50.00%            
Percentage of fixed costs   50.00%            
VEC Imaging GmbH & Co. KG                
Related Party Transaction [Line Items]                
Equity method investment, ownership percentage               50.00%
Equity method investments     $ 3.0     3.0 $ 2.0  
Payments to acquire equity method investments           $ 4.2    
Scenario, Forecast | VEC Imaging GmbH & Co. KG                
Related Party Transaction [Line Items]                
Payments to acquire equity method investments $ 1.1              
Scenario, Forecast | Fixed Cost Commitments | dpiX Holding | Varian                
Related Party Transaction [Line Items]                
Purchases from related party         $ 12.7      
XML 52 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details) - Direct Conversion AB - USD ($)
$ in Millions
Apr. 29, 2019
Apr. 30, 2019
Business Acquisition [Line Items]    
Percentage of voting interests acquired 98.20% 98.20%
Net cash paid $ 69.5  
Debt assumed in acquisition 4.5  
Deferred consideration $ 9.9  
Deferred consideration, value of common stock (in shares) 300,000  
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORIES (Tables)
 3 Months Ended
Jan. 03, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
The following table summarizes the Company’s inventories:
(In millions)
January 3, 2020
 
September 27, 2019
Raw materials and parts
$
184.2


$
160.1

Work-in-process
27.6


27.9

Finished goods
57.3


60.2

Total inventories
$
269.1


$
248.2
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET (LOSS) EARNINGS PER SHARE (Tables)
 3 Months Ended
Jan. 03, 2020
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
 
Three Months Ended
(In millions, except per share amounts)
January 3, 2020
 
December 28, 2018
Net earnings attributable to Varex
$
(1.3
)
 
$
3.0

Weighted average shares outstanding - basic
38.5

 
38.1

Dilutive effect of potential common shares
—

 
0.2

Weighted average shares outstanding - diluted
38.5

 
38.3

Net earnings per share attributable to Varex - basic
$
(0.03
)
 
$
0.08

Net earnings per share attributable to Varex - diluted
$
(0.03
)
 
$
0.08

Anti-dilutive shared based awards, excluded
1.7

 
2.1
XML 55 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
 3 Months Ended
Jan. 03, 2020
Noncontrolling Interest [Abstract]  
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS
In April 2019, a subsidiary of Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion. As the Company has majority voting rights it has consolidated Direct Conversion's operations in its consolidated financial statements and recorded the noncontrolling interest. The noncontrolling interest related to Direct Conversion is included in noncontrolling interest in the equity section of the Company's consolidated balance sheet. Earnings representing the noncontrolling interest's portion of Direct Conversion's income from operations is included in the Company's consolidated statements of earnings.
In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in our consolidated financial statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest in the joint venture is included in noncontrolling interest in the equity section of the Company’s consolidated balance sheet. Earnings representing the noncontrolling partner's share of income from operations is included in the Company's consolidated statements of earnings.
In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015; and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity.
At January 3, 2020, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.
Changes in redeemable noncontrolling interests were as follows:
(In millions)
Redeemable Noncontrolling Interests
 
Noncontrolling Interest
Balance at beginning of period, September 27, 2019
$
10.5

 
$
3.3

Net earnings attributable to noncontrolling interests
0.1

 
—

Other, including foreign currency remeasurement
0.1

 
—

Balance at end of period, January 3, 2020
$
10.7

 
$
3.3
XML 56 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE
 3 Months Ended
Jan. 03, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Assets/Liabilities Measured at Fair Value on a Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
 
Fair Value Measurements at January 3, 2020
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
4.7

 
$
—

 
$
4.7

Derivative assets
—

 
1.3

 
—

 
1.3

Total assets measured at fair value
$
—

 
$
6.0

 
$
—

 
$
6.0

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
2.7

 
$
—

 
$
2.7

Deferred consideration
9.7

 
—

 
—

 
9.7

Total liabilities measured at fair value
$
9.7

 
$
2.7

 
$
—

 
$
12.4


As of January 3, 2020, the outstanding borrowings under the Company's credit agreement were $381.3 million, net of deferred loan costs, which approximated its fair value. The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable and accounts payable, also approximate their fair values due to their short maturities. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. There were no financial assets or liabilities measured on a recurring basis using significant unobservable inputs (Level 3) and there were no transfers in or out of Level 1, 2 or 3 during the three months ended January 3, 2020.
At September 27, 2019, the Company determined the following levels of inputs at fair value for the following assets or liabilities:
 
Fair Value Measurements at September 27, 2019
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
8.8

 
$
—

 
$
8.8

Total assets measured at fair value
$
—

 
$
8.8

 
$
—

 
$
8.8

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
0.7

 
$
—

 
$
0.7

Deferred Consideration
8.9

 
—

 
—

 
8.9

Total liabilities measured at fair value
$
8.9

 
$
0.7

 
$
—

 
$
9.6
XML 57 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION
 3 Months Ended
Jan. 03, 2020
Business Combinations [Abstract]  
BUSINESS COMBINATION BUSINESS COMBINATION
On April 29, 2019, Varex completed the acquisition of 98.2% of the outstanding shares of common stock of Direct Conversion AB (publ) (“Direct Conversion”) for $69.5 million in cash, net of cash acquired, the assumption of Direct Conversion's debt of $4.5 million and deferred consideration equal to $9.9 million or 0.3 million shares of the Company’s common stock (subject to reduction to settle indemnity claims) to be paid on the first anniversary of the closing with a mixture of cash and shares of Varex common stock. The acquisition of Direct Conversion expands our detector product portfolio to include photon counting technology.  This technology will allow Varex to expand its range of imaging applications and offer new solutions to both Medical and Industrial customers.
The following table summarizes the preliminary purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts receivable
$
2.4

Inventories
5.7

Prepaid expenses and other current assets
0.7

Property, plant, and equipment
0.9

Goodwill
47.2

Intangible assets
32.9

Total assets acquired
$
89.8

Accounts payable
$
(1.0
)
Accrued liabilities and other current liabilities
(1.5
)
Current maturities of long-term debt
(1.0
)
Deferred revenues
(0.9
)
Long-term debt
(3.5
)
Other long-term liabilities
(1.1
)
Total liabilities assumed
$
(9.0
)
Noncontrolling interest
$
(1.4
)
Net assets acquired, less noncontrolling interest
$
79.4

Net cash paid
$
69.5

Deferred consideration
9.9

Total consideration
$
79.4



The Company recorded the assets acquired and liabilities assumed at their preliminary estimated fair values. Intangibles were valued primarily using a discounted cash flow, which included estimated revenue growth and discount rate. Due to the complexity of this transaction as of January 3, 2020, the Company had not finalized the determination of the fair values allocated to various assets and liabilities, including, but not limited to, deferred tax assets and liabilities; intangible assets and the residual amount allocated to goodwill. The fair value assigned to goodwill is primarily attributable to expected synergies. The goodwill related to the Direct Conversion acquisition is not tax deductible.
The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated Weighted Average
Useful Life
(In Years)
Backlog
$
0.2

 
1
Trade names
2.5

 
5
Developed technology
18.4

 
10
In-process research and development
2.8

 
indefinite
Customer relationships
9.0

 
10
Total intangible assets acquired
$
32.9

 
 

The acquisition of Direct Conversion did not have a significant impact on our consolidated results of operations on a pro forma basis for the prior year period.

During the first quarter of fiscal year 2020, the Company made a $1.2 million acquisition to enhance our X-ray tube development and manufacturing operations.
XML 58 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Jan. 03, 2020
Accounting Policies [Abstract]  
Summary of Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended January 3, 2020
 
Three Months Ended December 28, 2018
 
Beginning of Period
 
End of Period
 
Beginning of Period
 
End of Period
Cash and cash equivalents
$
29.9

 
$
30.0

 
$
51.9

 
$
55.1

Restricted cash
1.4

 
1.4

 
1.5

 
1.4

Cash and cash equivalents and restricted cash as reported per statement of cash flows
$
31.3

 
$
31.4

 
$
53.4

 
$
56.5
Summary of Customers with a Significant Portion of Revenue During the periods presented, one of the Company's Medical segment customers accounted for a significant portion of revenues, as follows:
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Canon Medical Systems Corporation
18.8%
 
18.3%
Schedule of Product Warranty Liability
The following table reflects the changes in the Company’s accrued product warranty:
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Accrued product warranty, at beginning of period
$
8.1

 
$
7.3

Charged to cost of revenues
4.1

 
2.0

Product warranty expenditures
(3.2
)
 
(2.7
)
Accrued product warranty, at end of period
$
9.0

 
$
6.6
XML 59 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS
 3 Months Ended
Jan. 03, 2020
Share-based Payment Arrangement [Abstract]  
EMPLOYEE STOCK PLANS EMPLOYEE STOCK PLANS
Share-Based Compensation Expense
Share-based compensation expense recognized in the condensed consolidated statements of earnings is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.
The table below summarizes the effect of recording the share-based compensation expense (which includes the option component of the employee stock purchase plan shares):
 
Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Cost of revenues
$
0.3

 
$
0.3

Research and development
0.6

 
0.5

Selling, general and administrative 
2.3

 
1.8

Total share-based compensation expense
$
3.2

 
$
2.6


Stock Option Activity
The following table summarizes the activity for stock options under Varex’s 2017 Omnibus Stock Plan and 2017 Employee Stock Purchase Plan for the Company’s employees:
 
Options Outstanding
(In thousands, except per share amounts and the remaining term)
Options
 
Price Range
 
Weighted Average Exercise Price
 
Weighted Average Remaining Term (in years)
 
Aggregate Intrinsic Value(1)
Outstanding at September 27, 2019
2,269

 
$22.63 - $37.60

 
$
30.60

 
 
 
 
Granted
—

 
—

 
—

 
 
 
 
Canceled, expired or forfeited
(19
)
 
$22.84 - $37.10

 
30.99

 
 
 
 
Exercised
(49
)
 
$22.84 - $22.84

 
22.84

 
 
 
 
Outstanding at January 3, 2020
2,201

 
$22.63 - $37.60

 
$
30.77

 
3.92
 
$
1,735.0

 
 
 
 
 
 
 
 
 
 
Exercisable at January 3, 2020
1,500

 
$22.63 - $37.60

 
$
30.04

 
3.34
 
$
1,735.0

(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $30.00 as of January 3, 2020, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
Restricted Stock Units
The following table summarizes the activity for restricted stock units under Varex’s 2017 Omnibus Stock Plan for the Company’s employees:
(In thousands, except per share amounts)
Number of Shares

Weighted Average Grant-Date Fair Value
Balance at September 27, 2019
678


$
33.18

Granted
3


26.78

Vested
(2
)

30.21

Canceled or expired
(8
)

33.49

Balance at January 3, 2020
671


$
33.16
XML 60 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING (Tables)
 3 Months Ended
Jan. 03, 2020
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Costs Incurred Below is a detail of restructuring charges incurred during the three months ended January 3, 2020 and December 28, 2018, respectively, which predominately relate to the Company's Medical segment:
 
 
 
Three Months Ended
(In millions)
Location of Restructuring Charges in Consolidated Statements of Earnings
 
January 3, 2020
 
December 28, 2018
Accelerated depreciation
Cost of revenues
 
$
0.3

 
$
4.2

Severance costs
Selling, general and administrative
 
0.5

 
0.9

Total restructuring charges
 
 
$
0.8

 
$
5.1
XML 61 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Total Varex Equity
Noncontrolling Interests
Common stock, shares, outstanding, beginning balance (in shares) at Sep. 28, 2018   38,000,000.0          
Stockholders' equity, beginning balance at Sep. 28, 2018 $ 428.3 $ 0.4 $ 357.6 $ 5.8 $ 62.4 $ 426.2 $ 2.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings 2.8       3.0 3.0 (0.2)
Common stock issued under employee stock purchase plan (in shares)   100,000          
Common stock issued under employee stock purchase plan 1.9   1.9     1.9  
Share-based compensation 2.6   2.6     2.6  
Unrealized loss on interest rate swap contracts, net of tax (2.3)     (2.3)   (2.3)  
Common stock, shares, outstanding, ending balance (in shares) at Dec. 28, 2018   38,100,000          
Stockholders' equity, ending balance at Dec. 28, 2018 $ 429.2 $ 0.4 362.1 3.5 61.3 427.3 1.9
Common stock, shares, outstanding, beginning balance (in shares) at Sep. 27, 2019 38,371,305 38,400,000          
Stockholders' equity, beginning balance at Sep. 27, 2019 $ 448.2 $ 0.4 371.8 (1.7) 74.4 444.9 3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings (1.3)       (1.3) (1.3) 0.0
Exercise of stock options 1.1   1.1     1.1  
Common stock issued under employee stock purchase plan (in shares)   100,000          
Common stock issued under employee stock purchase plan 1.8   1.8     1.8  
Share-based compensation 3.2   3.2     3.2  
Unrealized loss on interest rate swap contracts, net of tax 0.0            
Currency translation adjustments (0.9)     (0.9)   (0.9)  
Other $ (0.3)   (0.3)     (0.3)  
Common stock, shares, outstanding, ending balance (in shares) at Jan. 03, 2020 38,494,349 38,500,000          
Stockholders' equity, ending balance at Jan. 03, 2020 $ 451.2 $ 0.4 $ 377.6 $ (2.6) $ 72.5 $ 447.9 $ 3.3
XML 62 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Statement of Comprehensive Income [Abstract]    
Net (loss) earnings $ (1.2) $ 3.0
Other comprehensive (loss) earnings, net of tax:    
Unrealized (loss)/gain on interest rate swap contracts   (2.3)
Unrealized (loss)/gain on interest rate swap contracts 0.0 (2.3)
Foreign currency translation adjustments (0.9) 0.0
Other comprehensive (loss) earnings, net of tax (0.9) (2.3)
Comprehensive (loss) earnings (2.1) 0.7
Less: Comprehensive earnings attributable to noncontrolling interests 0.1 0.0
Comprehensive (loss) earnings attributable to Varex $ (2.2) $ 0.7
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Sep. 27, 2019
Lessee, Lease, Description [Line Items]    
Lease renewal term 6 years  
Operating lease payments due in 2019, under topic 840   $ 7.5
Operating lease payments due in 2020, under topic 840   5.4
Operating lease payments due in 2021, under topic 840   4.7
Operating lease payments due in 2022, under topic 840   1.8
Operating lease payments due in 2023, under topic 840   0.9
Operating lease payments due thereafter, under topic 840   $ 0.2
Minimum    
Lessee, Lease, Description [Line Items]    
Remaining lease term 1 year  
Maximum    
Lessee, Lease, Description [Line Items]    
Remaining lease term 5 years  
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)
 3 Months Ended
Jan. 03, 2020
segment
Accounting Policies [Abstract]  
Number of reportable operating segments 2
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 28, 2019
Sep. 27, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating lease assets $ 25.1    
Finance lease, right-of-use asset 0.6    
Operating lease liability 25.8    
Present value of lease liabilities 0.6    
Decrease to retained earnings upon adoption of new accounting guidance $ (72.5)   $ (74.4)
Accounting Standards Update 2016-02      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating lease assets   $ 26.8  
Finance lease, right-of-use asset   0.6  
Operating lease liability   27.5  
Present value of lease liabilities   0.6  
Decrease to retained earnings upon adoption of new accounting guidance   $ 0.3  
XML 66 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)
$ in Millions
Jan. 03, 2020
USD ($)
Goodwill [Roll Forward]  
Balance at September 27, 2019 $ 290.8
Balance at January 3, 2020 290.8
Medical  
Goodwill [Roll Forward]  
Balance at September 27, 2019 173.0
Balance at January 3, 2020 173.0
Industrial  
Goodwill [Roll Forward]  
Balance at September 27, 2019 117.8
Balance at January 3, 2020 $ 117.8
XML 67 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)
$ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
Derivatives designated as cash flow hedges  
Derivative [Line Items]  
Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months $ (0.3)
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION - Intangibles Acquired (Details) - Direct Conversion AB
$ in Millions
Apr. 29, 2019
USD ($)
Business Acquisition [Line Items]  
Fair Value $ 32.9
In-process research and development  
Business Acquisition [Line Items]  
Fair Value 2.8
Backlog  
Business Acquisition [Line Items]  
Fair Value $ 0.2
Estimated Weighted Average Useful Life (In Years) 1 year
Trade names  
Business Acquisition [Line Items]  
Fair Value $ 2.5
Estimated Weighted Average Useful Life (In Years) 5 years
Developed technology  
Business Acquisition [Line Items]  
Fair Value $ 18.4
Estimated Weighted Average Useful Life (In Years) 10 years
Customer relationships  
Business Acquisition [Line Items]  
Fair Value $ 9.0
Estimated Weighted Average Useful Life (In Years) 10 years
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details)
$ in Millions
 3 Months Ended
Jan. 03, 2020
USD ($)
Leases [Abstract]  
Total operating lease costs $ 2.1
Total finance lease costs 0.1
Operating cash flows from operating leases 2.0
Financing cash flows from finance leases 0.1
Total cash paid for amounts included in the measurement of lease liabilities $ 2.1
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING - Summary of Restructuring Cost Incurred (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Restructuring and Related Activities [Abstract]    
Accelerated depreciation $ 0.3 $ 4.2
Severance costs 0.5 0.9
Total restructuring charges $ 0.8 $ 5.1
XML 71 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Earnings Per Share [Abstract]    
Net earnings attributable to Varex $ (1.3) $ 3.0
Weighted average common shares outstanding, basic (in shares) 38.5 38.1
Dilutive effect of potential common shares (in shares) 0.0 0.2
Weighted average common shares outstanding, diluted (in shares) 38.5 38.3
Earnings per share, basic (in USD per share) $ (0.03) $ 0.08
Earnings per share, diluted (in USD per share) $ (0.03) $ 0.08
Anti-dilutive employee shared based awards, excluded (in shares) 1.7 2.1
XML 72 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Reconciliation (Details)
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Income Tax Disclosure [Abstract]    
Effective tax rate percent 0.90% 26.80%
XML 73 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Jan. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
The following table reflect goodwill by reportable operating segment:
(In millions)
Medical
 
Industrial
 
Total
Balance at September 27, 2019
$
173.0

 
$
117.8

 
$
290.8

Balance at January 3, 2020
$
173.0

 
$
117.8

 
$
290.8


The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the condensed consolidated balance sheets:
 
January 3, 2020
 
September 27, 2019
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Acquired existing technology
$
74.1

 
$
(30.8
)
 
$
43.3

 
$
74.1

 
$
(28.4
)
 
$
45.7

Patents, licenses and other
12.7

 
(8.7
)
 
4.0

 
12.7

 
(8.4
)
 
4.3

Customer contracts and supplier relationship
50.7

 
(19.0
)
 
31.7

 
50.7

 
(17.2
)
 
33.5

Total intangible assets with finite lives
137.5

 
(58.5
)
 
79.0

 
137.5

 
(54.0
)
 
83.5

In-process R&D with indefinite lives
2.8

 
0.0

 
2.8

 
2.8

 
0.0

 
2.8

Total intangible assets
$
140.3

 
$
(58.5
)
 
$
81.8

 
$
140.3

 
$
(54.0
)
 
$
86.3

 
 
 
 
 
 
 
 
 
 
 
 

Amortization expense for intangible assets was $4.5 million and $3.7 million for the three months ended January 3, 2020 and December 28, 2018, respectively.
XML 74 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING
 3 Months Ended
Jan. 03, 2020
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURING
In July 2018, the Company committed to a plan to relocate the production of amorphous silicon glass for digital detectors, from its Santa Clara facility, to the jointly owned dpiX fabrication facility in Colorado. In July 2019, the Company committed to close its Santa Clara facility and to relocate the remaining production to its other existing facilities. The Company expects operations at the Santa Clara facility to cease by the end of September 2020 and all activities related to the closure of the facility to be complete by the end of December 2020. In connection with the relocation of the glass production and site closure the Company recorded $0.8 million and $5.1 million for the three months ended January 3, 2020 and December 28, 2018, respectively. The Company expects to incur an additional $7.3 million to $11.3 million of restructuring charges through December 2020.
Cash outflows associated with these restructuring charges are limited to employee termination expenses, facility closure and equipment sales and disposals. Below is a detail of restructuring charges incurred during the three months ended January 3, 2020 and December 28, 2018, respectively, which predominately relate to the Company's Medical segment:
 
 
 
Three Months Ended
(In millions)
Location of Restructuring Charges in Consolidated Statements of Earnings
 
January 3, 2020
 
December 28, 2018
Accelerated depreciation
Cost of revenues
 
$
0.3

 
$
4.2

Severance costs
Selling, general and administrative
 
0.5

 
0.9

Total restructuring charges
 
 
$
0.8

 
$
5.1
XML 75 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS (Tables)
 3 Months Ended
Jan. 03, 2020
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation
 
Three Months Ended
 
January 3, 2020
 
December 28, 2018
Estimated effective tax rate
0.9
%
 
26.8
%
XML 76 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)
 3 Months Ended
Jan. 03, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments he following table shows the notional amounts of outstanding foreign currency contracts as of January 3, 2020:
 
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions)
Buy contracts
 
Sell contract
Japanese yen
$
2.3

 
$
—

Swiss franc
—

 
(1.0
)
Chinese renminbi
1.7

 
—

Euro
—

 
(3.4
)
 
$
4.0

 
$
(4.4
)

s of January 3, 2020, the Company had the following outstanding derivatives designated as hedging instruments:
(In millions, except for number of instruments)
 
Number of Instruments
 
Notional Value
Interest Rate Swap Contracts
 
6

 
$
253.1

s of January 3, 2020, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except for number of instruments)
Number of Instruments
 
Notional Value
Cross Currency Swap Contracts
4
 
$
77.7
Schedule of Interest Rate Derivatives
he following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the
accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as cash flow hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Interest rate swap contracts
 
Accrued liabilities and other current liabilities
 
$
(0.3
)
 
$
—

Interest rate swap contracts
 
Other long-term liabilities
 
(0.2
)
 
(0.5
)
 
 
 
 
$
(0.5
)
 
$
(0.5
)
Schedule of Net Investment Hedges he following table summarizes the amount of pre-tax earnings recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
 
Amount of Gain (Loss) Recognized in OCI on Derivative
Three months ended
 
Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
 
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
(In millions)
January 3, 2020
 
December 28, 2018
 
 
January 3, 2020
 
December 28, 2018
Cross Currency Swap Contracts
$
(0.8
)
 
$
—

 
Interest expense
 
$
0.4

 
$
—

These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying consolidated balance sheets where the instruments are recorded:
(In millions)
 
 
 
Derivative Assets and Liabilities
Derivatives designated as net investment hedges
 
Balance sheet location
 
January 3, 2020
 
September 27, 2019
Cross Currency Swap Contracts
 
Other current assets
 
$
1.3

 
$
—

Cross Currency Swap Contracts
 
Other long-term liabilities
 
(2.2
)
 
—

 
 
 
 
$
(0.9
)
 
$
—
XML 77 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BORROWINGS (Tables)
 3 Months Ended
Jan. 03, 2020
Debt Disclosure [Abstract]  
Schedule of Debt
The following table summarizes the Company's short-term and long-term debt:
 
January 3, 2020
 
September 27, 2019
 
$ Change
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
 
 
Current maturities of long-term debt
 
 
 
 
 
 
 
 
 
Term facility
$
29.4

 
5.3
%
 
$
29.4

 
5.6
%
 
$
—

Other debt
1.0

 
 
 
1.3

 
 
 
(0.3
)
Total current maturities of long-term debt
$
30.4

 
 
 
$
30.7

 
 
 
$
(0.3
)
 
 
 
 
 
 
 
 
 
 
Non-current maturities of long-term debt:
 
 
 
 
 
 
 
 
 
Revolving credit facility
$
52.0

 
5.3
%
 
$
59.0

 
5.6
%
 
$
(7.0
)
Term facility
301.1

 
5.3
%
 
308.6

 
5.6
%
 
(7.5
)
Other debt
2.6

 
 
 
2.5

 
 
 
0.1

Debt issuance costs
(4.8
)
 
 
 
(5.7
)
 
 
 
0.9

Non-current maturities of long-term debt
350.9

 
 
 
364.4

 
 
 
(13.5
)
Total long-term debt, net
$
381.3

 
 
 
$
395.1

 
 
 
$
(13.8
)
JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "varex10q2020q1.htm": { "axisCustom": 1, "axisStandard": 30, "contextCount": 193, "dts": { "calculationLink": { "local": [ "var-20200103_cal.xml" ] }, "definitionLink": { "local": [ "var-20200103_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "varex10q2020q1.htm" ] }, "labelLink": { "local": [ "var-20200103_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "var-20200103_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "var-20200103.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 598, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 14, "http://www.varex.com/20200103": 12, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 31 }, "keyCustom": 28, "keyStandard": 407, "memberCustom": 20, "memberStandard": 51, "nsprefix": "var", "nsuri": "http://www.varex.com/20200103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover", "role": "http://www.varex.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - LEASES", "role": "http://www.varex.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - BUSINESS COMBINATION", "role": "http://www.varex.com/role/BusinessCombination", "shortName": "BUSINESS COMBINATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - RELATED-PARTY TRANSACTIONS", "role": "http://www.varex.com/role/RelatedPartyTransactions", "shortName": "RELATED-PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - RESTRUCTURING", "role": "http://www.varex.com/role/Restructuring", "shortName": "RESTRUCTURING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivities", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - FAIR VALUE", "role": "http://www.varex.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - INVENTORIES", "role": "http://www.varex.com/role/Inventories", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.varex.com/role/GoodwillAndIntangibleAssets", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - BORROWINGS", "role": "http://www.varex.com/role/Borrowings", "shortName": "BORROWINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS", "role": "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)", "role": "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - NET (LOSS) EARNINGS PER SHARE", "role": "http://www.varex.com/role/NetLossEarningsPerShare", "shortName": "NET (LOSS) EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - EMPLOYEE STOCK PLANS", "role": "http://www.varex.com/role/EmployeeStockPlans", "shortName": "EMPLOYEE STOCK PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - TAXES ON EARNINGS", "role": "http://www.varex.com/role/TaxesOnEarnings", "shortName": "TAXES ON EARNINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - SEGMENT INFORMATION", "role": "http://www.varex.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - REVENUE RECOGNITION (Tables)", "role": "http://www.varex.com/role/RevenueRecognitionTables", "shortName": "REVENUE RECOGNITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "var:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - LEASES (Tables)", "role": "http://www.varex.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "var:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - BUSINESS COMBINATION (Tables)", "role": "http://www.varex.com/role/BusinessCombinationTables", "shortName": "BUSINESS COMBINATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - RESTRUCTURING (Tables)", "role": "http://www.varex.com/role/RestructuringTables", "shortName": "RESTRUCTURING (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited)", "role": "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) EARNINGS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesTables", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - FAIR VALUE (Tables)", "role": "http://www.varex.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - INVENTORIES (Tables)", "role": "http://www.varex.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.varex.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - BORROWINGS (Tables)", "role": "http://www.varex.com/role/BorrowingsTables", "shortName": "BORROWINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)", "role": "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - NET (LOSS) EARNINGS PER SHARE (Tables)", "role": "http://www.varex.com/role/NetLossEarningsPerShareTables", "shortName": "NET (LOSS) EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - EMPLOYEE STOCK PLANS (Tables)", "role": "http://www.varex.com/role/EmployeeStockPlansTables", "shortName": "EMPLOYEE STOCK PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - TAXES ON EARNINGS (Tables)", "role": "http://www.varex.com/role/TaxesOnEarningsTables", "shortName": "TAXES ON EARNINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.varex.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_srt_MajorCustomersAxis_var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_srt_MajorCustomersAxis_var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "var:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details)", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Adopted Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2020Q1Sep282019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details)", "role": "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails", "shortName": "REVENUE RECOGNITION - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_srt_StatementGeographicalAxis_srt_AmericasMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details)", "role": "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails", "shortName": "REVENUE RECOGNITION - Summary of Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - REVENUE RECOGNITION - Performance Obligation (Details)", "role": "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails", "shortName": "REVENUE RECOGNITION - Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.varex.com/role/LeasesNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "var:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details)", "role": "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails", "shortName": "LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "var:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "lang": null, "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "var:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)", "role": "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails", "shortName": "LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "var:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details)", "role": "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails", "shortName": "LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details)", "role": "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails", "shortName": "LEASES - Schedule of Operating and Finance Lease Liability Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details)", "role": "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "shortName": "BUSINESS COMBINATION - Acquisition of Direct Conversion AB Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "D2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "lang": null, "name": "us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details)", "role": "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails", "shortName": "BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404405 - Disclosure - BUSINESS COMBINATION - Intangibles Acquired (Details)", "role": "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "shortName": "BUSINESS COMBINATION - Intangibles Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2019Q2Apr29_us-gaap_BusinessAcquisitionAxis_var_DirectConversionABMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1QTD_us-gaap_BusinessAcquisitionAxis_var_ReliableHealthcareImagingTechnologyMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404406 - Disclosure - BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details)", "role": "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "shortName": "BUSINESS COMBINATION - Acquisition of Reliable Healthcare Imaging Technology Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1QTD_us-gaap_BusinessAcquisitionAxis_var_ReliableHealthcareImagingTechnologyMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details)", "role": "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails", "shortName": "RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_var_DpiXHoldingMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - RESTRUCTURING - Narrative (Details)", "role": "http://www.varex.com/role/RestructuringNarrativeDetails", "shortName": "RESTRUCTURING - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1QTD_us-gaap_RestructuringPlanAxis_var_SantaClaraFacilityRelocationMember", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveAcceleratedDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - RESTRUCTURING - Summary of Restructuring Cost Incurred (Details)", "role": "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails", "shortName": "RESTRUCTURING - Summary of Restructuring Cost Incurred (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveAcceleratedDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "derivative", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CrossCurrencyInterestRateContractMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Income Recognized From Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CrossCurrencyInterestRateContractMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_PositionAxis_us-gaap_LongMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details)", "role": "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Notional Amount and Net Unrealized Gain (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_PositionAxis_us-gaap_LongMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - FAIR VALUE (Details)", "role": "http://www.varex.com/role/FairValueDetails", "shortName": "FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - INVENTORIES (Details)", "role": "http://www.varex.com/role/InventoriesDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "role": "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4_us-gaap_StatementBusinessSegmentsAxis_var_MedicalMember", "decimals": "-5", "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "role": "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - BORROWINGS - Schedule of Debt (Details)", "role": "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails", "shortName": "BORROWINGS - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "var:ProceedsFromRepaymentsOfLongTermDebtCurrentMaturities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited)", "role": "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - BORROWINGS - Narrative (Details)", "role": "http://www.varex.com/role/BorrowingsNarrativeDetails", "shortName": "BORROWINGS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details)", "role": "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails", "shortName": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS - Noncontrolling Interest (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details)", "role": "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails", "shortName": "NET (LOSS) EARNINGS PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net (Loss) Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "role": "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "shortName": "EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "role": "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails", "shortName": "EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "role": "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails", "shortName": "EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - TAXES ON EARNINGS - Reconciliation (Details)", "role": "http://www.varex.com/role/TaxesOnEarningsReconciliationDetails", "shortName": "TAXES ON EARNINGS - Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - TAXES ON EARNINGS - Narrative (Details)", "role": "http://www.varex.com/role/TaxesOnEarningsNarrativeDetails", "shortName": "TAXES ON EARNINGS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details)", "role": "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails", "shortName": "SEGMENT INFORMATION - Income Statement Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_var_MedicalMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - SEGMENT INFORMATION - Assets (Details)", "role": "http://www.varex.com/role/SegmentInformationAssetsDetails", "shortName": "SEGMENT INFORMATION - Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FI2020Q1_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_var_MedicalMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.varex.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - REVENUE RECOGNITION", "role": "http://www.varex.com/role/RevenueRecognition", "shortName": "REVENUE RECOGNITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "varex10q2020q1.htm", "contextRef": "I2019Q1Sep29", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - varex10q2020q1.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - varex10q2020q1.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 72, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "Chinese renminbi" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Japan, Yen", "terseLabel": "Japanese yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.varex.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "APAC" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r145", "r155" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r158", "r232", "r236", "r443" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.varex.com/role/LeasesNarrativeDetails", "http://www.varex.com/role/RestructuringNarrativeDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.varex.com/role/LeasesNarrativeDetails", "http://www.varex.com/role/RestructuringNarrativeDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.varex.com/role/LeasesNarrativeDetails", "http://www.varex.com/role/RestructuringNarrativeDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails", "http://www.varex.com/role/LeasesNarrativeDetails", "http://www.varex.com/role/RestructuringNarrativeDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r157", "r232", "r235", "r442", "r445", "r448" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r203", "r392" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r111", "r385", "r418", "r436" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Accounts payable, related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r17", "r160", "r161", "r233" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r39" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r57", "r59", "r60" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r60", "r62", "r306" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated Weighted Average Useful Life (In Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r242", "r243", "r265", "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r243", "r261", "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r75", "r97", "r365" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred loan costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r176", "r184" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive employee shared based awards, excluded (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r149", "r413", "r428" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Identifiable assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/SegmentInformationAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/FairValueDetails", "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r48" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r350" ], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r323", "r328" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails", "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails", "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r283" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedLabel": "Noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r291", "r292", "r294" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "verboseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r290", "r293", "r296" ], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATION" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "negatedLabel": "Current maturities of long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets", "verboseLabel": "Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "negatedLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "auth_ref": [ "r282" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "totalLabel": "Net assets acquired, less noncontrolling interest" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Allocation of the purchase consideration:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r32", "r99" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents - Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r100", "r106", "r412" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r92", "r99", "r105" ], "calculation": { "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash and cash equivalents and restricted cash as reported per statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r92", "r359" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Derivatives designated as cash flow hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerAssetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Asset [Abstract]", "terseLabel": "Change in Contract with Customer, Asset [Abstract]" } } }, "localname": "ChangeInContractWithCustomerAssetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r202", "r419", "r435" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r106", "r206", "r446", "r447" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Loss Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common stock, shares, outstanding, ending balance (in shares)", "periodStartLabel": "Common stock, shares, outstanding, beginning balance (in shares)", "terseLabel": "Common stock, shares, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r16" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $.01 par value: 150,000,000 shares authorized, 38,494,349 issued and outstanding as of January 3, 2020 ; 38,371,305 issued and outstanding as of September 27, 2019" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r65", "r67", "r68" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive (loss) earnings attributable to Varex" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r67", "r301", "r310" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive (loss) earnings" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r356", "r357" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r356", "r357", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r356", "r357", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r132", "r426" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r356", "r357" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r135", "r137", "r138", "r139", "r356", "r358" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r356", "r357" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r106", "r302", "r312", "r314" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of Contract Asset and Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "auth_ref": [ "r166", "r226", "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "negatedTerseLabel": "Costs recovered from product returns during the period" } } }, "localname": "ContractWithCustomerAssetCreditLossExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r223", "r225", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Balance at January 3, 2020", "periodStartLabel": "Balance at September 28, 2019" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r223", "r224", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Balance at January 3, 2020", "periodStartLabel": "Balance at September 28, 2019" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r223", "r224", "r233" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTerseLabel": "Release of refund liability included in beginning of year refund liability" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r238", "r338" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Swap Contracts" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect of accounting changes" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "BORROWINGS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r414", "r415", "r427" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r109", "r218", "r219", "r220", "r221", "r363", "r364", "r366", "r425" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r34", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r107", "r274", "r275" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r269", "r272" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "terseLabel": "Deferred tax liabilities of undistributed foreign earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r189" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r50", "r51", "r355" ], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r49", "r52", "r326", "r397" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative assets fair value, gross" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r49", "r52", "r326", "r397" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative liabilities fair value, gross" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Derivative assets and liabilities, net" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r324", "r327", "r333", "r340" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r321", "r324", "r333" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Recorded component of accumulated other comprehensive income (loss) that will be reclassified in the statements of comprehensive earnings over the next 12 months" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r332", "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r50", "r51", "r355" ], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r317", "r319" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Value" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r317", "r319" ], "lang": { "en-US": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of Instruments" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r112", "r316", "r318", "r319", "r321", "r322", "r329", "r333", "r342", "r343", "r346" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired existing technology", "verboseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue by Geographic Location" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "EMPLOYEE STOCK PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net (loss) earnings per common share attributable to Varex" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r74", "r116", "r121", "r123", "r124", "r125", "r128", "r423", "r439" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings per share, basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r74", "r116", "r121", "r123", "r124", "r125", "r128", "r423", "r439" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings per share, diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET (LOSS) EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/NetLossEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r359" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r110", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/TaxesOnEarningsNarrativeDetails", "http://www.varex.com/role/TaxesOnEarningsReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvesteeMember": { "auth_ref": [ "r163", "r400", "r402", "r404", "r406", "r408", "r410" ], "lang": { "en-US": { "role": { "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.", "label": "Equity Method Investee [Member]", "terseLabel": "Varian" } } }, "localname": "EquityMethodInvesteeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r33", "r150", "r164" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r350", "r351", "r352", "r354" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r350", "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r238", "r239", "r241", "r351", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r238", "r239", "r241", "r351", "r394" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r238", "r239", "r241", "r351", "r395" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r238", "r239", "r241", "r351", "r396" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r350", "r351" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Purchases of property, plant and equipment financed through accounts payable" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal Funds Effective Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r371", "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities (current)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease Liability Maturities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities (non-current)" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total future lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020 remaining" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r372", "r378" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "var_CashPaidForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance lease, right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r380", "r383" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r379", "r383" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Intangible Assets Acquired" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r183" ], "calculation": { "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r177", "r180", "r183", "r186", "r398" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r183", "r398" ], "calculation": { "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r177", "r182" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r183" ], "calculation": { "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total intangible assets with finite lives, net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r298", "r311", "r313" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Period, Policy [Policy Text Block]", "terseLabel": "Fiscal Year" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r238", "r337" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at January 3, 2020", "periodStartLabel": "Balance at September 27, 2019", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails", "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r76" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross margin", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r321", "r341" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesNarrativeDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r116", "r411", "r421", "r440" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Earnings before taxes", "totalLabel": "(Loss) earnings before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r72", "r97", "r147", "r164", "r420", "r437" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "(Loss) Income from equity method investments", "negatedTerseLabel": "Income from equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "TAXES ON EARNINGS" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/TaxesOnEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r148", "r276" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Tax expense (benefit)", "terseLabel": "Taxes on earnings" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails", "http://www.varex.com/role/TaxesOnEarningsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r94", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other current and long-term operating liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities, net of effects of acquisition:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r122", "r127" ], "calculation": { "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of potential common shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r179", "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r185" ], "calculation": { "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-process research and development with indefinite lives" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r179", "r185" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Total intangible assets, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r175", "r181" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Patents, licenses and other" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r70", "r146", "r362", "r365", "r424" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r90", "r93", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap Contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativeInstrumentsDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails", "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r23", "r169" ], "calculation": { "http://www.varex.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r47", "r168" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.varex.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r25", "r26", "r169" ], "calculation": { "http://www.varex.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "terseLabel": "Raw materials and parts" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r24", "r169" ], "calculation": { "http://www.varex.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r33" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in privately-held companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost and Supplemental Cash Flow Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020 remaining" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r382" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails", "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r417", "r433" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable noncontrolling interests and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable noncontrolling interests and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r350" ], "calculation": { "http://www.varex.com/role/FairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Used capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Available borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r36", "r109" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Buy contracts" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r209", "r415", "r429" ], "calculation": { "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt outstanding, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails", "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Current Maturities [Abstract]", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net", "verboseLabel": "Non-current maturities of long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails", "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Weighted-Average Interest Rate" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt [Abstract]", "terseLabel": "Non-current maturities of long-term debt:" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r416", "r432" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period, January 3, 2020", "periodStartLabel": "Balance at beginning of period, September 27, 2019", "verboseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Majority voting rights, percent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r46", "r77", "r300", "r307" ], "lang": { "en-US": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r92", "r95", "r98" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r63", "r66", "r73", "r98", "r127", "r422", "r438" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings attributable to Varex", "totalLabel": "Net (loss) earnings attributable to Varex" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r66", "r304", "r309" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net earnings attributable to noncontrolling interests", "verboseLabel": "Less: Comprehensive earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited", "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r214", "r304", "r305" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "terseLabel": "Net earnings" } } }, "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r115", "r117" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental non-cash activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Debt Assumed", "terseLabel": "Debt assumed in acquisition" } } }, "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other income (expenses), net", "totalLabel": "Interest and other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of reportable operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r377", "r383" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Total operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r371" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingAndFinanceLeaseLiabilityMaturitiesDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r371" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Operating lease liabilities (current)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r371" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liabilities (non-current)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r373", "r378" ], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "var_CashPaidForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/LeasesScheduleOfLeaseRightOfUseAssetsAndLiabilitiesDetails", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r380", "r383" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r379", "r383" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating lease payments due in 2019, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating lease payments due in 2023, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating lease payments due in 2022, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating lease payments due in 2021, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating lease payments due in 2020, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r367", "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating lease payments due thereafter, under topic 840" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r145", "r155" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrderOrProductionBacklogMember": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination.", "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog" } } }, "localname": "OrderOrProductionBacklogMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r114", "r118", "r143", "r315" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "netLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "auth_ref": [ "r53", "r58", "r361" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax", "negatedTerseLabel": "Currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r54", "r57" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized (loss)/gain on interest rate swap contracts", "verboseLabel": "Unrealized loss on interest rate swap contracts, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited", "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r54", "r57", "r325", "r330", "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r57", "r61", "r332" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Amount of Gain (Loss) Reclassified from Accumulated OCI into Income Three months ended" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "auth_ref": [ "r55", "r57", "r331", "r335", "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53", "r360" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r67", "r69", "r217" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive (loss) earnings, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) earnings, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r54", "r57", "r347" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Amount of Gain (Loss) Recognized in OCI on Derivative Three months ended" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfIncomeRecognizedFromDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r54", "r57", "r347" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "Unrealized (loss)/gain on interest rate swap contracts" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfDerivativesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Varex Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r83", "r295" ], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Net cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r83" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Payments to acquire equity method investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r83" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "negatedTerseLabel": "Contributions and advances to joint ventures" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r15" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r30", "r31" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r86" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under credit agreements" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r87", "r89", "r113" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "verboseLabel": "Change in current portion of Term Facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfOtherDebt": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) for debt classified as other.", "label": "Proceeds from (Repayments of) Other Debt", "terseLabel": "Change in current portion of other long-term debt" } } }, "localname": "ProceedsFromRepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from other long-term debt.", "label": "Proceeds from (Repayments of) Other Long-term Debt", "terseLabel": "Change in long-term portion of other debt" } } }, "localname": "ProceedsFromRepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r85", "r263" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r85" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from shares issued under employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyLiabilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Warranty Liability [Line Items]", "terseLabel": "Product Warranty Liability [Line Items]" } } }, "localname": "ProductWarrantyLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyLiabilityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about product warranty liability, including, but not limited to, reductions in the liability for payments made under the warranty, changes in the liability for accruals related to product warranties issued, and changes in the liability for accruals related to preexisting warranties.", "label": "Product Warranty Liability [Table]", "terseLabel": "Product Warranty Liability [Table]" } } }, "localname": "ProductWarrantyLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r63", "r66", "r91", "r149", "r156", "r301", "r303", "r305", "r309", "r310" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) earnings", "totalLabel": "Net (loss) earnings" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.varex.com/role/CondensedConsolidatedStatementsOfComprehensiveLossEarningsUnaudited", "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r190", "r434" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r152", "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r212", "r213", "r215", "r216" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable noncontrolling interests" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "RedeemableNoncontrollingInterestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r240", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Purchases from related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r240", "r386", "r387", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r88" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Repayments of borrowing under credit agreements" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r268", "r449" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r105", "r412", "r430" ], "calculation": { "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "RESTRUCTURING" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expected cost remaining for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost Remaining", "terseLabel": "Restructuring and related costs expected remaining" } } }, "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "auth_ref": [ "r97" ], "calculation": { "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs and Asset Impairment Charges", "terseLabel": "Restructuring charges", "totalLabel": "Total restructuring charges" } } }, "localname": "RestructuringCostsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails", "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserveAcceleratedDepreciation": { "auth_ref": [], "calculation": { "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.", "label": "Restructuring and Related Cost, Accelerated Depreciation", "terseLabel": "Accelerated depreciation" } } }, "localname": "RestructuringReserveAcceleratedDepreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r222", "r431" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Decrease to retained earnings upon adoption of new accounting guidance", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r230", "r232" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/RevenueRecognitionDisaggregationOfRevenueDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE RECOGNITION" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RevenueRecognitionPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails", "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Summary of Cash and Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r112", "r316", "r318", "r319", "r321", "r322", "r329", "r333", "r342", "r343" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/NetLossEarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/TaxesOnEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r243", "r260", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r243", "r260", "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r177", "r182" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r173", "r174" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r173", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r185", "r187" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Derivatives" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r6", "r27", "r28", "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Net Investment Hedges" } } }, "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Purchase Price Allocation" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r108", "r386", "r387", "r388", "r389", "r390" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r195", "r196", "r198" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r195", "r196", "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring Costs Incurred" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r144", "r149", "r151", "r153", "r173" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r144", "r149", "r151", "r153", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r244", "r262" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r245", "r256", "r258" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r135", "r137", "r138", "r139", "r356", "r358" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Summary of Customers with a Significant Portion of Revenue" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails", "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r79", "r167" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r97", "r193", "r197", "r199" ], "calculation": { "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RestructuringSummaryOfRestructuringCostIncurredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted stock units, canceled or expired in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock units, canceled or expired, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock units, grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock units, grants in period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted stock units, nonvested, ending balance, number of shares (in shares)", "periodStartLabel": "Restricted stock units, nonvested, beginning balance, number of shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted stock units, nonvested, end of period, weighted average grant date fair value (in USD per share)", "periodStartLabel": "Restricted stock units, nonvested, beginning of period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Restricted stock units, vested in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock units, vested in period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansRestrictedStockAndPerformanceStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options, exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options, exercisable, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options, canceled, forfeited and expired in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options, canceled, forfeited and expired in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r247", "r262" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, outstanding, ending balance (in shares)", "periodStartLabel": "Options, outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares [Rollforward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options, outstanding, weighted average exercise price, ending (in USD per share)", "periodStartLabel": "Options, outstanding, weighted average exercise price, beginning (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options, exercises in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options, grants in period, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options, exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options, exercisable, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options, outstanding, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell contract" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/FinancialDerivativesAndHedgingActivitiesSummaryOfNotionalAmountAndNetUnrealizedGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time.", "label": "Short-term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Weighted-Average Interest Rate" } } }, "localname": "ShortTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Accrued product warranty, at end of period", "periodStartLabel": "Accrued product warranty, at beginning of period" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Product warranty expenditures" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Charged to cost of revenues" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r106", "r206" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r149", "r173", "r192", "r194", "r200", "r441" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails", "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r45", "r217" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r15", "r16", "r217", "r222" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r217", "r222", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options, exercises in period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r15", "r16", "r217", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r217", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r162" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Varex equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r299", "r300", "r308" ], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' equity, ending balance", "periodStartLabel": "Stockholders' equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodStartLabel": "Balance at beginning of period, September 27, 2019", "terseLabel": "Balance at end of period, January 3, 2020" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net earnings attributable to noncontrolling interests" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityOtherChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.", "label": "Temporary Equity, Other Changes", "terseLabel": "Other, including foreign currency remeasurement" } } }, "localname": "TemporaryEquityOtherChanges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r7", "r211" ], "lang": { "en-US": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary equity, redemption price per share (in euros per share)" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary equity, shares outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r130", "r131", "r133", "r134", "r140", "r141", "r142" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r120", "r125" ], "calculation": { "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r119", "r125" ], "calculation": { "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.varex.com/role/NetLossEarningsPerShareReconciliationOfNumeratorAndDenominatorForBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "var_AmortizationOfDebtIssuanceCostsAndCostsWrittenOffDuetoReductionOfAvailableFundsForRevolvingCreditFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization Of Debt Issuance Costs And Costs Written Off Due to Reduction Of Available Funds For Revolving Credit Facility", "label": "Amortization Of Debt Issuance Costs And Costs Written Off Due to Reduction Of Available Funds For Revolving Credit Facility", "verboseLabel": "Change in debt issuance costs" } } }, "localname": "AmortizationOfDebtIssuanceCostsAndCostsWrittenOffDuetoReductionOfAvailableFundsForRevolvingCreditFacility", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information, Weighted Average Remaining Lease Terms and Discount Rates" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "var_BusinessAcquisitionAnnualRecurringCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Annual Recurring Compensation", "label": "Business Acquisition, Annual Recurring Compensation", "terseLabel": "Annual recurring compensation (in euros per share)" } } }, "localname": "BusinessAcquisitionAnnualRecurringCompensation", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "perShareItemType" }, "var_BusinessAcquisitionEquityInterestIssuedOrIssuableContingentConsiderationValueAssigned": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned", "label": "Business Acquisition, Equity Interest Issued Or Issuable, Contingent Consideration, Value Assigned", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableContingentConsiderationValueAssigned", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "var_BusinessAcquisitionEquityInterestIssuedorIssuableContingentConsideration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration", "label": "Business Acquisition, Equity Interest Issued or Issuable, Contingent Consideration", "terseLabel": "Deferred consideration, value of common stock (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedorIssuableContingentConsideration", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails" ], "xbrltype": "sharesItemType" }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities", "negatedLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRevenueFromContractWithCustomerLiability": { "auth_ref": [], "calculation": { "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Revenue From Contract With Customer, Liability", "negatedLabel": "Deferred revenues" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRevenueFromContractWithCustomerLiability", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]", "label": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]", "terseLabel": "Canon Medical Systems Corporation" } } }, "localname": "CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesCustomerConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "var_CashPaidForOperatingAndFinanceLeases": { "auth_ref": [], "calculation": { "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash Paid For Operating And Finance Leases", "label": "Cash Paid For Operating And Finance Leases", "totalLabel": "Total cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForOperatingAndFinanceLeases", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "var_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Additions", "label": "Contract With Customer, Liability, Additions", "terseLabel": "Additions to refund liabilities" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "var_ContractwithCustomerAssetShipments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Asset, Shipments", "label": "Contract with Customer, Asset, Shipments", "terseLabel": "Contract asset from shipments of products, subject to return during the period" } } }, "localname": "ContractwithCustomerAssetShipments", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RevenueRecognitionSummaryOfContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "var_CustomerContractsandSupplierRelationshipsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Contracts and Supplier Relationships [Member]", "label": "Customer Contracts and Supplier Relationships [Member]", "terseLabel": "Customer contracts and supplier relationship" } } }, "localname": "CustomerContractsandSupplierRelationshipsMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentPeriodicPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percentage", "label": "Debt Instrument, Periodic Payment, Percentage", "terseLabel": "Repayment percentage" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentage", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "var_DebtInstrumentRepaymentPeriodFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Five [Member]", "label": "Debt Instrument, Repayment, Period Five [Member]", "terseLabel": "Debt Instrument, Repayment, Period Five" } } }, "localname": "DebtInstrumentRepaymentPeriodFiveMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Four [Member]", "label": "Debt Instrument, Repayment, Period Four [Member]", "terseLabel": "Debt Instrument, Repayment, Period Four" } } }, "localname": "DebtInstrumentRepaymentPeriodFourMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period One [Member]", "label": "Debt Instrument, Repayment, Period One [Member]", "terseLabel": "Debt Instrument, Repayment, Period One" } } }, "localname": "DebtInstrumentRepaymentPeriodOneMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Three [Member]", "label": "Debt Instrument, Repayment, Period Three [Member]", "terseLabel": "Debt Instrument, Repayment, Period Three" } } }, "localname": "DebtInstrumentRepaymentPeriodThreeMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtInstrumentRepaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Repayment, Period Two [Member]", "label": "Debt Instrument, Repayment, Period Two [Member]", "terseLabel": "Debt Instrument, Repayment, Period Two" } } }, "localname": "DebtInstrumentRepaymentPeriodTwoMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DebtRepaymentPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Repayment Period [Axis]", "label": "Debt Repayment Period [Axis]", "terseLabel": "Debt Repayment Period [Axis]" } } }, "localname": "DebtRepaymentPeriodAxis", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "var_DebtRepaymentPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Repayment Period [Axis]", "label": "Debt Repayment Period [Domain]", "terseLabel": "Debt Repayment Period [Domain]" } } }, "localname": "DebtRepaymentPeriodDomain", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_DirectConversionABMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Direct Conversion AB [Member]", "label": "Direct Conversion AB [Member]", "terseLabel": "Direct Conversion AB" } } }, "localname": "DirectConversionABMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfDirectConversionAbNarrativeDetails", "http://www.varex.com/role/BusinessCombinationIntangiblesAcquiredDetails", "http://www.varex.com/role/BusinessCombinationScheduleOfPurchasePriceAllocationForDirectConversionAbAcquisitionDetails", "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "var_DpiXHoldingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "dpiX Holding [Member]", "label": "dpiX Holding [Member]", "terseLabel": "dpiX Holding" } } }, "localname": "DpiXHoldingMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_EquityMethodInvestmentsNumberofFullOwnershipMembers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method Investments, Number of Full Ownership Members", "label": "Equity Method Investments, Number of Full Ownership Members", "terseLabel": "Number of consortium members" } } }, "localname": "EquityMethodInvestmentsNumberofFullOwnershipMembers", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "integerItemType" }, "var_ExercisePriceRangeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range [Abstract]", "label": "Exercise Price Range [Abstract]", "terseLabel": "Price range" } } }, "localname": "ExercisePriceRangeAbstract", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "var_FinanceLeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Leases [Abstract]", "label": "Finance Leases [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeasesAbstract", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "stringItemType" }, "var_FixedCostCommitmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed Cost Commitments [Member]", "label": "Fixed Cost Commitments [Member]", "terseLabel": "Fixed Cost Commitments" } } }, "localname": "FixedCostCommitmentsMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_IndustrialMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industrial [Member]", "label": "Industrial [Member]", "terseLabel": "Industrial" } } }, "localname": "IndustrialMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails", "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "domainItemType" }, "var_JointVentureInSaudiArabiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint Venture In Saudi Arabia [Member]", "label": "Joint Venture In Saudi Arabia [Member]", "terseLabel": "Joint Venture In Saudi Arabia" } } }, "localname": "JointVentureInSaudiArabiaMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "var_LeaseCostFinanceLeaseCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lease, Cost, Finance Lease Costs", "label": "Lease, Cost, Finance Lease Costs", "terseLabel": "Total finance lease costs" } } }, "localname": "LeaseCostFinanceLeaseCosts", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfOperatingLeaseCostAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "var_LeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease, Remaining Lease Term", "label": "Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LeaseRemainingLeaseTerm", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "var_LongtermDebtExcludingCurrentMaturitiesGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt Excluding Current Maturities, Gross", "label": "Long-term Debt Excluding Current Maturities, Gross", "terseLabel": "Long-term debt excluding current maturities, gross" } } }, "localname": "LongtermDebtExcludingCurrentMaturitiesGross", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_MeVisMedicalSolutionsAGMeVisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MeVis Medical Solutions AG (MeVis) [Member]", "label": "MeVis Medical Solutions AG (MeVis) [Member]", "terseLabel": "MeVis Medical Solutions AG (MeVis)" } } }, "localname": "MeVisMedicalSolutionsAGMeVisMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "domainItemType" }, "var_MedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical [Member]", "label": "Medical [Member]", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/GoodwillAndIntangibleAssetsGoodwillRollforwardDetails", "http://www.varex.com/role/SegmentInformationAssetsDetails", "http://www.varex.com/role/SegmentInformationIncomeStatementInformationDetails" ], "xbrltype": "domainItemType" }, "var_NoncontrollingInterestOtherChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling Interest, Other Changes", "label": "Noncontrolling Interest, Other Changes", "terseLabel": "Other, including foreign currency remeasurement" } } }, "localname": "NoncontrollingInterestOtherChanges", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RedeemableNoncontrollingInterestsNoncontrollingInterestsNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "var_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Leases [Abstract]", "label": "Operating Leases [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/LeasesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "stringItemType" }, "var_OtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Debt [Member]", "label": "Other Debt [Member]", "terseLabel": "Other Debt" } } }, "localname": "OtherDebtMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "var_PercentageOfFixedCosts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay.", "label": "Percentage Of Fixed Costs", "terseLabel": "Percentage of fixed costs" } } }, "localname": "PercentageOfFixedCosts", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "percentItemType" }, "var_PercentageOfManufacturingCapacity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to.", "label": "Percentage Of Manufacturing Capacity", "terseLabel": "Percentage of manufacturing capacity" } } }, "localname": "PercentageOfManufacturingCapacity", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "percentItemType" }, "var_ProceedsFromRepaymentsOfDebtNetOfIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Repayments Of) Debt, Net Of Issuance Costs", "label": "Proceeds From (Repayments Of) Debt, Net Of Issuance Costs", "terseLabel": "Change in total debt outstanding, net" } } }, "localname": "ProceedsFromRepaymentsOfDebtNetOfIssuanceCosts", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_ProceedsFromRepaymentsOfLongTermDebtCurrentMaturities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Repayments Of) Long-Term Debt, Current Maturities", "label": "Proceeds From (Repayments Of) Long-Term Debt, Current Maturities", "terseLabel": "Change in current maturities of long-term debt" } } }, "localname": "ProceedsFromRepaymentsOfLongTermDebtCurrentMaturities", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_ProceedsFromRepaymentsOfLongTermDebtExcludingCurrentMaturities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Repayments Of) Long-Term Debt, Excluding Current Maturities", "label": "Proceeds From (Repayments Of) Long-Term Debt, Excluding Current Maturities", "terseLabel": "Change in maturities of long-term debt" } } }, "localname": "ProceedsFromRepaymentsOfLongTermDebtExcludingCurrentMaturities", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_ProceedsFromRepaymentsOfLongTermLineOfCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From (Repayments Of) Long Term Line Of Credit", "label": "Proceeds From (Repayments Of) Long Term Line Of Credit", "verboseLabel": "Change in revolving credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLongTermLineOfCredit", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "var_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization", "label": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization", "terseLabel": "Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "var_ReliableHealthcareImagingTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reliable Healthcare Imaging Technology [Member]", "label": "Reliable Healthcare Imaging Technology [Member]", "terseLabel": "Reliable Healthcare Imaging Technology" } } }, "localname": "ReliableHealthcareImagingTechnologyMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BusinessCombinationAcquisitionOfReliableHealthcareImagingTechnologyNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_RevolvingCreditFacilityMay2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving Credit Facility May 2017 [Member]", "label": "Revolving Credit Facility May 2017 [Member]", "terseLabel": "Revolving Credit Facility May 2017" } } }, "localname": "RevolvingCreditFacilityMay2017Member", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails", "http://www.varex.com/role/BorrowingsScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "var_SantaClaraFacilityRelocationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Santa Clara Facility Relocation [Member]", "label": "Santa Clara Facility Relocation [Member]", "terseLabel": "Santa Clara Facility Relocation" } } }, "localname": "SantaClaraFacilityRelocationMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_SecondRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second Revolving Credit Facility [Member]", "label": "Second Revolving Credit Facility [Member]", "terseLabel": "Second Revolving Credit Facility [Member]" } } }, "localname": "SecondRevolvingCreditFacilityMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price", "terseLabel": "Outstanding at period beginning and ending (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price", "terseLabel": "Exercisable at January 3, 2020 (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price", "terseLabel": "Canceled, expired or forfeited (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsExercisesinPeriodPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Price", "terseLabel": "Exercised (in USD per share)" } } }, "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsExercisesinPeriodPrice", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/EmployeeStockPlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "var_VECImagingGmbHCo.KGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VEC Imaging GmbH & Co. KG [Member]", "label": "VEC Imaging GmbH & Co. KG [Member]", "terseLabel": "VEC Imaging GmbH & Co. KG" } } }, "localname": "VECImagingGmbHCo.KGMember", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/RelatedPartyTransactionsInvestmentInPrivatelyHeldCompaniesNarrativeDetails" ], "xbrltype": "domainItemType" }, "var_WarrantyTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warranty Term", "label": "Warranty Term", "terseLabel": "Warranty term" } } }, "localname": "WarrantyTerm", "nsuri": "http://www.varex.com/20200103", "presentation": [ "http://www.varex.com/role/SummaryOfSignificantAccountingPoliciesProductWarrantyDetails" ], "xbrltype": "durationItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(3)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02(b))", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03(b))", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=118875152&loc=SL5864739-113975" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r451": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r452": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r453": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r454": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r455": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" } }, "version": "2.1" } XML 79 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RESTRUCTURING - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Restructuring Cost and Reserve [Line Items]    
Restructuring charges $ 0.8 $ 5.1
Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Restructuring charges 0.8 $ 5.1
Minimum | Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Restructuring and related costs expected remaining 7.3  
Maximum | Santa Clara Facility Relocation    
Restructuring Cost and Reserve [Line Items]    
Restructuring and related costs expected remaining $ 11.3  
XML 81 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION - Schedule of Purchase Price Allocation for Direct Conversion AB Acquisition (Details) - USD ($)
$ in Millions
Apr. 29, 2019
Jan. 03, 2020
Sep. 27, 2019
Allocation of the purchase consideration:      
Goodwill   $ 290.8 $ 290.8
Direct Conversion AB      
Allocation of the purchase consideration:      
Accounts receivable $ 2.4    
Inventories 5.7    
Prepaid expenses and other current assets 0.7    
Property, plant, and equipment 0.9    
Goodwill 47.2    
Intangible assets 32.9    
Total assets acquired 89.8    
Accounts payable (1.0)    
Accrued liabilities and other current liabilities (1.5)    
Current maturities of long-term debt (1.0)    
Deferred revenues (0.9)    
Long-term debt (3.5)    
Other long-term liabilities (1.1)    
Total liabilities assumed (9.0)    
Noncontrolling interest (1.4)    
Net assets acquired, less noncontrolling interest 79.4    
Net cash paid 69.5    
Deferred consideration 9.9    
Total consideration $ 79.4    
XML 82 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)
Jan. 03, 2020
Operating Leases  
Weighted average remaining lease term 5 years 2 months 12 days
Weighted average discount rate 4.20%
Finance Leases  
Weighted average remaining lease term 3 years
Weighted average discount rate 3.80%
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Allocated share-based compensation expense $ 3.2 $ 2.6
Cost of revenues    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Allocated share-based compensation expense 0.3 0.3
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Allocated share-based compensation expense 0.6 0.5
Selling, general and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Allocated share-based compensation expense $ 2.3 $ 1.8
XML 84 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
TAXES ON EARNINGS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Income Tax Disclosure [Abstract]    
Tax expense (benefit) $ 0.0 $ (1.1)
Effective tax rate percent 0.90% 26.80%
Deferred tax liabilities of undistributed foreign earnings $ 0.1  
XML 85 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORIES
 3 Months Ended
Jan. 03, 2020
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
The following table summarizes the Company’s inventories:
(In millions)
January 3, 2020
 
September 27, 2019
Raw materials and parts
$
184.2


$
160.1

Work-in-process
27.6


27.9

Finished goods
57.3


60.2

Total inventories
$
269.1


$
248.2
XML 86 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
RELATED-PARTY TRANSACTIONS
 3 Months Ended
Jan. 03, 2020
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
Investment in Privately-Held Companies
The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a four-member consortium that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays for digital flat panel image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.
The equity investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated. During the three months ended January 3, 2020 and December 28, 2018, the Company recorded (loss) and income on the equity investment in dpiX Holding of $0.9 million and $(0.7) million, respectively. Income and loss on the equity investment in dpiX Holding is included in other expense, net in the condensed consolidated statements of earnings. The carrying value of the equity investment in dpiX Holding was $48.5 million and $48.1 million at January 3, 2020 and September 27, 2019, respectively.
During the three months ended January 3, 2020 and December 28, 2018, the Company purchased glass transistor arrays from dpiX totaling $5.9 million and $2.8 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the condensed consolidated balance sheets or cost of revenues in the condensed consolidated statements of earnings.
As of January 3, 2020, and September 27, 2019, the Company had accounts payable to dpiX totaling $3.4 million and $3.6 million, respectively.
In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of January 3, 2020, the Company had no remaining fixed cost commitments related to the agreement remaining for calendar year 2019. In January 2020, the fixed cost commitment was determined and approved by the dpiX board of directors to be $12.7 million for calendar year 2020. The amended agreement will continue unless the ownership structure of dpiX changes as provided in the amended agreement.
The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment of $48.5 million and fixed cost commitments.
In November 2018, the Company and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging Verwaltungsgesellschaft GmbH (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method. As of January 3, 2020, the Company has made contributions totaling $4.2 million, and has committed to contribute an additional $1.1 million as milestones are achieved, and to provide certain full-time employees to support prototyping and manufacturing activities in exchange for a 50% interest in VEC. CETTEEN made contributions of certain assets including intellectual property in exchange for a 50% interest in VEC. The Company's investment in VEC was $3.0 million and $2.0 million at January 3, 2020 and September 27, 2019, respectively .
XML 87 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE (Tables)
 3 Months Ended
Jan. 03, 2020
Fair Value Disclosures [Abstract]  
Fair Value, Liabilities Measured on Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
 
Fair Value Measurements at January 3, 2020
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
4.7

 
$
—

 
$
4.7

Derivative assets
—

 
1.3

 
—

 
1.3

Total assets measured at fair value
$
—

 
$
6.0

 
$
—

 
$
6.0

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
2.7

 
$
—

 
$
2.7

Deferred consideration
9.7

 
—

 
—

 
9.7

Total liabilities measured at fair value
$
9.7

 
$
2.7

 
$
—

 
$
12.4
Fair Value, Assets Measured on Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
 
Fair Value Measurements at January 3, 2020
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
4.7

 
$
—

 
$
4.7

Derivative assets
—

 
1.3

 
—

 
1.3

Total assets measured at fair value
$
—

 
$
6.0

 
$
—

 
$
6.0

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
2.7

 
$
—

 
$
2.7

Deferred consideration
9.7

 
—

 
—

 
9.7

Total liabilities measured at fair value
$
9.7

 
$
2.7

 
$
—

 
$
12.4


At September 27, 2019, the Company determined the following levels of inputs at fair value for the following assets or liabilities:
 
Fair Value Measurements at September 27, 2019
(In millions)
Quoted Prices in Active Markets for Identical Assets and Liabilities
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents - Money market funds
$
—

 
$
8.8

 
$
—

 
$
8.8

Total assets measured at fair value
$
—

 
$
8.8

 
$
—

 
$
8.8

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Derivative liabilities
$
—

 
$
0.7

 
$
—

 
$
0.7

Deferred Consideration
8.9

 
—

 
—

 
8.9

Total liabilities measured at fair value
$
8.9

 
$
0.7

 
$
—

 
$
9.6
XML 88 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REDEEMABLE NONCONTROLLING INTERESTS & NONCONTROLLING INTERESTS (Tables)
 3 Months Ended
Jan. 03, 2020
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interest
Changes in redeemable noncontrolling interests were as follows:
(In millions)
Redeemable Noncontrolling Interests
 
Noncontrolling Interest
Balance at beginning of period, September 27, 2019
$
10.5

 
$
3.3

Net earnings attributable to noncontrolling interests
0.1

 
—

Other, including foreign currency remeasurement
0.1

 
—

Balance at end of period, January 3, 2020
$
10.7

 
$
3.3
XML 89 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION (Tables)
 3 Months Ended
Jan. 03, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information related to the Company’s segments is as follows:

Three Months Ended
(In millions)
January 3, 2020
 
December 28, 2018
Revenues
 
 
 
Medical
$
155.6


$
143.9

Industrial
44.5


41.8

Total revenues
$
200.1


$
185.7

Gross margin
 
 
 
Medical
$
43.8

 
$
45.1

Industrial
17.3

 
14.9

Total gross margin
$
61.1

 
$
60.0

Total operating expenses
56.5

 
49.6

Interest and other income (expenses), net
(5.8
)
 
(6.3
)
Earnings before taxes
(1.2
)
 
4.1

Taxes on earnings
—

 
1.1

Net earnings
(1.2
)
 
3.0

Less: Net earnings attributable to noncontrolling interests
0.1

 
—

Net earnings attributable to Varex
$
(1.3
)
 
$
3.0
Reconciliation of Assets from Segment to Consolidated
The following table summarizes the Company’s total assets by its reportable segments:
(In millions)
January 3, 2020
 
September 27, 2019
Identifiable assets
 
 
 
Medical
$
830.8


$
794.3

Industrial
237.6


244.6

Total reportable segments
$
1,068.4


$
1,038.9
XML 90 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
BUSINESS COMBINATION (Tables)
 3 Months Ended
Jan. 03, 2020
Business Combinations [Abstract]  
Schedule of Purchase Price Allocation
The following table summarizes the preliminary purchase price allocation:
(In millions)
Fair Value
Allocation of the purchase consideration:
 
Accounts receivable
$
2.4

Inventories
5.7

Prepaid expenses and other current assets
0.7

Property, plant, and equipment
0.9

Goodwill
47.2

Intangible assets
32.9

Total assets acquired
$
89.8

Accounts payable
$
(1.0
)
Accrued liabilities and other current liabilities
(1.5
)
Current maturities of long-term debt
(1.0
)
Deferred revenues
(0.9
)
Long-term debt
(3.5
)
Other long-term liabilities
(1.1
)
Total liabilities assumed
$
(9.0
)
Noncontrolling interest
$
(1.4
)
Net assets acquired, less noncontrolling interest
$
79.4

Net cash paid
$
69.5

Deferred consideration
9.9

Total consideration
$
79.4
Schedule of Intangible Assets Acquired
The following amounts represent the determination of the fair value and estimated weighted average useful lives of identifiable intangible assets for the Direct Conversion, which are amortized straight-line:
(In millions)
Fair Value
 
Estimated Weighted Average
Useful Life
(In Years)
Backlog
$
0.2

 
1
Trade names
2.5

 
5
Developed technology
18.4

 
10
In-process research and development
2.8

 
indefinite
Customer relationships
9.0

 
10
Total intangible assets acquired
$
32.9

 
 
XML 91 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Jan. 03, 2020
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited. These condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods.
Consolidation These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements for the fiscal years ended 2019, 2018 and 2017 included in the Company’s Form 10-K, which was filed with the SEC on December 20, 2019.
Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures.
Segment Reporting
Segment Reporting
The Company has two reportable operating segments, Medical and Industrial, which align with how its Chief Executive Officer, who has been identified as the Company's Chief Operating Decision Maker ("CODM"), views and measures the Company’s business performance. See Note 16, Segment Information, for further information on the Company’s segments.
Fiscal Year
Fiscal Year
The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2020 is the 53-week period ending October 2, 2020. Fiscal year 2019 was the 52-week period that ended on September 27, 2019.  The fiscal quarters ended January 3, 2020 and December 28, 2018 were 14-week and 13-week periods, respectively.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates
include the valuation of inventories, goodwill and intangible assets, impairment on investments, and taxes on earnings. Actual results could differ from these estimates.
Restricted Cash
Restricted Cash
Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the condensed consolidated balance sheet.
Concentration of Risk
Concentration of Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for doubtful accounts based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. The Company has neither experienced nor expects any significant disruptions to its operations due to supplier concentration.
Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required.
Loss Contingencies
Loss Contingencies
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision.
Product Warranty
Product Warranty
The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, the Company bases warranty
estimates on historical experience for similar products and adds a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
Leases
Leases
The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represents the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate ("IBR"). The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its condensed consolidated balance sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its condensed consolidated balance sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that
Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (the"FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases ("Topic 842"), referred to as ASC 842. The purpose of ASC 842 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under U.S. GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and is effective for the Company in fiscal year 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases ("Topic 842"): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 28, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840.
Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 28, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Also, the Company applied the hindsight practical expedient. Furthermore, as a lessee the Company elected to combine lease and non-lease components for the majority of its leases, which means that the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. The only asset class that did not combine lease and non-lease components were vehicle leases.
The most significant impact of the standards for the Company relate to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $26.8 million and $0.6 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $27.5 million and $0.6 million, respectively. This includes the recording of the Company’s existing capital leases as finance leases at transition. The cumulative impact of adoption was a $0.3 million decrease to retained earnings. Refer to Note 3, Leases, for a detailed impact of adopting this standard and its impact on the consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional
disclosures. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Effective September 28, 2019, the Company adopted ASU 2018-02 and it did not have a material effect on the Company’s financial statements and related disclosures.
Recent Accounting Standards or Updates Not Yet Effective
In December 2019, the FASB issued ASU 2019-12 which simplifies the accounting for income taxes by removing certain exceptions to the current guidance, and improving the consistent application of and simplification of other areas of the guidance. The standard is effective for the Company beginning in the first quarter of fiscal year 2022. Early adoption is permitted. The Company is evaluating the impact of adopting this guidance to its condensed consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04 which clarified its guidance to simplify the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021. The amendment is required to be adopted prospectively. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This ASU replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. In addition, the ASU requires new disclosures. This standard will be effective for the Company's interim and annual periods beginning with the first quarter of fiscal 2021 and must be applied on a modified retrospective basis. The Company is evaluating the potential impact of this standard to its condensed consolidated financial statements.
XML 92 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
NET (LOSS) EARNINGS PER SHARE
 3 Months Ended
Jan. 03, 2020
Earnings Per Share [Abstract]  
NET (LOSS) EARNINGS PER SHARE NET (LOSS) EARNINGS PER SHARE
Basic net (loss) earnings per common share is computed by dividing the net (loss) earnings for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) earnings per common share reflects the effects of potentially dilutive securities, which is computed by dividing net (loss) earnings by the sum of the weighted average number of common shares outstanding and dilutive common shares, which consists of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
 
Three Months Ended
(In millions, except per share amounts)
January 3, 2020
 
December 28, 2018
Net earnings attributable to Varex
$
(1.3
)
 
$
3.0

Weighted average shares outstanding - basic
38.5

 
38.1

Dilutive effect of potential common shares
—

 
0.2

Weighted average shares outstanding - diluted
38.5

 
38.3

Net earnings per share attributable to Varex - basic
$
(0.03
)
 
$
0.08

Net earnings per share attributable to Varex - diluted
$
(0.03
)
 
$
0.08

Anti-dilutive shared based awards, excluded
1.7

 
2.1


The Company excludes potentially dilutive common shares (consisting of shares underlying stock options, unvested stock awards and purchase rights granted under the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the inclusion of the shares underlying these stock awards would be anti-dilutive to (loss) earnings per share. Because the Company incurred a net loss for the three months ended January 3, 2020, none of the potentially dilutive common shares were included in the diluted share calculation for that period as they would have been anti-dilutive.
XML 93 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Dec. 28, 2018
Sep. 28, 2018
Accounting Policies [Abstract]        
Cash and cash equivalents $ 30.0 $ 29.9 $ 55.1 $ 51.9
Restricted cash 1.4 1.4 1.4 1.5
Cash and cash equivalents and restricted cash as reported per statement of cash flows $ 31.4 $ 31.3 $ 56.5 $ 53.4
XML 94 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Disaggregation of Revenue [Line Items]    
Revenues, net $ 200.1 $ 185.7
Americas    
Disaggregation of Revenue [Line Items]    
Revenues, net 70.3 68.4
EMEA    
Disaggregation of Revenue [Line Items]    
Revenues, net 65.2 62.6
APAC    
Disaggregation of Revenue [Line Items]    
Revenues, net 64.6 54.7
UNITED STATES    
Disaggregation of Revenue [Line Items]    
Revenues, net $ 68.9 $ 67.2
XML 95 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Cash flows from operating activities:    
Net (loss) earnings $ (1.2) $ 3.0
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Share-based compensation expense 3.2 2.6
Depreciation 5.2 9.8
Amortization of intangible assets 4.5 3.7
Deferred taxes 0.5 (2.5)
Income from equity method investments (0.7) (0.8)
Amortization of deferred loan costs 0.6 0.6
Other, net 0.0 0.1
Changes in assets and liabilities, net of effects of acquisition:    
Accounts receivable 18.5 20.6
Inventories (21.1) (22.0)
Prepaid expenses and other assets 3.7 3.7
Accounts payable 15.4 (0.5)
Accrued liabilities and other current and long-term operating liabilities (4.8) 3.1
Deferred revenues (0.8) (1.4)
Net cash provided by operating activities 23.0 20.0
Cash flows from investing activities:    
Purchases of property, plant and equipment (8.1) (3.4)
Acquisitions of businesses, net of cash acquired (1.2) 0.0
Contributions and advances to joint ventures (1.3) 0.0
Net cash used in investing activities (10.6) (3.4)
Cash flows from financing activities:    
Borrowings under credit agreements 3.0 4.0
Repayments of borrowing under credit agreements (17.8) (19.0)
Proceeds from exercise of stock options 1.1 0.0
Proceeds from shares issued under employee stock purchase plan 1.8 1.9
Other financing activities (0.1) 0.0
Net cash used in financing activities (12.0) (13.1)
Effects of exchange rate changes on cash and cash equivalents and restricted cash (0.3) (0.4)
Net increase in cash and cash equivalents and restricted cash 0.1 3.1
Cash and cash equivalents and restricted cash at beginning of period 31.3 53.4
Cash and cash equivalents and restricted cash at end of period 31.4 56.5
Supplemental cash flow information:    
Cash paid for interest 5.0 3.0
Cash paid for income tax 0.5 0.6
Supplemental non-cash activities:    
Purchases of property, plant and equipment financed through accounts payable $ 0.8 $ 1.8
XML 96 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Jan. 03, 2020
Dec. 28, 2018
Income Statement [Abstract]    
Revenues, net $ 200.1 $ 185.7
Cost of revenues 139.0 125.7
Gross margin 61.1 60.0
Operating expenses:    
Research and development 21.7 18.8
Selling, general and administrative 34.8 30.8
Total operating expenses 56.5 49.6
Operating earnings 4.6 10.4
Interest expense (5.4) (5.1)
Other expense, net (0.4) (1.2)
Interest and other expense, net (5.8) (6.3)
(Loss) earnings before taxes (1.2) 4.1
Taxes on earnings 0.0 1.1
Net (loss) earnings (1.2) 3.0
Less: Net earnings attributable to noncontrolling interests 0.1 0.0
Net (loss) earnings attributable to Varex $ (1.3) $ 3.0
Net (loss) earnings per common share attributable to Varex    
Earnings per share, basic (in USD per share) $ (0.03) $ 0.08
Earnings per share, diluted (in USD per share) $ (0.03) $ 0.08
Weighted average common shares outstanding    
Weighted average common shares outstanding, basic (in shares) 38.5 38.1
Weighted average common shares outstanding, diluted (in shares) 38.5 38.3
XML 97 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details)
$ in Millions
Jan. 03, 2020
USD ($)
Assets  
Operating lease assets $ 25.1
Finance lease, right-of-use asset 0.6
Liabilities  
Operating lease liabilities (current) 6.7
Finance lease liabilities (current) 0.2
Operating lease liabilities (non-current) 19.2
Finance lease liabilities (non-current) $ 0.4
XML 98 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
INVENTORIES (Details) - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Inventory Disclosure [Abstract]    
Raw materials and parts $ 184.2 $ 160.1
Work-in-process 27.6 27.9
Finished goods 57.3 60.2
Total inventories $ 269.1 $ 248.2
XML 100 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Summary of Derivatives at Fair Value (Details) - Derivatives designated as cash flow hedges - Designated as Hedging Instrument - USD ($)
$ in Millions
Jan. 03, 2020
Sep. 27, 2019
Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative liabilities fair value, gross $ (0.5) $ (0.5)
Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative assets and liabilities, net (0.9) 0.0
Accrued liabilities and other current liabilities | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative liabilities fair value, gross (0.3) 0.0
Accrued liabilities and other current liabilities | Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative assets fair value, gross 1.3 0.0
Other long-term liabilities | Interest Rate Swap Contracts    
Derivative [Line Items]    
Derivative liabilities fair value, gross (0.2) (0.5)
Other long-term liabilities | Cross Currency Swap Contracts    
Derivative [Line Items]    
Derivative liabilities fair value, gross $ (2.2) $ 0.0

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